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Summary 
 
There  is  increasing  evidence  to  support  a  role  for  vascular  oxidative  stress  in  the 
development  of  endothelial  dysfunction  and  coronary  artery  disease  (CAD).  The 
prevalence of CAD in patients with type 2 diabetes (T2D) is more than ten times greater 
than  in  the  general  population  and  CAD  patients  with  T2D  display  poorer  clinical 
outcomes than those  without. Previous investigations carried out within this laboratory 
have  demonstrated  endothelial  dysfunction  and  elevated  superoxide  (O2
-)  production 
throughout  the  vessel  wall  in  saphenous  veins  from  patients  with  advanced  CAD. 
However, the molecular basis for these findings was not investigated, nor was the effect of 
T2D.  Consequently,  the  aim  of  this  study  was  to  investigate  a  number  of  molecular 
determinants  of  oxidative  stress  in  primary  human  saphenous  vein  endothelial  cells 
(HSVECs)  from  CAD  patients  both  with  and  without  T2D,  the  hypothesis  being  that 
oxidative  stress  leads  to  endothelial  dysfunction  in  CAD  and  is  exacerbated  in  those 
patients with T2D. 
 
Initial  experiments  confirmed  the  findings  of  previous  studies,  revealing  significantly 
elevated  O2
-  levels  and  impaired  endothelium-dependent  relaxation  in  portions  of 
saphenous vein from patients with CAD related to those from healthy control subjects. In 
addition, results demonstrated more severe endothelial dysfunction in vessels from CAD 
patients with T2D relative to those CAD patients without this additional cardiovascular 
risk factor.  
 
Attempts to characterise cellular sources of elevated O2
- production in the endothelium of 
patients with CAD revealed that while HSVEC endothelial nitric oxide synthase (eNOS) is 
not  a  major  source  of  O2
-  generation  in  CAD,  nicotinamide  adenine  (phosphate) 
dinucleotide (NAD(P)H) oxidase contributes to excess O2
- production in the endothelium 
of patients with this cardiovascular disease.  
 
Further cellular investigation revealed a significant increase in expression of mitochondrial 
superoxide dismutase (SOD2) in HSVECs from CAD patients, in particular those with 
T2D. Mitochondrially-derived reactive oxygen species (mtROS) are reported to contribute 
to oxidative stress and endothelial dysfunction in CAD and T2D and, as such, this increase 
in SOD2 expression is likely to represent an adaptive response to elevated mitochondrial 
O2
-  production.  In  addition,  analysis  of  gene  expression  microarray  data  revealed 22 
differential expression of a number of genes potentially linked to mitochondrial function, 
serving to support a key role for mitochondrial dysfunction in the pathogenesis of CAD 
and T2D.  
 
Additional molecular studies focused on AMP-activated protein kinase (AMPK). Proposed 
as  a  candidate  target  for  therapeutic  intervention  in  endothelial  dysfunction,  AMPK 
stimulates eNOS, leading to nitric oxide (NO) production in cultured endothelial cells. 
Furthermore, it has recently been reported that endothelial AMPK is activated in a mtROS-
mediated manner. With SOD2 expression data indicating an increase in mtROS production 
in the endothelium of patients with CAD, AMPK activity was investigated and compared 
in  HSVECs  isolated  from  these  patients  and  control  subjects.  AMPK  activity  was 
significantly  greater in  cells from patients with CAD, despite no change in activity of 
upstream  kinases,  LKB1  and  Ca
2+/calmodulin-dependent  kinase  kinase  (CaMKK).  On 
stratifying CAD patients according to the presence of T2D, AMPK activity was found to 
be  significantly  increased  in  the  endothelium  of  those  patients  with  CAD  and  T2D  as 
compared  to  those  with  CAD  alone.  Given  the  potentially  elevated  levels  of  mtROS 
production  in  the  endothelium  of  patients  with  CAD,  it  seemed  likely  that  endothelial 
AMPK activation in CAD patients was occurring in an mtROS-mediated manner and that 
this activation was enhanced in those CAD patients with T2D who display more severe 
endothelial dysfunction and increased SOD2 expression, consistent with increased mtROS 
production. In order to test this hypothesis, HSVECs isolated from vessels of CAD patients 
were treated with the mitochondria-targeted antioxidant, MitoQ10. Results demonstrated a 
significant decrease in AMPK activation in cells from those CAD patients with T2D on 
treatment with MitoQ10. The same effect was not seen in cells from CAD patients without 
T2D. These findings indicate that AMPK is activated in a mtROS-mediated manner in 
endothelial cells isolated from CAD patients with T2D and suggest a role for the kinase in 
defence against oxidative stress and endothelial dysfunction in these individuals. 
 
In summary,  a wide range of molecular techniques have been employed to investigate 
cellular mechanisms underlying the oxidative stress and endothelial dysfunction associated 
with CAD. Results suggest mitochondria contribute to the increased O2
- production and 
endothelial  dysfunction  observed  in  vessels  from  CAD  patients.  In  addition,  findings 
indicate a novel, mtROS-mediated activation of AMPK in the endothelium of patients with 
CAD and T2D. Therefore, mitochondria-targeted antioxidants, used in combination with 23 
pharmacological  activators  of  AMPK,  may  have  enhanced  potential  in  prevention  and 
treatment of coronary artery disease in patients with type 2 diabetes.  24 
 
 
 
 
 
1. Introduction 
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1.1 Cardiovascular Disease 
 
Cardiovascular disease (CVD) refers to disorders of the heart and circulatory system and 
represents a major cause of morbidity and mortality in the world today. Indeed, according 
to the World Health Organisation (WHO), an estimated 17.5 million, or approximately 
30% of total global deaths resulted from CVD in 2005 and of these deaths, 7.6 million 
were due to coronary artery disease (CAD) (1). Furthermore, in the United Kingdom in 
2006, the calculated annual direct cost of the care of patients with CAD was around £3.2 
billion, with the indirect cost of loss of productivity even greater at over £3.9 billion (2). 
Consequently,  the  identification  and  characterisation  of  molecular  mechanisms 
contributing to the pathogenesis of CAD is highly desirable. 
 
In addition to CAD, stroke, peripheral vascular disease and renal failure / end stage renal 
disease are among cardiovascular disease phenotypes. CVD aetiology is observed to be 
multifactorial in nature with lifestyle, environmental and genetic factors implicated (3-6). 
Hypertension,  type  2  diabetes  mellitus  and  atherosclerosis  are  often  observed  in  early 
development of CVD and are considered major modifiable risk factors for disease (3;4). 
Further modifiable risk factors include hypercholesterolaemia, obesity and those associated 
with low socioeconomic status, such as cigarette smoking, sedentary lifestyle, unhealthy 
diet and alcohol consumption (2). Conversely, aging, family history of CVD, gender and 
ethnicity  represent  non-modifiable  disease  risk  factors  (3)  (Figure  1.1).  Recent  WHO 
statistics suggest that the major modifiable CVD risk factors account for around 80% of 
new  CAD  and  stroke  cases  (1),  highlighting  the  overwhelming  need  for  research  into 
conditions such as type 2 diabetes. 
 
 
1.1.1 Type 2 Diabetes Mellitus 
 
It is universally recognised that diabetes mellitus increases CVD risk (7;8). One of the 
most common chronic diseases, diabetes mellitus results from a combination of defects in 
insulin secretion and action (9) and affects more than 180 million people worldwide, a 
number predicted to more than double by 2030 (10). While microvascular complications of 
the condition, such as nephropathy and retinopathy, are well documented, macrovascular 
complications,  including  diseases  of  coronary  arteries,  peripheral  arteries  and  carotid 26 
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Figure  1.1.  Cardiovascular  Disease  Risk  Factors.  Multiple  interactions  between  genetic  and 
environmental factors result in the target organ damage characteristic of cardiovascular disease. 
Adapted from (3). 27 
vessels are reaching epidemic proportions (7). Diabetic macrovascular disease is observed 
to have a more severe course with greater prevalence of multiple vessel coronary artery 
disease and more diffuse, elongated atheromas in affected blood vessels (11-14). With the 
NHS  reportedly  spending  £1  million  an  hour,  10%  of  its  yearly  budget,  treating  the 
condition and its complications (15), diabetes mellitus represents a major public health 
concern. 
 
There are two major diabetes mellitus categories; type 1 and type 2. Type 1 diabetes is 
characterised by a lack of insulin production, rendering patients absolutely dependent on 
exogenous insulin. This form of the disease accounts for only 5%-10% of all diabetes cases 
and its diagnosis is made most commonly in childhood. Type 1 diabetes is thought to result 
from the autoimmune destruction of the insulin-producing pancreatic β-cells of the islets of 
Langerhans. Type 2 or non-insulin dependent diabetes mellitus represents the far more 
common form of the disease, usually with onset in adult life and associated with insulin 
resistance and relative insulin deficiency, as opposed to the absolute deficiency observed in 
type  1  (9).  Type  2  diabetes  (T2D)  is  a  heterogenous  disorder  with  clinical  expression 
requiring interaction between genetic and environmental factors (16). 
 
There are currently over 2.5 million people with diabetes in the United Kingdom and it is 
believed a further half a million cases remain undiagnosed (17). Recent findings suggest 
that  the  prevalence  and  incidence  of  diabetes  in  the  U.K.  has  increased  over  the  past 
decade and is mainly attributable to an increase in T2D (18). Patients with type 2 diabetes 
have almost twice the risk of CVD of non diabetic individuals after adjustment for other 
cardiovascular  risk  factors  (19).  Consequently,  while  the  relative  burden  of  CVD 
attributable  to  traditional  risk  factors,  such  as  smoking,  hypertension  and 
hypercholesterolaemia,  has  declined  in  recent  years,  findings,  such  as  those  from  The 
Framingham Heart Study, suggest an increasing prevalence of T2D has led to an increase 
in the proportion of CVD due to diabetes mellitus (20;21). Furthermore, after their first CV 
event, patients suffering from T2D and CAD consistently display poorer clinical outcomes 
than  their  non  diabetic  counterparts  (22-27),  potentially  the  result  of  impaired  insulin-
related  metabolism  (28),  increased  oxidative  stress  and/or  an  altered  inflammatory 
response (29). Indeed, the mortality rate for patients with T2D has been observed to be 
almost twice as high as those without (30) with around 65% of deaths in these individuals 
related to CAD or stroke (8). 
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1.1.1.1 Hormonal Regulation of Metabolic and Hemodynamic Homeostasis 
 
A continuous supply of glucose is necessary to ensure appropriate function and survival of 
all organs. Glucose homeostasis is regulated primarily by the opposing actions of insulin 
and glucagon, hormones secreted by pancreatic β-cells and α-cells respectively (31;32). 
Under physiological conditions, insulin secretion is increased in response to elevated blood 
glucose (i.e. after consumption of a meal). Insulin acts to maintain normoglycaemia by 
stimulating glucose uptake, utilisation and storage in classical insulin responsive tissues, 
namely skeletal muscle, adipose tissue and liver, and by reducing glucose production via 
inhibition  of  hepatic  gluconeogenesis  (33;34).  Conversely,  stimulation  of  glucagon 
secretion occurs during periods of hypoglycaemia when the hormone promotes hepatic 
glucose production and ultimately raises blood glucose levels (31;32) (Figure 1.2). Type 2 
diabetes develops as a consequence of failure to regulate glucose metabolism efficiently. 
 
In addition to its role in regulation of glucose metabolism, insulin has an important role in 
cardiovascular  physiology,  regulating  vascular  tone  by  stimulating  production  of  the 
vasodilator, nitric oxide (NO) (35), and the vasoconstrictor, endothelin-1 (ET-1) (35-38), 
from  the  vascular  endothelium.  As  such,  the  insulin  resistance  of  T2D  contributes  to 
endothelial  dysfunction,  a  common  feature  of  cardiovascular  diseases,  and  thus  is  a 
potential contributor to the pathogenesis of vascular disease in type 2 diabetes (39). 
 
 
1.1.1.2 Insulin Secretion 
 
At a cellular level, elevated blood glucose triggers exocytosis of insulin secretory vesicles 
and  release  of  insulin  into  the  bloodstream.  During  normal  insulin  secretion,  glucose 
transporter 2 (GLUT2) facilitates the entry of glucose into the pancreatic β-cells. Once 
inside  the  cell,  glucose  is  converted  by  a  specific  glucokinase  to  glucose  6-phosphate 
before being metabolised to form adenosine triphosphate (ATP). The resultant alteration in 
the ATP:ADP (adenosine diphosphate) ratio causes inhibition of ATP-sensitive potassium 
channels in the cellular membrane. The ensuing inhibition of potassium efflux results in 
depolarisation of the β-cell and activation of voltage-sensitive calcium channels, enabling 
an influx of calcium. It is this increase in the intracellular calcium concentration which 29 
 
 
 
 
 
 
 
 
 
Figure  1.2.  Regulation  of  Glucose  Metabolism.  Insulin  is  secreted  from  the  β-cells  of  the 
pancreas in response to elevations in plasma glucose. The hormone decreases glucose production 
from  the  liver  (gluconeogenesis),  and  increases  glucose  uptake,  utilisation  and  storage  in  fat 
(adipose tissue) and skeletal muscle, thus reducing plasma glucose levels. Glucose is stored as 
glycogen in liver and muscle and as lipid in adipocytes. When plasma glucose levels fall (during 
fasting or exercise), glucagon promotes the release of stored and newly synthesised glucose into the 
bloodstream.  In  this  way  glucose  homeostasis  is  maintained  (34). The fat cell  is  important  in 
metabolic regulation, releasing free fatty acids (FFAs) which reduce glucose uptake in muscle, 
insulin secretion from the β-cell, and increase glucose production from the liver. The fat cell can 
also secrete adipokines, such as leptin, adiponectin and tumour necrosis factor-α (TNF-α), which 
regulate  food  intake,  energy  expenditure  and  insulin  sensitivity  (34;40).  Figure  from  (34). 
Reprinted with permission from Macmillan Publishers Ltd: Nature; 414(6865):799-806, copyright 
2001. 30 
stimulates fusion of the insulin-containing secretory vesicles with the plasma membrane, 
resulting in the pulsatile release of insulin into the bloodstream (9;34) (Figure 1.3). 
 
 
1.1.1.3 Insulin Signalling 
 
In addition to serving as a primary regulator of glucose and cardiovascular homeostasis, 
insulin  regulates  gene  transcription,  protein  synthesis  and  cell  proliferation  and 
differentiation (34;41). On its release, the hormone binds to a high affinity transmembrane 
receptor,  promoting  phosphorylation  of  intrinsic  tyrosine  kinases  (42),  resulting  in 
activation  of  insulin  receptor  substrates  (IRS)  (43).  Subsequent  downstream  signalling 
events  ultimately  determine  which  physiological  response  occurs  (34;41;44;45)  (Figure 
1.4).  
 
In conventional insulin-sensitive tissues, the hormone acts through Akt / protein kinase B 
(PKB) to promote translocation of glucose transporter 4 (GLUT4) which facilitates glucose 
uptake  (46;47)  (Figure  1.4).  A  second,  PKB-independent  pathway,  involving  the  Cbl 
protooncogene,  has  also  been  reported  to  facilitate  insulin-stimulated  glucose  transport 
(48-50) (Figure 1.4).  
 
Acting through PKB, insulin is able to stimulate glycogen synthesis through inhibition of 
glycogen  synthase  kinase-3  (GSK3)  (51)  (Figure  1.4).  Gluconeogenesis  in  the  liver  is 
inhibited  by  insulin  via  phosphatidylinositol  (PtdIns)  3-kinase  (PI3K)-mediated 
suppression  of  the  genes  for  the  key  gluconeogenic  enzymes,  phosphoenolpyruvate 
carboxylkinase  (PEPCK)  (52)  and  glucose-6-phosphatase  (G6Pase)  (53).  In  addition, 
insulin  inhibits  lipolysis  by  reducing  cyclic  adenosine  monophosphate  (cAMP)  levels 
through PKB-mediated activation of  phosphodiesterase 3B (PDE3B) (54).  
 
Insulin activates cellular protein synthesis via the mTOR (mammalian target of rapamycin) 
complex 1 (mTORC1) (55-57) and exerts mitogenic effects by means of the mitogen-
activated protein kinase (MAPK) cascade (58) (Figure 1.4). 
 
In cardiovascular tissue, the MAPK signalling pathway also stimulates the secretion of ET-
1  (36-38)  (Figure  1.4),  in  addition  to  the  cellular  adhesion  molecules,  vascular  cell 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.3.  Insulin Secretion.  Insulin  secretion  in  β-cells  is triggered  by  rising  blood 
glucose levels. Starting with the uptake of glucose by the glucose transporter 2 (GLUT2), 
the glycolytic phosphorylation of glucose causes a rise in the ATP:ADP ratio. This rise 
subsequently  activates  the  potassium  (K
+)  channel  which  depolarises  the  membrane, 
causing the calcium (Ca
2+) channel to open, allowing Ca
2+ ions to flow in to the cell. 
Elevated Ca
2+ levels result in insulin exocytosis (9;34). G6Pase, glucose-6-phosphatase 
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adhesion molecule-1 (VCAM-1) and E-selectin (59), while PKB directly phosphorylates 
and  activates  endothelial  nitric  oxide  synthase  (eNOS),  leading  to  production  of  NO 
(35;60;61) (Figure 1.4). 
 
 
1.1.1.4 Insulin Resistance 
 
Insulin resistance describes a decreased sensitivity and / or responsiveness to metabolic 
actions of insulin (34;40). Insulin resistance is present and precedes the development of 
T2D in the majority of patients (62) and is characterised by a variety of defects in insulin 
signalling,  including  decreases  in  receptor  concentration  and  kinase  activity,  the 
concentration  and  phosphorylation  of  IRS,  PI3K  and  PKB  activity,  glucose  transporter 
translocation, and the activity of intracellular enzymes (40;63;64). In many cases, insulin 
resistance can be attributed to an increase in visceral adiposity (62;65-67) (Figure 1.2). 
 
The  underlying  pathogenic  mechanisms  by  which  visceral  adiposity  contributes  to  the 
etiology of insulin resistance and T2D are complex and still partially undetermined but 
studies have shown that on comparison with peripheral fat, visceral fat is more resistant to 
the  metabolic  effects  of  insulin  and  more  sensitive  to  lipolytic  hormones  (68;69). 
Consequently, visceral adipocytes contribute to elevated free fatty acid (FFA) levels in the 
circulation. FFAs adversely affect the insulin signalling cascade, inhibiting glucose uptake, 
glycogen synthesis and glucose oxidation, while stimulating hepatic gluconeogenesis (70) 
(Figure  1.2).  These  effects  have  been  attributed  to  the  ability  of  FFAs  to  promote 
accumulation of triglycerides and fatty acid-derived metabolites (diacylglycerol, fatty acyl-
CoA  and  ceramides)  in  non-adipose  cells,  such  as  hepatocytes  and  myocytes,  a 
phenomenon  termed  ‘lipotoxicity’  (67;71).  Recent  evidence  suggests  elevated 
concentrations of FFAs may also induce endoplasmic reticulum stress (increased unfolded 
protein response due to the disruption of the smooth operation of endoplasmic reticulum) 
which in turn has been implicated in the development of peripheral insulin resistance (72). 
 
Increased visceral adiposity is often accompanied by a disproportionate increase in pro-
inflammatory  adipokines  (73;74),  including  tumour  necrosis  factor-α  (TNF-α)  (75;76) 
(Figure 1.2), monocyte chemoattractant protein (MCP-1) (77), interleukin-6 (IL-6) (78) 33 
P
CAP
PtdIns(3,4, 5)P3
SHIP2
p70S6K
mTORC1
eIF4E 
PI3K
protein 
synthesis
PtdIns(3,4)P2
insulin
PtdIns(4,5)P2
GSK3
glycogen 
synthesis
glucose 
transport
AS160,
TBC1D1
Ras 
MAPK 
pathway
glucose 
transport
GLUT4
glucose
PTEN
PDK1
mTORC2
aPKC
α
β β
α
P
PKB P
SOS
Grb2 p110
IRS-1
p85
Cbl
Crk C3G
TC10
gene 
transcription
protein 
synthesis
cellular 
proliferation/ 
differentiation
ET-1 NO
vascular 
constriction
vascular 
relaxation
eNOS
vascular endothelium
liver, skeletal muscle, adipose tissue
P
P P
skeletal muscle, 
adipose tissue
P P
CAP
PtdIns(3,4, 5)P3
SHIP2
p70S6K
mTORC1
eIF4E 
PI3K
protein 
synthesis
PtdIns(3,4)P2
insulin
PtdIns(4,5)P2
GSK3
glycogen 
synthesis
glucose 
transport
AS160,
TBC1D1
Ras 
MAPK 
pathway
glucose 
transport
GLUT4
glucose
PTEN
PDK1
mTORC2
aPKC
α
β β
α α α
β β β β
α α
P P
PKB P PKB P P
SOS
Grb2 p110
IRS-1
p85
SOS SOS
Grb2 Grb2 p110 p110
IRS-1 IRS-1
p85 p85
Cbl Cbl
Crk Crk C3G C3G
TC10 TC10
gene 
transcription
protein 
synthesis
cellular 
proliferation/ 
differentiation
gene 
transcription
protein 
synthesis
cellular 
proliferation/ 
differentiation
ET-1 NO
vascular 
constriction
vascular 
relaxation
eNOS
vascular endothelium
liver, skeletal muscle, adipose tissue
P P
P P P P
skeletal muscle, 
adipose tissue
 
Figure 1.4. Overview of Insulin Signalling – continued overleaf 34 
Figure 1.4. Overview of Insulin Signalling. The interaction of insulin with its receptor on the outer surface of the plasma membrane activates the protein-tyrosine 
kinase activity associated with the β subunit of the receptor. The receptor then phosphorylates itself and insulin receptor substrate-1 (IRS-1) which binds the 
regulatory p85 subunit of phosphatidylinositol (PtdIns) 3-kinase (PI3K). The catalytic p110 subunit of PI3K then phosphorylates PtdIns-4-5-biphosphate (PtIns (4,5) 
P2) at the plasma membrane, thus converting it to PtdIns-3,4,5-triphosphate (PtdIns (3,4,5) P3). The increased amount of PtdIns (3,4,5) P3 results in recruitment of 
AKT / protein kinase B (PKB) and phosphoinositide-dependent protein kinase 1 (PDK1) to the membrane. This positions PDK1 and PKB such that PDK1 can 
phosphorylate (activate) PKB on Thr 308. Activated PtdIns (3,4,5) P3 also triggers activation of the mammalian target of rapamycin complex-2 (mTORC2) which 
further phosphorylates PKB at Ser 473 for maximum activation. PDK1 additionally acts to activate the atypical protein kinase C (aPKC) isoforms, PKC-ζ and –λ, 
which appear to be required for insulin-stimulated glucose transport in classically insulin-responsive tissues. Activity of the PI3K pathway is partly determined by 
phosphatidylinositol-3-phosphatases such as phosphatase and tensin homologue (PTEN) and the SH2 domain-containing inositol-5-phosphatase (SHIP2). Protein 
tyrosine phosphatases, including PTP1B, that dephosphorylate the insulin receptor and IRS-1, also play an important role in negative regulation of insulin-signalling 
pathways. Effects of PKB activation include phosphorylation of glycogen synthase kinase-3 (GSK3) which reduces GSK3 activity, thus enhancing the conversion of 
blood glucose to glycogen. Another downstream effect of activated PKB is activation of the mTOR complex 1 (mTORC1) which acts to control cellular translation 
machinery by phosphorylation of p70 ribosomal S6 kinase (p70S6K) and the inhibitor of the initiation factor 4E for eukaryotic translation (eIF4E), resulting in its 
activation. Insulin binding also results in activation of the adaptor protein, Grb-2 which recruits the Son-of-sevenless (SOS) exchange protein to the plasma 
membrane  for  activation of  Ras,  thus  stimulating  gene  transcription  and  cellular  proliferation  or  differentiation through  the  mitogen-activated  protein  kinase 
(MAPK) cascade. In addition, binding of insulin to its receptor causes tyrosine phosphorylation of the Cbl protein which, in most insulin responsive cells, is 
associated with the adaptor protein, CAP. This results in the Cbl-CAP complex being recruited to a region of the plasma membrane termed a lipid raft. Here, Cbl 
interacts with the adaptor protein, Crk, which is constitutively associated with the Rho-family guanide nucleotide exchange factor, C3G. C3G in turn activates the G-
protein,  TC10  which  acts  to  promote  glucose  transporter  4  (GLUT4)  translocation  to  the  membrane.  This  occurs  in  parallel  with  activated  PKB  which 
phosphorylates the Rab GTPase-activating protein, Akt substrate of 160kDa (AS160) and its paralogue, TBC1D1, also promoting translocation of GLUT4 and 
uptake  of  glucose  from  blood.  In  cardiovascular  tissue,  the  MAPK  pathway  controls  secretion  of  ET-1  in  the  vascular  endothelium  while  PKB  directly 
phosphorylates endothelial nitric oxide synthase (eNOS), thus stimulating NO production (34;45). 35 
and interleukin-8 (IL-8), all of which have been implicated in the development of insulin 
resistance (79). Unlike these adipokines, adiponectin, which signals via AMP-activated 
protein  kinase  (AMPK)  (80),  is  found  at  decreased  concentrations  in  visceral  obesity, 
resulting in a reduction in its insulin-sensitising effects in liver and muscle (81;82) (Figure 
1.2).  
 
Under conditions of insulin resistance, the β-cells of the pancreas initially compensate, 
facilitating  an  increase  in  insulin  secretion  to  prevent  the  hyperglycaemia  of  T2D. 
However, as insulin resistance worsens, β-cell compensation becomes less effective and 
hyperglycaemia  of  progressively  greater  magnitude  occurs  as  the  patient  progresses 
towards frank type 2 diabetes (83). 
 
 
1.1.1.5 Type 2 Diabetes Mellitus & Cardiovascular Disease 
 
Recent medical literature has highlighted the importance of insulin resistance in increasing 
CVD risk (62;84-86), a risk which gradually increases as an individual progresses from 
insulin  resistance  to  T2D  (62).  Insulin  resistance  is  associated  with  a  dramatic 
downregulation of the insulin signalling pathway leading from PI3K, PDK1 and PKB to 
phosphorylation  and  activation  of  eNOS.  However,  the  MAPK  pathway  remains 
unaffected,  perhaps  allowing  for  some  of  the  detrimental  effects  of  chronic 
hyperinsulinemia on cellular growth in the vasculature (39). In the endothelium, a decrease 
in PI3K signalling and an increase in MAPK signalling may lead to decreased production 
of NO and increased secretion of ET-1, characteristic of the endothelial dysfunction of 
many cardiovascular diseases (39;87). 
 
The  elevated  circulating  FFA  levels  of  visceral  obesity  and  insulin  resistance  are  also 
known to contribute to diabetic vascular complications by  reducing eNOS activity and 
increasing  reactive  oxygen  species  (ROS)  production  in  the  vasculature  (39;88).  FFA-
associated  ROS  production  is  known  to  enhance  protein  kinase  C  (PKC)  activity  and 
increase formation of advanced glycation end-products (AGEs) which interact with AGE-
binding receptors to promote atherosclerosis directly through changes in the function of 
endothelial,  macrophage  and  smooth  muscle  cells  (39;88;89).  Furthermore,  circulating 
adipokines  recruit  and  activate  inflammatory  cells,  thus  perpetuating  a  systemic 36 
inflammatory  milieu  which  can  strongly  affect  vascular  function  and  development  of 
atherosclerosis (90).  
 
It has been reported that visceral adiposity and insulin resistance impair thrombolysis via a 
mechanism involving increased levels of plasminogen activator inhibitor-1 (PAI-1) (65;91-
94). Levels of this atherogenic factor have been observed to be particularly high in patients 
with T2D (91;92), serving as a predictor for CVD (95;96). 
 
In  addition,  hyperglycaemia  itself  is  implicated  in  the  pathogenesis  of  diabetic 
macrovascular disease (97;98), facilitating PKC activation and AGE formation (88;89;99) 
in  a  similar  manner  to  FFAs.  AGEs  induce  ROS  production  and  promote  vascular 
inflammation through activation of nuclear factor κB (NF-κB) which enhances expression 
of VCAM-1 and MCP-1 (87;88). Acute hyperglycaemia can also reduce eNOS activation 
and  NO  production,  thus  contributing  to  endothelial  dysfunction  and  the  vascular 
complications of type 2 diabetes (100). 
 
 
1.1.1.6 Genetics & Environment 
 
There is a wealth of evidence to support a profound influence of genetic factors on the 
development  of  T2D,  including  twin  studies  which  reveal  an  approximate  70% 
concordance in monozygotic twins, as compared to 20-30% in dizygotic twins (101;102). 
Furthermore, the life-time risk of developing the disease is around 40% in offspring of one 
parent with T2D but is seen to approach 70% if both parents have the disease (103). Large 
ethnic differences in the prevalence of T2D have also been explained by way of a genetic 
component  (104;105).  Additionally,  there  are  a  number  of  relatively  uncommon 
monogenic forms of  T2D, known as maturity onset diabetes of the young (MODY), which 
have roughly the same phenotypic expression as the adult onset form and follow a clear 
Mendelian mode of inheritance (106) (Table 1.1). While the incidence of MODY is not 
precisely known, it is believed to account for < 5% of all T2D cases, the remainder being 
attributed to polygenic defects (9). 37 
Type  Gene  Chromosome  Defect 
MODY 
1 
hepatic nuclear 
factor-4α 
(HNF4A) 
20q  progressive β-cell failure 
MODY 
2 
glucokinase 
(GCK) 
7p  impaired glucose-regulated insulin 
secretion 
MODY 
3 
hepatic nuclear 
factor-1α 
(HNF1A) 
12q  progressive β-cell failure 
MODY 
4 
insulin promoter 
factor 1 (IPF1) 
13q  impaired pancreatic development, 
impaired glucose-mediated stimulation 
of insulin gene transcription 
MODY 
5 
hepatic nuclear 
factor-1β 
(HNF1B) / 
hepatic 
transcription 
factor 2 (TCF2) 
17 cen-q  progressive β-cell failure,  
renal disease 
MODY 
6 
NEUROD1  2q  abnormal β-cell development and 
function 
 
 
Table 1.1. Common Variants in MODY Genes. There are a minimum six forms of MODY, each 
caused by mutations in a distinct gene. Common to all forms is that they result in impaired insulin 
secretion.  MODY  patients  are  identified  clinically  as  having  a  form  of  non-insulin  dependent 
diabetes mellitus, characterised by a mild to moderate insulin secretory deficiency, an autosomal 
dominant mode of inheritance and onset at less than 25 years of age in some family members 
(106;107). 38 
Attempts to define the more common, polygenic form of T2D, including linkage analysis, 
candidate gene studies and, more recently, genome wide association studies (GWAS), have 
identified a number of genes as being associated with the disease (16;108) (Table 1.2). Of 
particular interest are the results from several recent GWAS on both T2D and its risk 
factor, obesity, which have revealed at least eighteen genes consistently associated with 
T2D  (109-118).  Many  of  these  genes  implicate  pancreatic  β-cell  function  in  disease 
pathogenesis  whereas  only  one  appears  clearly  associated  with  insulin  resistance  (16) 
(Table 1.2). It is likely these discoveries represent but a small proportion of the genetic 
variation  underlying  the  susceptibility  to  the  disorder  and  further  investigation  will  be 
required to provide a more complete picture of the genetic complexity of T2D. 
 
While type 2 diabetes has a strong genetic component, its development is triggered by 
environmental factors in genetically susceptible individuals. The epidemic increase in T2D 
prevalence across the globe in the past 50 years can be ascribed to a change in environment 
as the world advances towards a more affluent, westernised lifestyle and the calorie rich 
diet  and  physical  inactivity  with  which  it  is  associated  (9).  One  explanation  for  the 
interaction between genes and environment in polygenic T2D etiology is outlined in the 
thrifty genotype hypothesis (119) and concerns evolution of a genotype which conferred 
survival benefits in the past but is detrimental in the current environment. An opposing 
theory,  the  so  called  thrifty  phenotype  hypothesis  (120),  proposes  that  the  condition 
represents an adult metabolic response to foetal malnutrition. 
 
 
1.1.1.7 Treatment of Type 2 Diabetes Mellitus 
 
Lifestyle modifications targeting weight reduction, and in particular reduction in visceral 
adiposity, have been shown to be beneficial as a first-line approach in treating glycaemic 
abnormalities  and  reducing  the  risk  for  diabetes  and  CVD  (121-123).  However, 
pharmacological  therapies  are  used  adjunctively  in  patients  at  higher  risk  and  in  those 
noncompliant with lifestyle modification (62). 
 
Given  the  key  role  of  insulin  resistance  in  the  development  of  T2D,  development  of 
pharmaceuticals has been primarily focused on insulin sensitising agents. At present, two 
classes of insulin sensitising agents are in use: biguanides, including metformin, and the 39 
Year of Major 
Publication 
Reference  Suggested Gene  Disease 
Mechanism 
2000  (113;114;117;124)  PPARG*  insulin sensitivity 
2000  (125)  CAPN10**  glucose transport 
2003  (113;114;117;126)  KCNJ11*  β-cell dysfunction 
2006  (113;114;117;127;128)  TCF7L2  β-cell dysfunction 
2007  (113;114;117;129;130)  CDKAL1  β-cell dysfunction 
2007  (113;114;117;131)  CDKN2A/2B  β-cell dysfunction 
2007  (113;114;117;128-
132) 
HHEX/IDE  β-cell dysfunction 
2007  (113;114;117;128;130)  SLC30A8  β-cell dysfunction 
2007  (113;114;117;131)  IGF2BP2  β-cell dysfunction 
2007  (113;114;117)  WFS1*  unknown 
2007  (133)  TCF2*  unknown 
2007  (109;110)  FTO  obesity 
2008  (112)  MC4R  obesity 
2008  (111;118)  NOTCH2  unknown 
2008  (111;118)  ADAMTS9  unknown 
2008  (111;118)  THADA  unknown 
2008  (111;118)  TSPAN8/LGR5  unknown 
2008  (111;118)  CDC123/CAMK1D  unknown 
2008  (111;118)  JAZF1  unknown 
2008  (115;116)  KCNQ1  β-cell dysfunction 
 
Table  1.2.  Type  2  Diabetes  Susceptibility  Genes.  PPARG,  peroxisome  proliferator-activated 
receptor gamma; CAPN10, calpain 10; KCNJ11, potassium inwardly rectifying channel, subfamily 
J,  member  11;  TCF7L2,  transcription  factor  7-like  2;  CDKAL1,  CDK5  regulatory  subunit 
associated  protein  1-like  1;  CDKN2A/B,  cyclin-dependent  kinase  inhibitor  2A/B;  HHEX, 
haematopoietically expressed homeobox; IDE, insulin-degrading enzyme; SLC30A8, solute carrier 
family 30 member 8; IGF2BP2, insulin-like growth factor 2mRNA binding protein 2; FTO, fat 
mass  and  obesity  associated;  MC4R,  melanocortin  4  receptor;  NOTCH2,  Notch  homolog  2 
Drosophila; ADAMTS9, ADAM metallopeptidase with thrombospondin type 1 motif, 9; THADA, 
thyroid  adenoma  associated;  TSPAN8,  tetraspanin  8;  LGR5,  leucine-rich  repeat-containing  G 
protein-coupled  receptor  5;  CDC123,  cell  division  cycle  123  homolog;  CAMK1D, 
calcium/calmodulin-dependent protein kinase ID; JAZF1, juxtaposed with another zinc finger gene 
1;  KCNQ1,  potassium  voltage-gated  channel,  KQT-like  subfamily,  member  1.  *,  indicates  a 
biological candidate gene confirmed by GWAS. **, indicates gene implicated in type 2 diabetes by 
considerable  functional  and  genetic  evidence  but  not  by  GWAS.  All  other  genes  have  been 
identified by GWAS. Adapted from (16). 40 
thiazolidinediones (134). Metformin is relatively more active in the suppression of hepatic 
glucose production, exerting a portion of its effect through AMPK (135-137). Metformin 
has  been  shown  to  have  a  beneficial  effect  on  cardiovascular  outcomes  (138-140). 
Thiazolidinediones act on the peroxisome proliferator-activated receptor-γ (PPAR-γ) and 
are more active in stimulation of muscle glucose uptake (141;142). They are also known to 
activate AMPK (143) and enhance vascular function, ameliorating the dyslipidemia and 
inflammatory milieu of T2D (144). In addition, certain antihypertensive therapies, known 
to  act  on  the  renin-angiotensin  system  (RAS),  such  as  angiotensin  converting  enzyme 
(ACE) inhibitors and angiotensin-II receptor blockers (ARBs), have been shown to have 
beneficial effects in T2D. Treatment of type 2 diabetics with lipid-lowering statins has also 
been shown to be of therapeutic benefit (39;40).  
 
 
 
1.2 The Vascular Endothelium 
 
More than a trillion endothelial cells line the luminal surface of the human vasculature, 
representing  a  critical  interface  between  circulating  blood  and  tissue  (145-148).  An 
important  endocrine  organ,  the  endothelium  plays  a  pivotal  role  in  maintaining 
cardiovascular  homeostasis  under  physiological  conditions  by  releasing  a  number  of 
vasoactive  substances  which  act  to  regulate  vascular  tone,  antiproliferation  and 
antiaggregation, in addition to limiting increases in blood pressure, controlling tissue blood 
flow  and  inflammatory  responses  and  maintaining  blood  fluidity  (146-148).  The 
endothelium releases these vasoactive substances in response to mechanical stimuli, such 
as pressure and shear stress, and various hormonal stimuli, such as insulin (39;87;146). 
Endothelium-derived  substances  with  vasodilatory  and  antiproliferative  effects  include, 
endothelium-derived  hyper-polarisation  factor  (EDHF)  (149;150),  NO  (151;152)  and 
prostacyclin (PGI2) (153), while ET-1 (154), angiotensin II (Ang II) and ROS are among 
those  mediators  which  exert  vasoconstrictor  effects  (87).  All  forms  of  cardiovascular 
disease have been shown to be associated with some degree of endothelial dysfunction 
(87;146).  
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1.2.1 Endothelial Dysfunction 
 
Endothelial dysfunction describes the situation when a shift in the equilibrium between 
vasodilators and vasoconstrictors occurs, allowing vasoconstrictor and proliferative effects 
to  predominate,  leading  to  the  development  of  hypertension,  atherosclerosis,  platelet 
aggregation and ischemia (87;145-148;155). With respect to functional investigation, the 
term endothelial dysfunction generally relates to an impaired maximal dilative response 
and/or  an  impaired  sensitivity  to  endothelium  dependent  vasodilators  such  as 
acetylcholine, bradykinin and calcium ionophore, under conditions of preserved response 
to endothelium-independent dilators including sodium nitroprusside (87;146). 
 
Endothelial dysfunction is an early and independent predictor of poor prognosis in most 
forms of CVD (87;156-158), with alterations in endothelial function consistently found in 
hypertension, atherosclerosis, CAD, T2D and obesity (39;87;157-162). An increasing body 
of evidence suggests oxidative stress underlies the endothelial dysfunction of CVD. 
 
 
 
1.3 Oxidative Stress in Cardiovascular Disease 
 
1.3.1 Reactive Oxygen Species 
 
All layers of the vascular wall have enzymatic systems capable of producing ROS and, 
under physiological conditions, these ROS act as important signalling molecules (146), 
stimulating  vascular  smooth  muscle  cell  (VSMC)  and  endothelial  cell  mitogenic  and 
apoptotic  signalling  (163-166).  ROS  is  a  collective  term  encompassing  both  oxygen 
radicals and certain nonradicals which act as oxidising agents and/or are easily converted 
into radicals. ROS include the superoxide anion (O2
-), the hydroxyl radical (OH
-), NO, 
lipid  radicals  (LOO
-),  hydrogen  peroxide  (H2O2),  hypochlorous  acid  (HOCl)  and 
peroxynitrite (ONOO
-) (167). Principal among these ROS is the superoxide anion, formed 
from the univalent reduction of oxygen, its unpaired electron renders it highly reactive and 
unstable with a short half-life. Superoxide
 acts as both an oxidising agent, being reduced to 42 
H2O2 (168), and a reducing agent, donating its extra electron to form ONOO
- with NO 
(169) (Figure 1.5). 
 
 
1.3.2. Nitric Oxide 
 
Nitric oxide, first identified as endothelium-derived relaxing factor (EDRF) (151;152),  is a 
potent signalling molecule and vasodilator, responsible for mediating many functions of 
the endothelium, including control of vascular tone, inhibition of platelet aggregation and 
leukocyte adhesion, and suppression of VSMC proliferation (145;147;148). Each of these 
events has been implicated in the initiation and progression of atherosclerosis and NO is 
therefore considered an anti-atherosclerotic agent (147;155;170). 
 
A freely diffusible molecule with a short half-life of 6-10 seconds in vivo, vascular NO is 
formed from L-arginine by the constitutively expressed endothelial isoform of NOS which 
requires  Ca
2+/calmodulin,  flavin  adenine  dinucleotide  (FAD),  flavin  mononucleotide 
(FMN), nicotinamide adenine dinucleotide phosphate (NADPH) and tetrahydrobiopterin 
(BH4) as cofactors (147;148;161;171-173). Endothelial NOS is activated in response to 
elevated cytosolic Ca
2+ which occurs on exposure to various stimuli, including shear stress. 
In addition, eNOS is known to be activated by hormones (including insulin) and platelet-
derived substances and agonists, such as bradykinin and acetylcholine (161;174). It has 
recently been demonstrated that eNOS is regulated by
 reversible phosphorylation and both 
PKB and AMPK have been shown to phosphorylate and activate the enzyme at serine 1177 
(Ser1177) in cultured endothelial cells (175;176).  
 
On its release from endothelial cells, NO diffuses to the lumen of the vessel where it exerts 
its  effects  on  platelet  and  blood  element  functions,  and  to  adjacent  VSMCs  where  it 
induces  vasodilation  and  inhibits  vascular  remodelling  and  smooth  muscle  cell 
proliferation via activation of soluble guanylyl cyclase, present in the cytosol. Activation 
of  guanylyl  cyclase  causes  an  increase  in  intracellular  cGMP,  which  in  turn  activates 
protein kinase G (PKG), leading to reduced intracellular calcium and vasodilation (177) 
(Figure  1.6).  While  this  represents  the  predominant  sensing  pathway  for  NO  in  the 
vasculature, it has been reported that under certain conditions, NO may cause vasodilation 
by activation of K
+ channels (178). 43 
 
 
 
 
Figure 1.5. Oxidative Stress in Cardiovascular Disease. Environmental and physiological factors 
lead to the generation of superoxide (O2
-) in the vasculature. O2
- is enzymatically converted to 
hydrogen peroxide (H2O2) by superoxide dismutases (SODs) and further processed by catalase and 
glutathione peroxidase (GPx). However, excess O2
- can generate a number of other reactive oxygen 
species (ROS), disrupting the balance of nitric oxide (NO) and ROS. Increased oxidative stress 
leads to reduced NO bioavailability, associated with endothelial dysfunction and cardiovascular 
disease (CVD). Adapted from (167). 
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Figure  1.6.  Nitric  Oxide  Signalling  in  the  Vessel  Wall.  Nitric  oxide  (NO),  produced  in  the 
endothelial cell (EC), acts to regulate vascular tone and inhibit platelet aggregation and leukocyte 
adhesion  (177;178).  BH4,  tetrahydrobiopterin;  Ca
2+,  calcium;  cGMP,  cyclic  guanosine 
monophosphate;  ECM,  extracellular  matrix;  eNOS,  endothelial  nitric  oxide  synthase;  GMP, 
guanosine monophosphate; GTP, guanosine triphosphate; K+, potassium; O2
-, superoxide anion; 
PDE, phosphodiesterases; PKG, protein kinase G; VSMC, vascular smooth muscle cell. 
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Given  its  cardioprotective  function  and  fundamental  role  in  maintaining  vascular 
homeostasis,  loss  of  endothelial  NO  bioavailability  is  a  maladaptive  event  and, 
unsurprisingly,  represents  a  common  manifestation  of  endothelial  dysfunction 
(87;148;161).  Indeed,  decreased  NO  bioavailability  has  been  observed  in  T2D  (179), 
hypertension (180), hypercholesterolaemia (181) and cigarette smoking (182). Reduction 
of NO bioavailability in the endothelium may be the result of impaired NO production due 
to reduced expression of eNOS (183), lack of substrate or cofactor (171-173), or alterations 
in  cellular  signalling  leading  to  reduced  eNOS  activation  (184).  However,  the  reduced 
endothelial  NO  bioavailability  associated  with  CVD  has  been  reported  to  occur  as  a 
consequence of elevated ROS production under conditions of oxidative stress (161;167). 
 
 
1.3.3 Oxidative Stress 
Oxidative  stress  describes  the  condition  wherein  an  excessive  production  of  ROS 
overwhelms  endogenous  anti-oxidant  defence  mechanisms  (Figure  1.5).  The  resultant 
elevation in ROS levels has a detrimental effect on cellular function, a consequence of 
ROS-induced damage to lipid membranes, enzymes and nucleic acids (167). CAD and its 
risk  factors,  including  T2D,  are  characterised  by  excess  vascular  production  of  ROS 
(167;185).  One  of  the  earliest  measurable  consequences  of  oxidative  stress  in  human 
subjects  is  impaired  endothelium-dependent  vasodilation  which  occurs  a  result  of 
accelerated NO degradation by ROS (167).  
 
The most likely candidate for accelerating NO degradation is O2
-. When present in excess, 
the superoxide anion rapidly inactivates NO (186), yielding the highly reactive radical, 
ONOO
- as a by-product. Peroxynitrite is more stable than either NO or O2
- and is a potent 
oxidant, capable of inducing oxidation of deoxyribonucleic acid (DNA), proteins and lipids 
(187;188) (Figure 1.5). 46 
1.3.4 Reactive Oxygen Species: Sources in The Vasculature 
 
Principal  sources  of  ROS  in  the  vasculature  include  NAD(P)H)  oxidase  (189-191), 
xanthine oxidase (167;192) and the mitochondrial electron transport chain (193-196). In 
addition, ‘uncoupled’ eNOS produces O2
- rather than NO under conditions of substrate (L-
arginine) or co-factor (BH4) deficiency (170;173) (Figure 1.5). Other potential sources of 
ROS  include  arachidonic  acid  pathway  enzymes,  such  as  lipoxygenase  and 
cyclooxygenase, cytochrome p450s, peroxidases and other haemoproteins (167). 
 
 
1.3.4.1 Endothelial Nitric Oxide Synthase 
 
Under  conditions  of  oxidative  stress,  eNOS  may  generate  O2
-  rather  than  NO,  a 
phenomenon termed eNOS uncoupling (Figures 1.5 and 1.6). Nitric oxide generation is 
dependent on eNOS homodimerisation in the presence of BH4. However, BH4 is highly 
susceptible to oxidative degradation by ONOO
- and in the absence of its cofactor, eNOS 
fails to dimerise fully, resulting in uncoupling of the enzyme and amplification of oxidative 
stress  (197)  (Figure  1.5  and  1.6).  Uncoupled  eNOS  has  been  shown  to  contribute  to 
increased  superoxide  production  and  endothelial  dysfunction  in  a  number  of  CVDs, 
including CAD (161) and T2D (179). 
 
 
1.3.4.2 NAD(P)H Oxidase 
 
NAD(P)H oxidase is the predominant source of O2
- in the human vasculature, catalysing 
the one electron reduction of oxygen using NADH or NAD(P)H as the electron donor 
(189;191).  The  enzyme  was  originally  characterised  in  neutrophils  but  is  present  in 
VSMCs  (198;199)  and  endothelial  cells  (200-202).  A  multisubunit  enzyme,  vascular 
NADPH  oxidase  consists  of  membrane  integrated  cytochrome  b558  and  a  number  of 
cytosolic  regulatory  components;  p47
phox,  p67
phox,  p40
phox  (where  phox  represents 
phagocyte  oxidase)  and  the  GTP-binding  protein,  Rac1.  The  cytochrome  b558  is  itself 
comprised  of  two  subunits,  p22
phox  and  nicotinamide  adenine  dinucleotide  phosphate 47 
oxidase  (NOX)  protein,  NOX2  (gp91
phox)  or  a  functional  isoform  of  this  differentially 
expressed  catalytic  subunit  (189;190)  (Figure  1.7).  Vascular  NADPH  oxidase  is  a 
constitutive enzyme but can also be regulated in VSMCs by humoral factors such as Ang II 
and  a  number  of  growth  factors,  including  TNFα  and  platelet-derived  growth  factor 
(PDGF) (190;203-205). In the endothelium, activity of the enzyme is upregulated by shear 
stress caused by increased blood flow (201). 
 
Vascular NAD(P)H oxidase-stimulated O2
- production has been shown to be positively 
correlated with endothelial dysfunction and clinical risk factors for CVD in humans (206) 
and inhibition of the enzyme is seen to improve endothelial function in both rat and human 
blood vessels (207). 
 
Antisense inhibition of the constitutively expressed p22
phox subunit of NAD(P)H oxidase 
identified  it  as  being  critical  for  enzymatic  function  (199)  and  significantly  increased 
p22
phox  protein  levels  and  upregulation  of  p22
phox  messenger  ribonucleic  acid  (mRNA) 
have been shown to be associated with enhanced NAD(P)H oxidase activity in vessels 
from patients with CAD (208). Consequently, common genetic polymorphisms within both 
promoter  and  coding  regions  of  the  p22
phox  gene  (CYBA)  have  been  the  object  of 
considerable research, the hypothesis being that they confer important functional effects, 
contributing  to  interindividual  variation  in  enzyme  activity.  Studies  have  shown  that  a 
number of these allelic variants are associated with cardiovascular disease (209-211).  
 
NAD(P)H oxidase NOX subunit expression varies among vascular cells. Endothelial cells 
predominantly express the NOX4 isoform with expression of NOX2 occurring to a lesser 
extent (212). Subunit expression has been shown to be associated with CAD, correlating 
with  severity  of  atherosclerosis  (212)  and  with  features  of  plaque  stability  in  human 
coronary arteries (213). Recent studies have demonstrated that NOX2 and NOX4-based 
NAD(P)H  oxidases  are  the  predominant  contributors  to  oxidative  stress  in  coronary 
arteries from patients with advanced CAD (208), while NOX5 has been identified as a 
novel, calcium-dependent source of ROS in these vessels (214). 48 
 
 
 
Figure 1.7. Structure of the Active NAD(P)H Oxidase Complex. Vascular NAD(P)H oxidase is 
a  heterodimer,  consisting  of    membrane-bound  p22
phox  and  NOX  subunits  and  cytoplasmic 
subunits, p67
phox, p47
phox and p40
phox. Rac1 is required for assembly of the subunits. The NAD(P)H-
binding domain is predicted to be on one side of the membrane, while superoxide (O2
-) generation 
is predicted to occur on the other. The oxidase may be located either on the plasma membrane or 
on intracellular membranes (190;191). ECM, extracellular matrix. Adapted from (190). 
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1.3.4.2.1 NAD(P)H Oxidase In Type 2 Diabetes Mellitus 
 
It has been shown that elevated O2
- production in human blood vessels from patients with 
T2D is mediated by upregulated NAD(P)H oxidase activity (179). Increased activity of the 
enzyme  has  also  been  implicated  in  the  impaired  endothelium-dependent  vasodilation 
observed in the OLETF rat, a model of T2D (215). In addition, a number of in vitro studies 
have  demonstrated  that  the  hyperglycaemia  and  AGE  formation  characteristic  of  T2D 
increases  NAD(P)H  oxidase-induced  O2
-  production  in  endothelial  cells  (216-218). 
Furthermore, increased protein levels of p22
phox, p47
phox and p67
phox have been observed in 
human  vessels  from  patients  with  T2D  (179)  while  p22
phox  mRNA  was  shown  to  be 
upregulated in vessels from streptozotocin-induced diabetic and OLETF rats (215;219). 
The specific mechanisms underlying enhanced NAD(P)H oxidase activity in T2D are yet 
to be fully elucidated but recent studies have indicated a crucial role for protein kinase C. 
A recognised stimulant of NAD(P)H oxidase activation, activity of PKC is increased as a 
result of hyperglycaemia (220;221). 
 
 
1.3.4.3 Mitochondria 
 
The oxidative phosphorylation (OXPHOS) pathway is essential for energy production in 
mitochondria of eukaryotic cells. Enzymes of the inner mitochondrial membrane transfer 
electrons  along  the  electron  transport  chain  (ETC)  which  generates  a  proton  gradient, 
enabling  ATP  synthase  to  generate  ATP.  Under  physiological  conditions,  this  process 
produces ROS as byproducts, a result of the one electron reduction of molecular oxygen 
(O2)  to  superoxide  (196;222;223)  (Figure  1.8).  As  such,  a  network  of  mitochondrial 
antioxidant systems is in place to protect against ROS-induced damage to mitochondrial 
proteins, lipids and nucleic acids (Figure 1.8).  However, under  conditions of oxidative 
stress, these antioxidant systems are overwhelmed, allowing ROS to exert their damaging 
effects  and  ultimately  alter  mitochondrial  function  (196;222).  Increased  production  of  
mitochondrial ROS (mtROS), leading to accumulation of mitochondrial DNA (mtDNA) 
damage and progressive mitochondrial dysfunction, has been shown to be associated with 
vascular diseases, including CAD and T2D (88;222;224;225). 50 
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Figure 1.8. Mitochondrial Oxidative Phosphorylation and Superoxide Production. Oxidative 
phosphorylation (OXPHOS) is composed of 5 multiple subunit complexes embedded in the inner 
mitochondrial membrane. Electrons (e
-) from reduced nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2) pass through complex I (NADH dehydrogenase) and 
complex II (succinate ubiquinone oxidoreductase) respectively and are then shuttled to complex III 
(ubiquinol  cytochrome  oxidoreductase)  via  ubiquinol  (ubiq).  Cytochrome  c  (cyt  c)  transfers 
electrons from complex III to complex IV, with the reduction of molecular oxygen (O2) to water 
(H2O),  a  reaction  inhibited  by  nitric  oxide.  Flow  of  electrons  is  accompanied  by  proton  (H
+) 
transfer  across  the  inner  mitochondrial  membrane  at  complexes  I,  III  and  IV,  creating  an 
electrochemical gradient ( ψ). Protons re-enter the mitochondrial matrix through complex V (ATP 
synthase) which utilises the proton-motive force to generate ATP. This force also drives ATP-ADP 
exchange by the adenine nucleotide translocase (ANT). Uncoupling proteins (UCPs) allow protons 
to return to the matrix, reducing ROS formation. Of the electrons entering the transport chain, it is 
estimated 2-4% are involved in superoxide (O2
-) formation. Complex I leaks electrons to generate 
O2
- in the matrix, whereas complex III generates O2
- in both the matrix and intermembrane space. 
The P66
Shc intermembrane protein has been identified as being involved in mitochondrial ROS 
production, subtracting electrons from cytochrome c to produce O2
-. Superoxide is dismutated to 
hydrogen peroxide (H2O2) by superoxide dismutase 2 (SOD2) in the matrix and by SOD1 or SOD3 
in the intermembrane space. H2O2 is then reduced by enzymes such as glutathione peroxidase 
(GPx) which uses reduced glutathione (GSH) as an electron donor, resulting in oxidised glutathione 
(GSSG) formation (88;196;222;223). Pi, inorganic phosphate. Adapted from (88). 51 
One  important  regulator  of  mtROS  production  is  NO  which,  at  physiological 
concentrations,  modulates  O2  consumption  by  inhibiting  cytochrome  c  oxidase  in  a 
reversible manner (88;226). In this way, NO is able to regulate the mitochondrial redox 
state, facilitating release of the O2
- anion and other free radicals which act as NO-regulated 
signalling molecules (88;227). Nitric oxide-mediated inhibition of cytochrome c oxidase is 
also thought to underlie the increased mtROS production observed in hypoxic conditions 
(228). However, during periods of oxidative stress, mitochondrial NO reacts with O2
- to 
form  ONOO
-  which,  in  turn,  enhances  O2
-    production  by  the  ETC
  and  disrupts 
mitochondrial  integrity,  thus  contributing  to  the  pathogenesis  of  vascular  disease 
(88;222;223). 
 
Recent studies have also revealed a potential link between NAD(P)H oxidase-derived ROS 
and  mitochondrial  dysfunction  in  endothelial  cells.  Superoxide  produced  by  NAD(P)H 
oxidase is believed to directly activate mitochondrial ATP-sensitive K
+ channels or react 
with  NO  to  form  ONOO
-,  leading  to  respiratory  complex  damage  and  impaired 
mitochondrial function (229). 
 
 
1.3.4.3.1 Mitochondria in Type 2 Diabetes Mellitus 
 
Mitochondrial  ROS  have  a  fundamental  role  in  the  development  and  progression  of 
endothelial dysfunction and macrovascular disease in T2D, with hyperglycaemia shown to 
increase  generation  of  O2
-  from  the  mitochondrial  ETC  in  endothelial  cells  (230). 
Intracellular hyperglycaemia causes an increase in the mitochondrial proton gradient, a 
consequence of electron donor (NADH and reduced flavin adenine dinucleotide, FADH2) 
overproduction by the citric acid cycle (also known as the tricarboxylic acid (TCA) cycle 
or  citrate  cycle).  This,  in  turn,  leads  to  increased  mitochondrial  production  of  ROS. 
Increased  levels  of  mtROS  are  implicated  in  processes  known  to  contribute  to  the 
pathogenesis  of  diabetic  macrovascular  disease,  including  PKC  activation  and  AGE 
formation (88;222;230;231) (Figure 1.9). In addition, the elevated FFA flux and oxidation 
characteristic of visceral obesity and insulin resistance is known to induce mitochondrial 
ETC ROS production in endothelial cells (232) (Figure 1.9). 52 
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Figure  1.9.  Insulin  Resistance  and  Hyperglycaemia-induced  Mitochondrial  Superoxide 
Production  in  Activation  of  Atherogenic  Signalling  Pathways.  Elevated  mitochondrial 
superoxide  (O2
-)  production  caused  by  high  glucose  flux  through  endothelial  cells,  leads  to 
increased protein kinase C (PKC) activation and advanced glycation end-product (AGE) formation. 
This results in downstream activation of nuclear factor κB (NF-κB) which induces transactivation 
of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-
1). Transactivation of additional proatherogenic genes, such as plasminogen activator inhibitor-1 
(PAI-1) and transforming growth factor β1 (TGF-β1), occurs via a similar pathway. Increased flux 
of free fatty acids (FFAs), released from insulin-resistant adipocytes through vascular endothelial 
cells,  also  activates  atherogenic  signalling  pathways,  including  PKC  and  AGE  pathways. 
Futhermore,  FFA-induced  excess  mitochondrial  O2
-  production  inactivates  antiatherogenic 
enzymes  such  as  prostacyclin  (PGI2)  synthase  and  endothelial  nitric  oxide  synthase  (eNOS) 
(88;222;230;231). Adapted from (88). 53 
1.4 Mechanisms in Defence Against Oxidative Stress 
 
A  number  of  endogenous  anti-oxidant  defence  mechanisms,  both  enzymatic  and  non-
enzymatic,  operate  to  limit  ROS  levels  in  the  vasculature.  Non-enzymatic  anti-oxidant 
molecules include ascorbic acid (vitamin C), α-tocopherol (vitamin E) and glutathione, 
while  superoxide  dismutases  (SODs),  catalase  and  glutathione  peroxidases  (GPxs) 
represent important anti-oxidant enzymes which act to directly scavenge ROS, converting 
them to less reactive species (188;233) . 
 
 
1.4.1 Superoxide Dismutases 
 
The SODs represent the first and most important line of enzymatic anti-oxidant defence 
against ROS. A ubiquitous family of enzymes, SODs catalyse the conversion of O2
- to 
H2O2 and O2 (188;233;234) (Figures 1.5 and 1.8). Three distinct isoforms of SOD have 
been identified in vascular tissue. The first isoform, cytosolic copper/zinc (Cu/Zn) SOD, is 
an unusually stable homodimer encoded by the SOD1 gene. SOD1 is believed to be the 
predominant SOD isoform in the endothelium and is thought to lower O2
- concentrations 
from  the  nanomolar  to  picomolar  range  (188;233;234).  A  second  isoform,  encoded  by 
SOD2, is localised in mitochondria (Figure 1.8). This mitochondrial SOD functions as a 
homotetramer  and  utilises  manganese  (Mn)  as  a  cofactor  (234).  SOD3  encodes  the 
extracellular  SOD  (ecSOD),  a  copper/zinc-containing  tetramer  which  has  a  C  terminal 
heparin-binding region and is principally located in arterial smooth muscle cells in the 
vascular wall (234). 
 
The importance of SODs as an anti-oxidant defence mechanism has been highlighted by 
gene  transfer  studies  wherein  SOD  overexpression  improved  endothelial  function 
(235;236) and provided protection against myocardial infarction (237). Overexpression of 
SOD2  has  also  been  shown  to  prevent  hyperglycaemia-associated  production  of  O2
-, 
activation of PKC and AGE formation (230), supporting a role for mtROS production in 
diabetic macrovascular disease. 
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Expression  of  SOD  genes  may  be  upregulated  by  mechanical,  chemical  or  biological 
stimuli  and  downregulated  in  certain  pathological  conditions  (234).  In  addition,  SOD2 
expression is regulated post-transcriptionally by a specific RNA-binding protein (238). 
 
 
1.4.2 Catalase 
 
Catalase is the homotetrameric, haem-containing enzyme principally responsible for H2O2 
metabolism following dismutation of O2
- by SOD (188;233). An intracellular anti-oxidase, 
catalase is primarily located in peroxisomes but also functions in the cytosol and catalyses 
the  conversion  of  H2O2 to  water  and  O2  (188;233;239)  (Figure  1.5).  Inherited  catalase 
deficiency  has  been  linked  to  elevated  cardiovascular  risk  and  increased  incidence  of 
diabetes  mellitus  in  affected  families  (233).  However,  experimental  investigation  has 
provided evidence that catalase affords only moderate protection against oxidative stress 
(240) and while gene transfer studies showed reduced ROS production on co-expression of 
SOD and catalase, the relative contribution of each gene was not ascertained (241). 
 
 
1.4.3 Glutathione Peroxidases 
 
Glutathione, a tripeptide comprised of glutamate, cysteine and glycine, is the principal low 
molecular weight, non-protein thiol in the cell (188). Mainly found in the reduced state 
(GSH), glutathione has numerous functions in metabolism, signal transduction and gene 
expression (242). GSH acts as an electron donor and can directly scavenge ROS but also 
acts as a cofactor in the conversion of H2O2 to H2O by GPxs (188;233). 
 
The GPxs are a family of tetrameric enzymes with a role in both first and second line anti-
oxidant defence. Like catalase, GPxs act to reduce the H2O2 produced as a result of the 
dismutation of O2
- by SOD, transferring electrons from GSH to H2O2 with the subsequent 
formation  of  H2O  and  O2  and  conversion  of  GSH  to  oxidised  glutathione  disulphide 
(GSSG) (188;233;242;243) (Figures 1.5 and 1.8). 
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Despite the  actions of  first line anti-oxidant defence mechanisms, interactions between 
ROS  and  cellular  macromolecules  do  occur,  giving  rise  to  reactive  species  capable  of 
causing damage to lipids, proteins and nucleic acids. Detoxification of secondary oxidation 
products is therefore crucial and GPxs play their part, reducing lipid peroxides to their 
corresponding alcohols via the conjugation and oxidation of GSH (188;233;243) (Figure 
1.5). 
 
There  are  four  known  GPx  isoforms,  each  containing  selenocysteine  at  the  active  site 
(233). GPx1 knockout mice displayed increased susceptibility to ROS-induced oxidative 
stress (244), while induction of this isoform has been shown to offer protection against 
oxidative damage in endothelial cells (245). Furthermore, transgenic GPx1 expression was 
observed to impair endothelial dysfunction (246). Similarly, deficiency of GPx3 has been 
associated with decreased NO bioavailability and increased platelet-dependent thrombosis 
(233). 
 
Additional  selonoproteins  with  similar  anti-oxidant  activities  to  GPxs  include  the 
thioredoxins  (233),  while  the  glutathione-s-transferases  (GSTs)  are  examples  of  non-
selenocysteine containing enzymes of significant importance in secondary oxidative stress 
defence, acting to detoxify reactive electrophiles (233;243). 
 
 
 
1.5 AMP-activated Protein Kinase 
 
AMPK is a key molecule in the regulation of cellular energy homeostasis. A heterotrimeric 
serine-threonine kinase, human AMPK consists of a catalytic α-subunit and regulatory β- 
and γ-subunits, each of which has two or more isoforms which are encoded by distinct 
genes and are differentially expressed in various tissues (Figure 1.10) (247;248). AMPK is 
activated  in  response  to  metabolic  stresses,  such  as  glucose  deprivation,  hypoxia  and 
exercise, which cause a decrease in the cellular energy charge (247-250). When ATP levels 
fall,  there  is  a  corresponding  increase  in  intracellular  AMP  levels.  When  present  at 
increased concentration, AMP binds to the γ-subunit of AMPK, allosterically activating the 
enzyme.  AMP  binding  also  promotes  phosphorylation  at  a  critical  threonine  residue 
(Thr172) of the α-subunit by an upstream kinase, generating full activation of AMPK (251) 
(Figure 1.10). This upstream AMPK kinase (AMPKK) has been identified as a complex 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. AMPK-regulated Pathways in Endothelial Cells. The AMPK heterotrimer consists 
of α-, β- and γ- subunits. The α-subunit is responsible for the catalytic activity of the enzyme, 
involved in transferring a phosphate (P) molecule from ATP to a target protein to activate or 
inactivate it. The α-subunit also contains a phosphorylation site for regulation of AMPK activity. 
The β-  and  γ-  regulatory  subunits  are important  for  regulation  and  cellular localisation  of  the 
protein. Assembly of the heterotrimeric complex is essential for enzyme activity. When the γ-
subunit binds AMP, AMPK is allosterically activated and becomes a better substrate for LKB1. 
AMPK  is  also  regulated  by  upstream  kinase  Ca
2+  calmodulin-dependent  kinase  kinase  β 
(CaMKKβ) and elevated free fatty acid (FFA) and reactive oxygen species (ROS) levels. Studies 
suggest  AMPK  activation  improves  hyperglycaemia-mediated  endothelial  dysfunction  via  a 
number  of  pathways,  including  endothelial  nitric  oxide  synthase  (eNOS)  activation,  protection 
against the adverse effects of ROS formation, FFA oxidation, and prevention of inflammation via 
the inhibition of nuclear factor κB (NF-κB). Adapted from (252). 
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between  the  tumour  suppressor,  LKB1,  and  two  accessory  subunits,  STRAD  (STE-20 
related adaptor protein) and MO25 (251;253;254).   
 
Activated AMPK (pAMPK) acts to restore cellular ATP levels via mechanisms including 
the  insulin-independent  translocation  of  GLUT4  to  the  plasma  membrane  in  skeletal 
muscle and the subsequent activation of glycolysis (247;248;255). AMPK activation also 
promotes fatty acid oxidation, inhibition of acetyl CoA carboxylase (ACC) and fatty acid 
synthesis (256) and, as recently suggested, modulation of gene expression (257;258).  In 
addition, pAMPK mediates the effects of hormones, such as ghrelin (259), and adipokines, 
including resistin (248), leptin (260) and adiponectin (80;261), and is therefore involved in 
maintenance of energy balance at both the cellular and whole body level. Already a target 
for anti-diabetic drugs, metformin (137) and the thiazolidinediones (143), the finding that 
artificial  activation  of  AMPK  with  5-aminoimidazole-4-carboxamide  ribonucleoside 
(AICAR) (262) can mimic the effects of repeated exercise / endurance training in mice 
(263) has led to heightened interest in the enzyme as a potential therapeutic target for 
intervention in obesity, T2D and cardiovascular diseases. 
 
More recently, mechanisms independent of bioenergetic changes have been shown to be 
involved in AMPK activation. A second AMPKK has been identified as Ca
2+/calmodulin-
dependent  protein  kinase  kinase  (CaMKK),  in  particular  the  β  isoform  (CaMKKβ) 
(264;265),  revealing  increased  intracellular  Ca
2+  as  an  alternative  stimulus  for  AMPK 
activation.  Additionally,  signalling  by  ROS  has  been  implicated  in  activation  of  the 
enzyme (228;266). Such findings imply AMPK may have a role outwith the regulation of 
energy homeostasis.  
 
 
1.5.1 AMP-activated Protein Kinase in Type 2 Diabetes Mellitus 
 
A key effect in the up-regulation of ATP-generating catabolic pathways by AMPK is the 
stimulation  of  glucose  uptake  which  occurs  as  a  result  of  increased  translocation  of 
GLUT4  to  the  plasma  membrane,  activation  of  GLUT1  at  the  plasma  membrane  and 
enhanced  transcription  of  the  GLUT4  gene.  The  latter  effect  may  be  responsible  for 
increased expression of GLUT4 in response to endurance training which can subsequently 
lead to increased insulin-stimulated glucose uptake (247). With reduced insulin-stimulated 58 
glucose uptake via GLUT4 a central feature of insulin resistance, the mechanism by which 
exercise and AMPK activation stimulate this process in an insulin-independent manner is 
currently of great interest in diabetes research. The exact manner in which AMPK mediates 
GLUT4 translocation remains to be fully elucidated but studies suggest a potential role for 
Akt substrate of 160kDa (AS160) (267;268) (Figure 1.4). 
 
As  previously  described,  the  hyperglycaemia  of  T2D  results  from  a  reduced  ability  of 
insulin  to  both  repress  glucose  production  by  the  liver  and  increase  glucose  uptake  in 
peripheral tissues. Hepatic AMPK activation has been shown to down-regulate expression 
of the gluconeogenic enzymes PEPCK and G6Pase (269) and activation of the kinase is 
thought to underlie the ability of adiponectin to reduce hepatic glucose production (80). 
The transcriptional co-activator, TORC2, a target of AMPK, has recently been proposed as 
being involved in mediating this effect (270).  
 
By inhibiting fatty acid synthesis and stimulating fatty acid oxidation, AMPK activation 
reduces  excessive  storage  of  triglycerides,  which  in  non-adipose  cells  results  in  the 
lipotoxicity associated with insulin resistance. AMPK inhibits fatty  acid synthesis both 
acutely, by phosphorylating and inactivating the ACC1 isoform of acetyl-CoA carboxylase 
(262), and in the longer term by switching off expression of lipogenic genes, including 
ACC1 and fatty acid synthase (271). The kinase stimulates oxidation of fatty acids by 
phosphorylating  and  inactivating  the  ACC2  isoform  of  acetyl-CoA  carboxylase.  This 
lowers malonyl-CoA, thus relieving inhibition of fatty acid uptake into mitochondria (272). 
 
A further catabolic action of AMPK is the promotion of mitochondrial biogenesis via up-
regulation  of  PPAR-γ  co-activator-1α  (PGC-1α)  (273).  Again,  this  is  likely  to  prove 
beneficial in insulin resistant states where a deficit in mitochondrial function is thought to 
predispose to development of T2D (225). 
 
In addition, AMPK activation is known to inhibit activation of the mTORC1 pathway by 
the insulin signalling pathway (Figure 1.4), via phosphorylation of the tuberous sclerosis 
complex (TSC), an upstream regulator of mTORC1 (55). The insulin-mTORC1 pathway is 
believed to exert a negative feedback effect on insulin signalling via activation of p70 
ribosomal S6 kinase (p70S6K) (see Figure 1.4) and subsequent phosphorylation and down-
regulation of IRS-1. Consequently, AMPK activation may increase insulin sensitivity by 59 
inhibiting mTORC1 (55;247;274). This effect could explain the ability of AMPK activator, 
AICAR to mimic the effects of exercise in increasing muscle insulin sensitivity. 
 
AICAR was the first relatively specific compound shown to activate AMPK in intact cells 
(262).  The  nucleoside  is  taken  up  and  accumulates  inside  the  cell  as  the 
monophosphorylated nucleotide 5’-aminoimidazole-4-carboxamide ribonucleotide (ZMP), 
which activates AMPK without disturbing cellular adenine nucleotide ratios (262;275). As 
such, effects observed on administration of AICAR are not merely due to depletion of 
ATP. AICAR has been shown to reverse insulin resistance and lower blood pressure in 
animal models such as the ob/ob mouse (276), the fa/fa rat (277) and the high fat-fed rat 
(278). 
 
As previously mentioned, anti-diabetic drugs, metformin and the thiazolidinediones also 
activate AMPK. Neither activate the kinase directly, potentially achieving activation by 
inhibiting  complex  I  of  the  ETC,  thus  increasing  the  cellular  AMP:ATP  ratio  (279). 
However, as stated, the major target of the thiazolidinediones is the transcription factor, 
PPAR-γ.  In  adipocytes,  the  thiazolidinediones  act  on  PPAR-γ  to  stimulate  release  of 
adiponectin  and  the  effects  of  the  drugs  in  reversing  insulin  resistance  and  improving 
glucose  tolerance  are  greatly  reduced  in  adiponectin  knockout  mice  (280;281).  Recent 
evidence  suggests  adiponectin  acts  primarily  by  activating  AMPK,  indicating  the 
thiazolidinediones  exert  a  portion  of  their  therapeutic  benefit  via  two  independent 
mechanisms serving to activate AMPK (247). 
 
 
1.5.2 AMP-activated Protein Kinase in The Vascular Endothelium 
 
Activated AMPK is known to phosphorylate eNOS at Ser1177 in cultured endothelial cells 
(176;282) and has been shown to increase endothelium-dependent vasodilation in response 
to shear stress (283). Infection of endothelial cells with adenoviruses expressing dominant-
negative  mutant  AMPK  has  demonstrated  a  key  role  for  AMPK  in  NO  production  in 
response  to  AICAR,  hypoxia,  ONOO
-,  metformin,  adiponectin,  shear  stress,  vascular 
endothelial  growth  factor  (VEGF)  and  rosiglitazone  (176;283-289).  It  has  also  been 
proposed  that  AMPK  mediates  adiponectin-  and  hypoxia-stimulated  angiogenesis 
(290;291). Incubation with AICAR has recently been reported to reduce TNFα-stimulated 60 
monocyte adhesion, NF-κB activation and mRNA expression of ICAM-1, VCAM-1 and E-
selectin in mouse brain endothelial cells (292;293), while metformin has been reported to 
have similar effects in human umbilical vein endothelial cells (HUVECs) (294), revealing 
the potential anti-atherogenic benefits of AMPK activation. With increasing evidence to 
suggest AMPK is activated in a ROS-mediated manner (228;266;289;295-297), it has been 
proposed that the enzyme exerts its beneficial effect on endothelial function by increasing 
NO  bioavailability  and  facilitating  an  anti-oxidative  response  in  the  endothelium  (252) 
(Figure 1.10). 
 
As stated, the endothelial dysfunction characteristic of T2D is associated with elevated 
levels  of  circulating  FFAs  (39;88;232).  Activated  AMPK  phosphorylates  and  inhibits 
ACC, thus accelerating mitochondrial fatty acid oxidation (256). However, high levels of 
FFAs may trigger inhibition of AMPK (252) (Figure 1.10) and reduced AMPK activation 
has  been  linked  to  FFA-induced  development  of  endothelial  dysfunction  in  obese  rats 
(298).  Furthermore,  AMPK  activation  inhibits  fatty  acid-induced  increases  in  NF-κB 
transactivation in vascular endothelial cells (252;294), further supporting a protective role 
for the enzyme in atherogenic and inflammatory vascular disease. 
 
These  downstream  consequences  of  endothelial  AMPK  activation  may  explain  the 
beneficial effects of metformin and the thiazolidinediones on vascular outcomes in patients 
with T2D and highlight why AMPK is increasingly recognised as a potential therapeutic 
target  in  defence  against  oxidative  stress  and  prevention  of  endothelial  dysfunction  in 
cardiovascular diseases such as CAD and T2D. 
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1.6 Aims 
 
Previously, studies within this laboratory have demonstrated endothelial dysfunction and 
elevated O2
- production in vessels from patients with advanced CAD (159). However, the 
molecular basis for this increase was not investigated, nor was the effect of type 2 diabetes. 
The aim of this study therefore, is to investigate a number of molecular determinants of 
oxidative stress and T2D in primary human vascular cells from patients with CAD, the 
hypothesis  being  that  oxidative  stress  leads  to  endothelial  dysfunction  in  CAD  and  is 
exacerbated in those patients with T2D. 
 
The specific aims of this study are: 
(1) to  establish  sources  of  O2
-  production  in  primary  vascular  cells  isolated  from 
patients with advanced CAD and determine how the presence of T2D affects their 
contribution to cellular ROS generation; 
(2) to examine the activity and activation of AMPK in primary cultures of endothelial 
cells isolated from patients with CAD and T2D; 
(3)  to  investigate  how  T2D  alters  gene  expression  in  the  endothelium  of  CAD 
patients. 62 
 
 
 
 
 
2. Materials & Methods 
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This chapter outlines general laboratory practices and methods that are common to more 
than  one  chapter.  Each  individual  results  chapter  has  a  specific  Materials  &  Methods 
section. 
 
 
2.1 General Laboratory Practice 
 
Laboratory equipment and reagents were of the highest available grades. A laboratory coat 
and latex powder-free  gloves were worn during all procedures. Handling of hazardous 
reagents was in accordance with Control of Substances Hazardous to Health regulations, 
utilising laboratory spectacles, facemasks and fume hoods where necessary. 
 
Laboratory glassware was cleaned in Decon 75 detergent (Decon Laboratories Ltd.), rinsed 
with distilled water and dried in a 37ºC cabinet. Sterile, disposable plastic-ware utilised 
included 0.5 ml, 1.5 ml and 2 ml microcentrifuge tubes (Greiner Bio-One), 15 ml and 50 
ml  Corning  centrifuge  tubes  and  5  ml  and  20  ml  Universal  containers  (Sterilin). 
Laboratory-ware requiring sterilisation was autoclaved in a Priorclave Tactrol 2. 
 
Reagents were weighed using an Ohaus Portable Advanced balance (sensitive to 0.01 g), 
or a Mettler HK160 balance (sensitive to 0.0001 g). The pH of solutions was determined 
using a Mettler Toledo digital pH meter, calibrated on a regular basis with solutions of pH 
4.0, 7.0 and 10.0 prepared from buffer tablets [Sigma-Aldrich Company Ltd (Sigma), St 
Louis, MO, U.S.A.]. Volumes from 0.1  l to 1,000  l were dispensed using appropriate 
Gilson pipettes (Gilson Medical Instruments). Volumes from 1 ml to 25 ml were measured 
with  sterile  disposable  pipettes  (Corning)  and  a  Gilson  battery-powered  pipetting  aid. 
Distilled water (dH20) was used to prepare aqueous solutions unless otherwise indicated 
and  a  Jenway  1000  hotplate/stirrer  used  to  aid  dissolving  and  mixing.  Vortexing  was 
carried out using an FSA Laboratory Supplies WhirliMixer. Centrifugation of samples up 
to 2 ml was performed at 4 - 20ºC in an Eppendorf 4515 microcentrifuge while samples of 
larger  volumes  were  centrifuged  in  a  Sigma  4K15,  compatible  with  15  ml  and  50ml 
centrifuge tubes, 20 ml Universal tubes and including carriers for standard reaction plates. 
A Julabo TW8 water bath was utilised for experiments requiring incubations from 37ºC to 
90ºC and a Grant SBB14 boiling water bath used where temperatures up to 100ºC were 
required. 
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For experiments involving ribonucleic acid (RNA), certified nuclease-free reagents and 
plastic-ware  were  used,  including  nuclease-free  H2O  (Ambion,  Austin,  TX,  U.S.A.), 
Ambion RNase-free microcentrifuge tubes and RAININ nuclease-free pipette tips. Pipettes 
and benches were wiped with Ambion RNaseZap reagent prior to all RNA experiments. 
 
 
 
2.2 Recruitment & Clinical Assessment of Study Participants 
 
Recruitment and clinical assessment of patients was carried out by Dr Jane Dymott. 
 
Seventy  nine  patients  with  severe  CAD  from  cardiothoracic  pre-operative  clinics  were 
recruited.  Twenty  three  patients  had  a  history  of  T2D  for  at  least  4  weeks  prior  to 
admission for surgery. Type 2 diabetes was defined as having fasting venous blood glucose 
≥ 6.1 mM or ≥ 10 mM two hours post oral glucose load (75 g). Nineteen control subjects 
free of evidence of CAD who were undergoing surgery for the removal of varicose veins 
were also recruited. The study was approved by the Glasgow West Ethics Committee and 
participants gave their written informed consent prior to participation.  
 
Demographic and clinical characteristics of patients and control subjects are given in Table 
2.1. As expected, patients with CAD were older and more likely to be on cardiovascular 
medication  than  control  subjects.  Total  and  low  density  lipoprotein  (LDL)  cholesterol 
levels were lower in patients with CAD compared to control subjects, consistent with lipid 
lowering therapy in the CAD patient group. High density lipoprotein (HDL) cholesterol 
levels were significantly greater in control subjects compared to patients. Patients with 
T2D had greater body mass index and greater percentage of glycosylated haemoglobin A1c 
but no other significant differences to patients without diabetes were observed. Forty three 
percent of patients with T2D were treated with metformin. 65 
 
  CAD  Controls 
  T2D 
 
n=23 
ND 
 
n=56 
P value 
T2D vs 
ND 
 
 
n=19 
P value 
CAD vs 
controls 
Age (years)  65±11  65±9  0.961  44±19  <0.001 
Sex (m:f)  20/3  45/11  0.747  8/11  0.001 
BMI (kg/m²)  31.7±5.2  28.6±4.7  0.026  26.5±1.9  0.004 
SBP (mmHg)  138±22  138±26  0.897  132±23  0.471 
DBP (mmHg)  73±13  80±11  0.065  84±12  0.162 
Total cholesterol 
(mmol/L) 
3.95±1.10  4.11±0.99  0.542  4.96±0.99  0.029 
LDL cholesterol 
(mmol/L) 
1.80±0.83  2.00±0.78  0.314  2.69±1.11  0.024 
HDL cholesterol 
(mmol/L) 
1.11±0.22  1.17±0.27  0.366  1.72±0.30  <0.001 
Triglycerides (mmol/L)  2.54±1.97  2.04±0.97  0.262  1.17±0.47  0.052 
CRP (mg/L)  2.5±2.9  5.0±10.5  0.280  3.5±4.2  0.843 
HbA1c (%)  7.2±1.3  5.6±0.4  <0.001  5.4±0.2  0.111 
Active smoking (y/n)  2/22  2/54  0.579  2/17  0.324 
ACEI/ARB (y/n)  18/5  32/24  0.122  1/18  <0.001 
Statin (y/n)  21/2  53/3  0.625  2/17  <0.001 
Metformin (y/n)  10/13  0/56  <0.001  0/19  <0.001 
 
Table 2.1. Characteristics of the Study Cohort. Continuous data are given as mean ± standard 
deviation irrespective of distribution or skewness. P values, however, derive from Student's t-test 
or Mann-Whitney U-test as appropriate. Comparison between categorical data was performed using 
Fisher's exact test. CAD, coronary artery disease; BMI, body mass index; SBP, systolic blood 
pressure;  DBP.  diastolic  blood  pressure;  LDL,  low  density  lipoprotein;  HDL,  high  density 
lipoprotein; CRP, C-reactive protein; HbA1c, glycosylated haemoglobin A1c; ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker 
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2.3 Human Vascular Tissue 
 
Freshly obtained saphenous veins from patients undergoing coronary artery bypass graft 
(CABG) surgery were stored in sterile saline solution by the surgical team at Glasgow 
Western  Infirmary  until  collection.  Control  vessels  from  patients  undergoing  elective 
varicose vein removal were stored in the same way by the surgical team at Glasgow’s 
Gartnavel General. Maximum storage time was 2 hours. Only non-varicosed portions of 
veins from control patients, as identified by the surgical team, were utilised. Samples were 
taken to the laboratory and cleaned of excess connective tissue. Endothelial cells were 
isolated from portions of vessels on the day of surgery and the remainder of samples stored 
at  4°C  in  a  Krebs  4-(2-hydroxyethyl)-1-piperazineethanesulfonic  acid  (HEPES)  buffer 
[118 mM NaCl, 10 mM Hepes, pH 7.4, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM MgSO4, 
1.2 mM KH2PO4, 11 mM glucose, 10 mM indomethacin, 50 µM ethylenediamine tetra-
acetic acid (EDTA)] for study of endothelial function and O2
- production the following 
day. 
 
 
 
2.4 Isolation & Culture of Primary Cells 
 
Primary cells were handled under sterile conditions using class II biological safety cabinets 
(Holten  Safe  2010).  Cabinets  were  cleaned  before  and  after  use  with  dH2O  and  70% 
ethanol. Waste plastics and fluid were decontaminated by steeping for 24 hours in (10%) 
bleach  before  plastics  were  incinerated  and  fluids  emptied  into  domestic  waste  drains. 
Cells were cultured in 100 mm x 20 mm cell culture dishes and 25 cm
2, 75 cm
2 and 150 
cm
2 culture flasks with vented caps (Corning). 
 
 
2.4.1  Isolation  of  Primary  Endothelial  Cells  from  Human  Saphenous 
Vein 
 
Human saphenous vein endothelial cells (HSVECs) were isolated on the day of surgery by 
standard collagenase digestion based on a modified version of the protocol described by 67 
Jaffe and colleagues (299). In summary, saphenous veins were gently flushed of remaining 
blood with wash medium [Dulbecco’s Modified Eagle’s Medium (DMEM), 1000 mg/l 
glucose, without phenol red (Invitrogen
™, Paisley, U.K.) and supplemented with 100 IU/ml 
penicillin, 100  g/ml streptomycin and 2 mM L-glutamine]. Veins were then filled with a 
solution of filter-sterilised collagenase [(Sigma), 2 mg/ml in wash medium] and the vessel 
incubated  at  37°C  in  a  sterile  petri  dish  in  5%  CO2  for  15  minutes.  Endothelial  cell 
suspensions were obtained by flushing the vein with wash medium and collecting flow-
through. Veins were then refilled with collagenase and incubated at 37°C for a further 10 
minutes.  Collagenase  was  flushed  through  and  cells  collected  and  pelleted  by 
centrifugation  (2,000  x  g,  5  minutes,  room  temperature).  Cells  were  resuspended  in 
complete  Large  Vessel  Endothelial  Cell  Basal  Medium  (TCS  Cellworks  Ltd,  Botolph 
Claydon, Bucks, U.K.), supplemented with 20% (v/v) foetal calf serum (FCS), 100 IU/ml 
penicillin,  100   g/ml  streptomycin  and  2  mM  L-glutamine  (endothelial  cell  growth 
medium), and then incubated for 24 hours before a complete medium change. Cells were 
cultured in complete growth medium and used between passages 1 and 5. 
 
 
2.4.2 Isolation of Primary Vascular Smooth Muscle Cells from Human 
Saphenous Vein 
 
Following HSVEC isolation, vessel portions were stored overnight at 4ºC in a HEPES-
containing  buffer  [DMEM,  1000  mg/l  glucose,  +  L-glutamine,  +  25  mM  HEPES,  + 
pyruvate  (Invitrogen
™),  supplemented  with  10%  (v/v)  FCS,  100  IU/ml  penicillin,  100 
 g/ml  streptomycin].  The  following  day  human  saphenous  vein  smooth  muscle  cells 
(HSVSMCs) were obtained from medial explants of these portions of saphenous veins 
according to the method described by Southgate and Newby (300). Briefly, segments of 
vein were cut longitudinally and pinned out with the endothelial surface uppermost. The 
medial layer was scored with a sterile scalpel, peeled away from the adventitial layer and 
then cut into 1mm
2 size pieces using  a McIlwain Tissue Chopper. Explants were then 
incubated  at  37°C  in  5%  CO2  in  minimal  medium  until  they  adhered  to  the  flask 
(approximately 24 hours). Subsequently, explants were cultured in 7.5 ml of DMEM (4500 
mg/L  glucose,  +  Glutamax-1),  supplemented  with  100  IU/ml  penicillin,  100   g/ml 
streptomycin and 20% (v/v) FCS (smooth muscle cell growth medium), at 37°C in 5% 68 
CO2. Medium was changed once a week until HSVSMCs had migrated from the explants 
and then every 3 days for subsequent passages. 
 
 
2.4.3 Primary Cell Culture & Passage 
 
As  stated,  cells  were  maintained  in  complete  growth  medium.  Confluent  cultures  of 
primary  cells  were  passaged  by  trypsin-EDTA.  Cells  were  washed  twice  in  sterile 
Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS, Lonza, Verviers, 
Belgium) and incubated at 37ºC in trypsin-EDTA (0.05% trypsin, 0.02% EDTA) for 5 
minutes or until the majority of cells had detached from the flask. The action of trypsin-
EDTA was then blocked by the addition of an equal volume of growth medium containing 
20% (v/v) FCS. Cells were harvested by centrifugation at 1,500 x g and resuspended in 
fresh growth media before plating. 
 
 
2.4.4 Immunocytochemical Characterisation of HSVECs & HSVSMCs 
 
HSVECs were identified by immunofluorescent staining for von Willebrand factor (vWF) 
and HSVSMCs by immunofluorescence for SMC-α-actin. Primary antibodies were mouse-
anti-human vWF (clone F8/86, MO616) and mouse-anti-human smooth muscle α actin 
(clone 1A4, M0851), both from Dako-Cytomation (Dako, Glostrup, Denmark). 
 
At passage 1 HSVECs and HSVSMCs were harvested and plated onto sterile coverslips in 
6 well plates. Sixteen hours later media were removed, cells washed twice in PBS and 
fixed in 4% paraformaldehyde for 5 minutes at room temperature. Cells were washed twice 
more in PBS and then incubated with the appropriate primary antibody (1:50 for anti-vWF 
and 1:2000 for anti-SMC-α-actin, both in 20% goat serum/PBS) at room temperature for 
30 minutes. This was followed by 3 washes in PBS. Cells were then incubated with goat-
anti-mouse IgG-fluoroscein isothiocyanate (FITC) conjugate (Dako) secondary antibody 
(1:200 in 20% goat serum/PBS) for 30 minutes at room temperature and washed a further 3 
times  in  PBS.  Cell-free  sides  of  coverslips  were  subsequently  washed  with  dH2O, 
coverslips mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, U.S.A.), 69 
containing  propidium  iodide  for  nucleic  counter-staining,  and  cells  visualised  under  a 
fluorescence microscope at x 40 and x 100 magnifications.  
 
 
2.4.5 Cryo-preservation of HSVECs 
 
At passage 3, cell cultures were harvested as described in section 2.4.3 and resuspended at 
a  density  of  approximately  1  -  2  x  10
7  cells/ml  in  cryo-preservation  media  [complete 
culture  media  supplemented  with  10%  (v/v)  dimethyl  sulphoxide  (DMSO,  Fisher 
Scientific, Pittsburgh, PA, U.S.A.). Cell suspensions were aliquoted into sterile 2 ml cryo-
vials and cooled at a constant -1ºC/minute to -80ºC using isopropanol. Vials were then 
transferred to liquid nitrogen and stored until required for analysis.  
 
For  resuscitation,  vials  were  removed  from  the  liquid  nitrogen  store  and  pre-warmed 
culture medium slowly added until contents thawed. Cells were then plated and DMSO-
containing medium replaced with fresh medium the following day. 
 
 
 
2.5 Extraction, Purification & Quantification of RNA from HSVECs 
 
2.5.1 RNA Extraction 
 
RNA was routinely extracted from HSVECs at passage 3.  
 
RNA  was  isolated  using  the  RNeasy
®  Mini  Kit  (QIAGEN)  and  according  to  the 
manufacturer’s guidelines. Cells were pelleted, supernatants removed and pellets loosened 
by flicking the tube. Cells were then resuspended in one volume (600  l) Buffer RLT 
containing  0.01%  (v/v)  β-mercaptoethanol.  Samples  were  homogenised  by  repeated 
pipetting. One volume of 70% ethanol was added to the homogenised lysate and samples 
mixed well by pipetting. Up to 700  l of sample was then applied to an RNeasy mini 
column placed in a collection tube and centrifuged for 15 seconds at 8,000 x g and room 
temperature.  Flow-through  was  discarded  and  700   l  Buffer  RW1  added  to  columns. 70 
Samples  were  then  centrifuged  as  before  and  flow-through  discarded.  Columns  were 
transferred to fresh collection tubes and 500  l Buffer RPE added. Centrifugation was 
carried out as before to wash columns and flow-through discarded before another 500  l 
Buffer RPE was added and samples centrifuged (2 minutes, 8,000 x g, room temperature) 
to  dry  the  RNeasy  silica-gel  membrane.  To  eliminate  the  possibility  of  Buffer  RPE 
carryover, collection tubes containing flow through were discarded and columns placed in 
fresh  tubes  for  centrifugation  at  14,000  x  g  (room  temperature)  for  1  minute.  RNeasy 
columns were transferred to new collecting tubes and 40  l RNase-free water pipetted 
directly onto the silica-gel membrane. Samples were then centrifuged for 1 minute at 8,000 
x g and room temperature to elute. To increase RNA yield, the elution step was repeated, 
re-using the original volume of RNAse-free water. RNA samples were stored at -70ºC until 
time of analysis. 
 
 
2.5.2 DNase Treatment of Extracted Total RNA 
 
In order to remove any contaminating DNA, extracted total RNA was treated with DNase 
using  the  TURBO  DNA-free™  kit  from  Ambion  and  according  to  the  manufacturer’s 
instructions. In summary, 0.1 volume (4 µl) 10 X TURBO DNase Buffer and 1 µl TURBO 
DNase (2 U/µl) were added to RNase-free tubes containing 40 µl RNA samples. Samples 
were then incubated at 37ºC for 25 minutes. Following incubation, 0.1 volume (4.4 µl) 
DNase  Inactivation  Reagent  was  added  to  tubes.  Samples  then  underwent  a  further  2 
minute  incubation  at  room  temperature  with  occasional  mixing,  before  a  1.5  minute 
centrifugation at 10,000 x g and 4ºC. Supernatants containing DNase treated total RNAs 
were  transferred  to  fresh,  RNase-free  tubes  and  stored  at  -70ºC  for  downstream 
applications. 
 
 
2.5.3 RNA Quantification 
 
Total  RNA  concentrations  were  quantified  using  the  NanoDrop
®  ND-100 
Spectrophotometer and  ND-1000 v3.1.0 programme (Labtech  International  Ltd,  Lewes, 
East Sussex, U.K.). For each sample, 2 µl total RNA was quantified. 71 
2.6 Extraction & Quantification of Protein from HSVECs 
 
2.6.1 Protein Extraction 
 
Protein was routinely extracted from HSVECs at passage 3.  
 
For protein extraction, cells were permeabilised in 0.2% Triton X 100 (Sigma) and samples 
homogenised by at least 20 passes through a 21-gauge needle (0.8 mm diameter) fitted to a 
syringe. Protein samples were stored at -20ºC until required.  
 
 
2.6.2 Determination of Protein Concentration 
 
Protein concentrations were determined using a Pierce BCA (bicinchoninic acid) Protein 
Assay  kit  (Thermo  Scientific,  Waltham,  MA,  U.S.A.)  according  to  the  manufacturer’s 
instructions. Assays were performed in 96-well plates. Dilutions of an albumin protein 
standard  (provided)  ranging  from  25  ng/ l  –  2   g/ l  were  made  in  PBS  and  used  to 
generate a standard curve for each assay. Reagents A and B included in the kit were mixed 
at a ratio of 50:1 respectively before being added to protein samples and standards at a 
ratio  of  8:1  (25   l  sample/standard,  200   l  BCA  reagents  mixture).  Plates  were 
subsequently protected from light in aluminium foil and placed at 37ºC for 30 minutes. 
Absorbance at 560 nm was determined for all wells using a Wallac Victor
2 plate reader 
(Wallac, Turku, Finland). Both samples and standards were measured in duplicate and an 
average value calculated. Concentration of protein in each sample was then interpolated 
from the standard curve by Work-Out software (Wallac). 
 
 
2.6.3 Cell Lysate Preparation 
 
Passage 3 HSVECs were grown in 100 mm diameter cell culture dishes until confluent and 
then serum-starved overnight. Medium was removed and cell lysates prepared. Briefly, 0.4 
ml of ice-cold lysis buffer [50 mM Tri-HCl, pH 7.4 at 4ºC, 50 mM NaF, 5 mM Na4P2O7, 1 72 
mM  NaVO3,  1mM  EDTA,  1mM  ethylene  glycol  tetra-acetic  acid  (EGTA),  0.1  mM 
benzamidine,  0.1  mM  phenylmethylsulfonylfluoride  (PMSF),  5  µg/ml  soybean  trypsin 
inhibitor, 1% (w/v) glycerol, 1% (w/v) Triton X 100] was added and cell extract scraped 
off  and  transferred  to  a  microcentrifuge  tube.  Extracts  were  then  vortexed-mixed  and 
centrifuged  (14,000  x  g,  1  min,  4ºC).  Total  protein  concentration  of  each  sample  was 
determined as outlined in section 2.6.2. Cell lysates were stored at -20ºC when not required 
immediately. 
 
 
 
2.7 HSVEC mRNA Expression 
 
RNA was routinely isolated from passage 3 HSVECs as described in section 2.5. 
 
 
2.7.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
First strand complementary DNA (cDNA) was synthesised from 1 µg of DNase-treated 
total  RNA  using  the  TaqMan
®  Reverse  Transcription  Reagents  kit  from  Applied 
Biosystems  and  following  the  manufacturer’s  guidelines.  RNA  samples  were  reverse 
transcribed to cDNA in a 20 µl reaction containing a final concentration of 5.5 mM MgCl2, 
500 µM of each deoxyribonucleotide triphosphate (dNTP), 2.5 µM Random Hexamers, 0.4 
U/µL RNase Inhibitor, 1.25 U/µL MultiScribe Reverse Transcriptase and 1 X TaqMan
® 
RT  Buffer.  Selected  samples  were  used  for  negative  control  reactions  which  did  not 
contain MultiScribe Reverse Transcriptase. Samples were then incubated at 25ºC for 10 
minutes  to  maximize  primer-RNA  template  binding  before  being  held  at  48ºC  for  30 
minutes  to  facilitate  reverse  transcription.  Reverse  Transcriptase  was  inactivated  by 
incubating samples at 95ºC for 5 minutes before samples were placed on ice and diluted, in 
nuclease-free water, to a final volume of 50 µl. When not being used immediately, samples 
were stored at -20ºC. 
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2.7.2 TaqMan
® Real-Time RT-PCR 
 
Real-time RT-PCR quantitation of samples was carried out via a two-step RT-PCR assay 
utilising TaqMan
® Gene Expression Assays (Applied Biosystems).  
 
Prior to real-time RT-PCR reactions, an efficiency assay was performed for each gene of 
interest. Serial dilutions of pooled, neat cDNAs were set up in singleplex and multiplex 
reactions to determine whether the gene of interest amplified with equal efficiency to that 
of a reference/housekeeping gene [β-actin or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH)]. Efficiencies, as calculated according to the manufacturer’s instructions (ABI 
PRISM 7700 Sequence Detection System User Bulletin #2), were considered to be equal if 
the absolute value of the slope was < 0.1. 
 
Following  efficiency  tests,  multiplex  reactions  were  carried  out  for  genes  of  interest 
reacting with similar efficiency to a reference gene. Each multiplex reaction was of 5 µl 
volume,  consisting  of  2.5  µl  TaqMan
®  Universal  PCR  Master  Mix,  1  X  VIC-labelled 
reference probe, 1 X FAM-labelled probe for gene of interest and 2  l cDNA. Reactions 
were  carried  out  in  barcoded  384-well  plates.  For  genes  of  interest  with  relative 
efficiencies dissimilar to those of reference genes, reactions were carried out in singleplex 
(with equal volumes of nuclease-free water in place of the relevant probe) but within the 
same plate. The 2
-  Ct comparative method (301) was used for the relative quantitation of 
gene expression according to the manufacturer’s instructions (ABI PRISM 7700 Sequence 
Detection System User Bulletin #2). 74 
2.8 HSVEC Protein Expression 
 
Cell  lysates  were  prepared  and  protein  routinely  isolated  from  passage  3  HSVECs  as 
described in section 2.6. 
 
 
2.8.1 Western Blot Assessment of Protein Expression 
 
Protein samples were mixed with an equal amount of reducing loading dye (125 mM Tris 
pH 6.8, 4% (v/v) SDS, 10% (v/v) glycerol, 0.006% (v/v) bromophenol blue, 2% (v/v) β-
mercaptoethanol) and subsequently denatured by incubating them for 10 minutes at 99ºC. 
Equal amounts (in the range of 20 µg to 50  g) of total protein were then resolved using 
sodium  dodecyl  sulphate  polyacrylamide  gel  electrophoresis  (SDS/PAGE).  12% 
polyacrylamide gels (containing 40% (v/v) polyacrylamide (30%), 11.25 mM Tris pH 8.8, 
0.1% (v/v) SDS, 300  l ammonium persulphate (APS) and 30 µl TEMED) were used. A 
4% stacking gel (13.3% (v/v) polyacrylamide (30%), 3.75 mM Tris pH 6.8, 0.1% SDS, 
300 µl APS and 30 µl TEMED) was used with each gel. 15  l of Amersham Rainbow 
Markers (GE Healthcare U.K. Ltd, Bucks, U.K.) were included in each blot. These protein 
molecular weight markers were either low range [2.5 kilodaltons (kDa) – 45 kDa] or full 
range (10 kDa – 250 kDa). 
 
Proteins were transferred onto Hybond-P nitrocellulose membranes (Amersham Bioscience 
U.K. Ltd) overnight at 90 milliAmps (mA) in transfer buffer containing 0.025 M Tris, 0.2 
M glycine, 20% (v/v) methanol, 0.01% (v/v) SDS. Membranes were then blocked (with 
shaking) in TBS-T [150 mM NaCl, 50 mM Tris, 0.1% (v/v) Tween-20] + 10% (w/v) fat-
free milk powder (blocking buffer) for approximately 6 hours before overnight incubation 
at 4ºC (with shaking) in a primary antibody solution. Primary antibodies were diluted to 
appropriate concentrations in blocking buffer. Membranes were then washed 6 times in 
TBS-T at room temperature with each wash lasting approximately 5 minutes. Secondary 
antibodies were also diluted in blocking buffer and incubated with membranes at room 
temperature for 2 hours with shaking. A further six 5 minute washes in TBS-T were then 
performed. 75 
Proteins were visualised using Amersham
™ ECL
™ (enhanced chemiluminescence) Western 
Blotting Detection Reagents (GE Healthcare) as per the manufacturer’s instructions. Films 
were exposed for varying lengths of time, ranging from 30 seconds to overnight. 
 
 
2.8.2 Densitometric Quantification of Protein Bands 
 
Immuno-detected bands on photographic film were scanned on a Mercury 1200c scanner, 
using  Adobe  Photoshop  software,  to  generate  a  digital  image.  Individual  bands  were 
labeled and demarcated by boxes using a drawing tool and the intensity of bands measured 
using Scion Image or ImageJ software and expressed in units of optical density per mm
2 
(ODU/mm
2). 
 
Two methods of background subtraction were used for densitometrical analyses. For blots 
with clean and constant background intensities, a ‘global’ background subtraction method 
was  used.  This  involved  drawing  a  box  in  an  area  of  the  image  representative  of  the 
background, thus allowing the software to calculate the average intensity of pixellation in 
this  box  and  subtracting  this  value  from  pixel  intensity  in  all  boxes  containing  bands. 
Alternatively,  a  ‘local’  background  subtraction  method  was  used  for  blots  where  the 
background intensity level was variable across the blot. Here, the software calculated an 
average background intensity for each box by measuring the average intensity of all pixels 
in a one pixel border around each box and subtracted this from each pixel in the box to 
determine band intensity. 
 
 
 
2.9 Statistical Analysis 
 
For clinical data and measurements in whole vessels, continuous data are given as mean ± 
standard  deviation  or  median  (interquartile  range),  unless  otherwise  indicated.  Values 
stated are means ± standard error of the mean (SEM) for cellular data, unless otherwise 
indicated. For comparisons of a continuous variable between 2 experimental groups, paired 
and unpaired Student's t-tests and Mann-Whitney U-tests were applied as appropriate. For 
comparisons of a continuous variable in data sets with more than 2 groups, analysis of 76 
variance (ANOVA) was applied, followed by the Tukey’s post-hoc test for all possible 
pairwise comparisons. Categorical data were analysed by Fisher's exact test. A P-value of 
less than 0.05 (two tailed) was considered significant. 77 
 
 
 
 
 
3. Mechanisms of Oxidative Stress in Coronary 
Artery Disease 78 
3.1 Introduction 
 
 
Levels of O2
- have been shown to be elevated in vessels from patients with advanced CAD 
relative to those from control subjects with no documented CAD (159;208;302) and studies 
carried out within our laboratory have shown endothelial dysfunction to be associated with 
this elevated O2
- production in saphenous veins from CAD patients (159). However, while 
these studies demonstrated elevated O2
- generation throughout the vessel wall in patients 
with CAD (159), the molecular basis for this increase was not investigated nor was the 
effect of the additional CVD risk factor, T2D. 
 
Traditional methods for the detection of O2
- in vascular tissue include lucigenin-enhanced 
chemiluminescence  and  fluorescence  techniques  involving  the  use  of  probes  such  as 
dihydroethidium  (DHE).  Employing  these  methods,  vascular  O2
-  production  has  been 
shown to be increased in a number of conditions recognised as risk factors for CVD and in 
which endothelial function is impaired, including T2D (303;304)  and various forms of 
hypertension such as Ang II-induced hypertension (180;305) and that found in the stroke 
prone  spontaneously  hypertensive  rat  (SHRSP)  (306;307).  In  addition,  more  recent 
applications of these techniques have succeeded in demonstrating increased levels of O2
- in 
vascular  tissue  from  patients  with  advanced  CAD  as  compared  to  individuals  with  no 
documented vascular disease (159;208), as previously described. However, the validity of 
lucigenin-enhanced  chemiluminescence  assays  has  been  questioned,  with  evidence  to 
suggest that at high concentrations, lucigenin itself may act as a source for O2
- via redox 
cycling  (308;309).  Similarly,  DHE  has  been  associated  with  potential  artefacts  (310). 
Consequently, the use of two independent methods for superoxide detection is considered 
necessary by most investigators in order to obtain reliable results. 
 
Cytochrome  c  reduction  is  another  well  established  approach  for  measurement  of  O2
- 
production.  While  this  method  is  useful  for  quantifying  O2
-  released  in  large  amounts 
during the respiratory burst of neutrophils or by isolated enzymes, for other tissues, such as 
vessels  and  endothelial  cells,  where  the  level  of  O2
-  production  is  much  lower,  its 
application is more difficult as investigators find themselves operating at the lower limit of 
the assay’s sensitivity (311). 
 
In recent years, intracellular O2
- production has increasingly been detected using DHE and 
high performance liquid chromatography (HPLC) (311;312) and/or electron paramagnetic 79 
resonance (EPR) spectroscopy (311;313). Currently one of the most accurate methods for 
the detection of radical species, EPR detects the transitions of unpaired electrons in an 
applied magnetic field (311) and has been used in conjunction with cyclic hydroxylamine 
spin probes to investigate O2
- levels in vascular tissue (314) and cultured endothelial cells 
(315-317).  Cyclic  hydroxylamines  include  1-hydroxy-3-carboxy-2,2,5-tetramethyl-
pyrrolidine  hydrochloride  (CPH)  and  1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH) and are effective scavengers of O2
-, oxidised to form stable 
nitroxide radicals which can readily be detected by EPR (311). 
 
As  stated  previously  (section  1.3),  principal  sources  of  O2
-  in  the  vasculature  include 
uncoupled eNOS and NAD(P)H oxidase and inhibitors of these enzymes have been shown 
to  reduce  O2
-  production  in  saphenous  veins  from  CAD  patients  (159;302;318). 
Preincubation  of  sections  of  saphenous  vein  with  N
G-nitro-L-arginine  methyl  ester  (L-
NAME),  an  eNOS  inhibitor,  and  diphenylene  iodonium  (DPI),  an  inhibitor  of  flavin-
containing oxidases such as NAD(P)H oxidases, caused significant reductions in vascular 
O2
- generation in patients with CAD (302), suggesting they represent enzymatic sources of 
O2
- generation in saphenous veins. Furthermore, incubation of saphenous veins with the 
NAD(P)H oxidase inhibitor, apocynin has been shown to improve endothelium-dependent 
relaxations in CAD patients, suggesting NAD(P)H oxidase contributes to O2
- production 
and endothelial dysfunction in these patients (159). 
 
As previously outlined, mitochondria are major sites of ROS generation within cells of the 
vasculature. However, the precise contribution of mitochondria to total ROS production in 
the vessel wall and other cardiovascular tissues remains unclear, a consequence of limited 
efficacy of conventional antioxidants due to the difficulty associated with delivering them 
to mitochondria in situ (319). Furthermore, although specific antagonists of the respiratory 
chain, such as the complex I inhibitor, rotenone, or the complex III inhibitor, antimycin, 
can  modify  mitochondria-derived  ROS  production,  they  have  confounding  effects  on 
mitochondrial ATP production and membrane potential, rendering interpretation of their 
effects on cellular ROS levels difficult (320).  
 
A  recently  developed  mitochondria  targeted  ubiquinone,  MitoQ10,  has  been  shown  to 
overcome the problem of direct delivery to the mitochondria. MitoQ10 is composed of a 
lipophilic  triphenylphosphonium  (TTP)  cation  covalently  attached  to  an  ubiquinol 
antioxidant (321;322). Lipophilic cations can easily move through phospholipid bilayers 80 
without requiring a specific uptake mechanism and, as such, the TTP cation concentrates 
MitoQ10 several hundred fold within the mitochondria, driven by the large mitochondrial 
membrane potential (321-324) (Figure 3.1). Within mitochondria, MitoQ10 is reduced by 
the respiratory chain to its active ubiquinol form, a highly  effective antioxidant which 
prevents lipid peroxidation and mitochondrial damage (321;323-325). MitoQ10 has been 
shown to prevent oxidative damage in endothelial cells in vitro (326) and to be effective 
against such damage in vivo, in rodent models of sepsis and reperfusion injury (327;328). 
 
 
 
The aims of the experimental work outlined in this chapter were as follows: 
 
1)  to compare endothelial function and levels of O2
- production in vessels from control 
subjects and CAD patients with and without T2D; 
2)  to isolate and culture HSVECs and HSVSMCs from control subjects and patients 
with CAD; 
3)  to compare levels of O2
- production
 in HSVECs isolated from control subjects and 
CAD patients with and without T2D; 
4)  to  investigate  SOD  expression  and  characterise  enzymatic  sources  of  O2
- 
production in HSVECs from CAD patients with and without T2D 81 
 
 
 
Figure 3.1. Accumulation of MitoQ10 in Cells and Mitochondria. MitoQ10 accumulates (~10- to 
20-fold) within the cell driven by the plasma membrane potential ( p). Further accumulation 
(~150- to 200-fold) in mitochondria is driven by the mitochondrial membrane potential ( m). 
Within the mitochondrial matrix, MitoQ10 is reduced to the active antioxidant form, ubiquinol by 
the respiratory chain. Ubiquinol in turn acts to prevent lipid peroxidation. Antioxidant activity 
produces  the  ubiquinone  form  which  is  recycled  back  to  ubiquinol  by  the  respiratory  chain 
(continual recycling). Adapted from (329). 
?? p -  70 mV 
MitoQ  10 
ubiquinol 
ubiquinone 
1
  Ψ p - 70 mV 
MitoQ  10 
ubiquinol 
ubiquinone 
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3.2 Materials & Methods 
 
3.2.1 Study Participants 
 
Patients with CAD and control subjects were as described in section 2.2.  
 
 
3.2.2 Human Vascular Tissue & Primary Cell Culture 
 
Vascular tissue was obtained and prepared as described in section 2.3 and HSVECs and 
HSVSMCs isolated, characterised and cultured as outlined in section 2.4.  
 
 
3.2.3 Assessment of Endothelial Function 
 
Portions of saphenous vein were studied in organ bath chambers as outlined by Hamilton 
and colleagues (330). Vessels were cleaned of connective tissue and cut into 2–3 mm rings. 
Rings were then suspended on wires in 10 ml organ chambers filled with physiological salt 
solution [(PSS), 130 mM NaCl, 4.7 mM KCl, 14.9 mM NaHCO3, 1.18 mM KH2PO4, 5.5 
mM glucose, 1.17 mM MgSO4.7H2O, 1.6 mM CaCl2.2H2O, and 0.03 mM CaNa2EDTA, 
0.02 mM indomethacin dissolved in DMSO (pH 7.49 ± 0.1)], maintained at 37°C, and 
aerated with a mixture of 95% O2-5% CO2. The rings were connected to force transducers, 
and  changes  in  isometric  tension  were  recorded.  Vessels  were  constricted  with 
phenylephrine    and  relaxation  in  response  to  the  endothelium  dependent  vasodilatator, 
calcium ionophore A23187 (0.01-10  M) was studied. Maximum relaxation was calculated 
and expressed as a percentage of constriction to phenylephrine. 
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3.2.4 Assessment of Vascular Superoxide Production 
 
Superoxide  production  was  measured  in  3-4  mm  rings  by  chemiluminescence  using 
lucigenin as described by Berry et al. (318). Samples were analysed in a liquid scintillation 
counter (Hewlett Packard Tricarb 2100TR). Readings were taken every 10 seconds for 3 
minutes and absolute counts quantified with a xanthine / xanthine oxidase calibration curve 
for O2
- generation and standardised to wet weight of the tissue. Calibration curves were in 
the range of 28 nM to 280 nM xanthine and prepared by adding 20  l xanthine oxidase (0.1 
U/ml), 5 µM lucigenin and increasing volumes of 20 µM xanthine to a scintillation vial 
containing 2 ml Krebs-Ringer HEPES (KRH) buffer (119 mM NaCl, 20 mM Na-HEPES, 
pH 7.4, 5 mM NaHCO3, 4.7 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4 (7H20), 10 mM 
glucose, NaH2PO4). Counts were reported as nmol/mg tissue/min. It has previously been 
shown  that  the  lucigenin  assay  responds  in  the  same  way  to  O2
-  as  the  conversion  of 
dihydroethidine to ethidium, with ethidium production being measured by its fluorescence 
(159). 
 
 
3.2.5 Assessment of HSVEC Superoxide Production 
 
3.2.5.1 Lucigenin-Enhanced Chemiluminescence 
 
For measurement of HSVEC O2
- levels by lucigenin chemiluminescence, cells were grown 
in 100 mm diameter cell culture dishes until confluent and then serum-starved overnight. 
Medium was removed and cell lysates prepared as per section 2.6.3. Serum-free medium 
was  removed  following  overnight  incubation  and  replaced  with  5  ml  KRH  buffer  +/- 
MitoQ10 as indicated. Cells were then incubated for 1 hour at 37ºC in a CO2–free incubator 
and lysates prepared as previously described. Total protein concentration of each sample 
was determined by Pierce BCA Protein Assay kit according to the manufacturer’s protocol 
and using the Wallac Victor
2 plate reader. 
 
Lucigenin (5 µM) was added to 350  g lysate and samples analysed immediately in a 
Hewlett Packard Tricarb 2100TR liquid scintillation counter. Readings were taken every 
10 seconds for 3 minutes and absolute counts quantified with a xanthine/xanthine oxidase 84 
calibration curve for O2
- generation. Calibration curves were prepared as per section 3.2.3 
and were in the range of 28 nM to 280 nM xanthine. Counts were reported as nmol/mg 
lysate/min. 
 
 
3.2.5.2 Electron Paramagnetic Resonance Spectroscopy 
 
Passage 3 HSVECs were grown in 100 mm diameter cell culture dishes until confluent and 
then serum-starved overnight (unless otherwise indicated) before being incubated in the 
presence or absence of test substances (Table 3.1). Concentrations and incubation times for 
test  substances  were  as  previously  optimised  within  the  laboratory  or  from  relevant 
literature where indicated. Cells were then detached using trypsin-EDTA as described in 
section  2.4.3.  Numbers  of  cells  from  each  dish  were  determined  in  triplicate  using  a 
Beckman Coulter AcT Diff II Haematology Analyser and an average value calculated. 
HSVECs  were  then  diluted  in  PBS  to  a  concentration  of  5  x  10
6  cells/ml  and  test 
substances re-added at appropriate concentrations before addition of the spin probe, CMH 
(331;332) (Noxygen, Elzach, Germany) to a final concentration of 500  M, determined 
optimal during previous studies within the laboratory. Cell suspensions were subsequently 
assessed in triplicate for O2
- release in an EPR spectrometer (e-scan R Bruker BioSpin 
GmbH, Rheinstetten Germany). Between assessments, suspensions were stored at 37ºC in 
an Eppendorf
® Thermomixer Compact, shaking at 800 rpm to ensure cells did not re-pellet. 
 
10 mM stock solutions of CMH dissolved in Krebs-HEPES buffer (99 mM NaCl, 4.69 mM 
KCl, 2.5 mM CaCl2.2H2O, 1.2 mM MgSO4.7H2O, 25 mM NaHCO3, 1.03 mM KH2PO4, 
5.6 mM D(+) glucose, 20 mM HEPES, pH 7.4) containing chelating agents, deferoxamine 
(25  M, Sigma) and Na diethyldithiocarbamate trihydrate (5  M, Sigma) were prepared 
daily and kept on ice. Krebs-HEPES buffer was prepared using double distilled water and 
ultra pure chemicals from Sigma with concentrations of Fe and Cu <0.0005 %. Prior to 
addition of chelators, buffer was sterile-filtered using a 0.22  m filter system.  
 
EPR spectra and kinetics were recorded from cell suspensions in 50  l glass capillary tubes 
(Hirschmann Laborgeräte, Eberstadt, Germany) at 37ºC. Instrument settings were: centre 
field, 3375 G; modulation amplitude, 2.27 G; sweep time, 5.24 seconds; sweep width, 60 
G; and 10 scans. Oxidation of CMH by O2
- results in formation of the stable nitroxide  85 
 
Test 
Substance 
Final 
Concentration  
Incubation 
Time 
Diluent  Source 
apocynin  2.5  M  1 hour  DMSO  Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
DTPP 
(328) 
1  M  I hour  ethanol  A generous gift 
from Dr M. P. 
Murphy, MRC 
Mitochondrial 
Biology Unit, 
Cambridge, U.K. 
DPI  5  M  1 hour  DMSO  Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
L-NAME  1 mM  30 minutes  dH2O  Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
MitoQ10 
(328) 
1  M  1 hour  ethanol  A generous gift 
from Dr M. P. 
Murphy, MRC 
Mitochondrial 
Biology Unit, 
Cambridge, U.K. 
rotenone 
(228) 
0.5  M  2 hours  DMSO  Sigma-Aldrich, 
St Louis, MO, 
U.S.A. 
 
 
Table 3.1. Test Substances for Electron Paramagnetic Resonance Spectroscopy Experiments. 
DTPP,  decyl  triphenylphosphonium  (TPP)  bromide;  dH2O,  distilled  water;  DMSO,  dimethyl 
sulphoxide; DPI, diphenyleneiodonium chloride; L-NAME, N
G-nitro-L-arginine methyl ester 86 
radical, 3-methoxy-carbonyl (CM) (331). Therefore, the amount of CM formed equals the 
concentration of the reacting oxidant species. The concentration of CM was determined 
from the amplitude of the low field component of EPR spectra according to a calibration 
curve, generated using standard solutions of the 3-carboxy-proxyl (CP) radical (Noxygen). 
CP standard solutions of 1  M, 5  M and 10  M were prepared from a 1 mM stock 
solution of CP dissolved in Krebs-HEPES buffer. Counts were recorded once a minute for 
10 minutes and O2
- formation recorded as  mol/minute. 
 
Measurements  of  the  background  activity  of  PBS  +/-  test  substances  to  final 
concentrations,  Krebs-HEPES  buffer  +/-  chelators,  and  CMH  dissolved  in  buffer  with 
chelators to 500  M were routinely carried out prior to assessment of HSVEC O2
- release. 
Signals were not usually observed for PBS +/- diluents and buffer +/- chelators but due to 
normal auto-oxidation of the probe, CMH dissolved in buffer with chelators produced a 
low-level background signal which was noted and subtracted from all sample readings 
obtained that day. 
 
 
3.2.6 HSVEC mRNA Expression 
 
RNA  was  extracted  from  HSVECs  as  per  section  2.5  and  mRNA  expression  levels 
assessed  as  outlined  in  section  2.7.  Applied  Biosystems  Custom  TaqMan
®  Gene 
Expression  Assays  for  eNOS  (NOS3,  Hs00167166_m1),  p22
phox  (CYBA, 
Hs00164370_m1),  SOD1  (Hs00166575_m1),  SOD2  (Hs00167309_m1)  and  SOD3 
(Hs00162090_m1)  were  used  with  TaqMan
®  Endogenous  Controls,  β-actin  (ACTB, 
4326315E) and GAPDH (4326317E) as indicated. Reactions were carried out in singleplex 
or multiplex as indicated. 
 
 
3.2.7 Western Blot Analysis 
 
Protein was isolated from HSVECs as outlined in section 2.6.1 and protein expression 
assessed by western blotting as described in section 2.8.1. 
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3.2.7.1 Primary Antibodies 
 
Primary antibodies utilised during this study are listed in Table 3.2. 
 
 
3.2.7.2 Secondary Antibodies 
 
Secondary antibodies utilised during this study are listed in Table 3.3. 
 
 
3.2.7.3 Densitometric Quantification of Protein Bands 
 
Densitometric quantification of protein bands was carried out as outlined in section 2.8.2. 
 
 
3.2.8 Relative Quantitation of HSVEC Mitochondria by qRT-PCR 
 
3.2.8.1 DNA Extraction 
 
Total DNA was isolated from HSVECs using the QIAamp
® DNA Mini Kit (QIAGEN) 
according  to  the  manufacturer’s  protocol.  Passage  3  HSVECs  were  pelleted  and 
resuspended in PBS to a final volume of 200  l before addition of 20  l QIAGEN Protease 
(or proteinase K). 200  l Buffer AL was then added to samples which were subsequently 
mixed by pulse-vortexing for 15 seconds. Samples were then incubated at 56ºC for 10 
minutes before 200  l of 100% ethanol was added and samples mixed again by pulse-
vortexing  for  15  seconds.  Samples  were  then  applied  to  a  QIAamp  Mini  spin  column 
placed in a collection tube and centrifuged for 1 minute at 6,000 x g. Flow-through was 
discarded and columns transferred to fresh collection tubes. 500  l Buffer AW1 was then 
added to columns and centrifugation carried out as before. Columns were again transferred 
to clean collection tubes and flow-through discarded before 500  l Buffer AW2 was added 
and samples centrifuged at 20,000 x g for 3 minutes. To eliminate the possibility of Buffer  88 
 
Epitope  Clonality  Host 
Species 
Dilution  Diluent   
(w/v in  
TBS-T) 
Source 
α-p22
phox 
(MW1866)     
monoclonal  mouse  1:250  5% fat-free 
milk powder 
Mast, Liverpool, 
U.K. 
α-p22
phox 
(FL-195) 
polyclonal  rabbit  1:200  5% fat-free 
milk powder 
Santa Cruz 
Biotechnology, CA, 
U.S.A.  
(sc-20781) 
α-p22
phox  monoclonal  mouse  1:1000  5% fat-free 
milk powder 
A generous gift from 
Prof. M. T. Quinn, 
Montana State 
University, Montana, 
U.S.A. 
α-p22
phox  polyclonal  rabbit  1:1000  5% fat-free 
milk powder 
A generous gift from 
Dr. F. Wientjes, 
University College 
London, London, 
U.K. 
α-p22
phox  monoclonal  mouse  1:1000  5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Harrison, 
Emory University,  
Atlanta, Georgia, 
U.S.A. 
α-SOD2  monoclonal 
(clone: 2A1) 
mouse  1:3000  5% fat-free 
milk powder 
AbCam, Cambridge, 
U.K.  
(ab16956) 
 
Table 3.2. Primary Antibodies 89 
 
 
Linked 
Molecule 
Epitope  Host 
Species 
Dilution  Diluent       
(w/v in TBST) 
Source 
HRP  α-mouse IgG   rabbit  1:2000  5% fat-free 
milk powder  
Dako-Cytomation, 
Glostrup, Denmark 
(#P0260) 
HRP  α-rabbit IgG   goat  1:5000  5% fat-free 
milk powder 
Vector 
Laboratories Inc., 
Burlingame, CA, 
U.S.A  
(#PI-1000) 
 
Table 3.3 Secondary Antibodies. IgG, immunoglobulin G 90 
AW2  carryover,  collection  tubes  containing  flow-through  were  discarded  and  columns 
placed in fresh tubes for centrifugation at 20,000 x g for 1 minute. QIAamp Mini spin 
columns were transferred to new collection tubes and 200  l Buffer AE added. Samples 
were then incubated at room temperature for 1 minute before being centrifuged at 6,000 x 
g for 1 minute to elute. To increase DNA yield, the elution step was repeated using the 
original volume of Buffer AE. DNA samples were stored at -20ºC until time of analysis. 
 
 
3.2.8.2 DNA Quantification 
 
DNA  concentrations  were  quantified  using  the  NanoDrop
®  ND-100  Spectrophotometer 
and ND-1000 v3.1.0 programme. For each sample, 2 µl DNA was quantified. 
 
 
3.2.8.3 Quantitation of Single-copy Mitochondrial & Nuclear DNA 
 
Using TaqMan
® probes for single copy nuclear β-haemoglobin (HBB, Hs00758889_s1) 
and mitochondrially encoded cytochrome b (MT-CYB, Hs02596867_s1) genes, abundance 
of mtDNA relative to nuclear DNA was determined by calculating Ct (cycle threshold 
value) ratios for each patient, a variation on the method of Miller and colleagues (333). 
Singleplex TaqMan
® real-time RT-PCR reactions were carried out as per section 2.7.2, 
using 2  l DNA (12.5 ng/ l) in place of cDNA.  
 
 
3.2.9 Statistical Analysis 
 
Statistical analyses were performed as outlined in section 2.9. 
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3.3 Results 
 
3.3.1 Endothelial Function 
 
Endothelium-dependent relaxation was impaired in vessels of patients with CAD compared 
to those obtained from control subjects (maximum relaxation to A23187, 43 ± 16 vs 62 ± 
16%;  P=0.001;  Figure  3.2A).  Patients  with  CAD  and  T2D  had  significantly  reduced 
endothelium  dependent  relaxation  compared  to  those  with  CAD  alone  (maximum 
relaxation to A23187, 34 ± 11% vs 47 ± 16%; P=0.008; Figure 3.2B).  
 
 
3.3.2 Vascular Superoxide Production 
 
Vascular O2
- production was greater in patients with CAD compared to control subjects 
(0.752 ± 0.482 vs 0.431 ± 0.284 nmol/mg/min; P=0.001; Figure 3.3A), as assessed by 
lucigenin  chemiluminescence.  Within  the  group  of  patients  with  CAD  there  was  no 
difference in vascular O2
- generation in patients with and without T2D (0.640 ± 0.433 vs 
0.791 ± 0.502 nmol/mg/min; P=0.226; Figure 3.3B). 
 
 
3.3.3 Isolation & Characterisation of HSVECs & HSVSMCs 
 
HSVECS  and  HSVSMCs  were  successfully  isolated  from  both  control  subjects  and 
patients with CAD. HSVECs showed typical cobblestone morphology and demonstrated 
positive immunofluorescent staining for the endothelial cell marker, von Willebrand factor 
(Figure 3.4A). Similarily, HSVSMCs displayed characteristic ‘hill and valley’ morphology 
and phenotype was further confirmed by positive immunofluorescence for SMC-α-actin 
(Figure  3.4B).  Unfortunately,  HSVSMCs  demonstrated  prohibitively  slow  growth  in 
culture and, consequently, all subsequent investigation was performed in HSVECs. 
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Figure 3.2. Vasorelaxation in Rings of Saphenous Vein. Vessel rings were constricted with 
phenylephrine and maximum relaxation to calcium ionophore A23187 examined and expressed as 
a percentage of constriction. (A) Endothelium-dependent relaxation was significantly impaired in 
vessels from patients with CAD (n=49) compared to vessels from controls (n=10). (B) Patients with 
CAD and type 2 diabetes (T2D, n=14) had significantly reduced endothelium dependent relaxation 
compared to those with CAD alone (ND, n=35).  93 
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Figure 3.3. Vascular Superoxide Production. Superoxide levels in rings of saphenous vein were 
measured  by  lucigenin  chemiluminescence.  (A)  Vascular  lucigenin  chemiluminescence  was 
significantly greater in patients with CAD (n=76) compared to controls (n=19), consistent with 
elevated superoxide production in these samples. (B) Within the group of patients with CAD, there 
was  no  statistically  significant  difference  in  vascular  lucigenin  chemiluminescence  between 
patients with (T2D, n=22) and without (ND, n=54) type 2 diabetes. 94 
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Figure 3.4 Representative Photomicrographs Showing Vascular Cells in Primary Culture. (A) 
Endothelial cells were successfully isolated from portions of human saphenous vein, as determined 
by characteristic cobblestone morphology (left-hand panel). Endothelial cell phenotype was further 
confirmed by positive staining (green) for von Willebrand Factor (middle and right-hand panels). 
(B) Successful isolation of smooth muscle cells from human saphenous vein was determined by 
observation of characteristic ‘hill and valley’ morphology in culture (left-hand panel) and positive 
staining (green) for smooth muscle cell-α-actin (middle and right-hand panels). For both cell types, 
nuclei are stained red (propidium iodide). 95 
3.3.4 HSVEC Superoxide Production 
3.3.4.1 Lucigenin-Enhanced Chemiluminescence 
 
To determine whether endothelial cells isolated from vascular tissue retained the elevated 
O2
-  phenotype,  levels  of  basal  O2
-  production  in  cultured  HSVECs  were  investigated. 
Lucigenin chemiluminescence was greater in HSVECs isolated from patients with CAD 
compared to control subjects (16.246 ± 1.262 vs 11.294 ± 1.024 nmol/mg/min; P=0.0382; 
Figure 3.5), consistent with elevated O2
- production in these samples.  
 
 
3.3.4.2 Electron Paramagnetic Resonance Spectroscopy 
 
In  order  to  confirm  lucigenin  chemiluminescence  findings  showing  increased  O2
- 
production  in  HSVECs  isolated  from  CAD  patients,  EPR  spectroscopy  was  employed. 
Results  demonstrated  a  trend  towards  elevated  O2
-  levels  in  patients  with  CAD  as 
compared to control subjects but just failed to reach statistical significance (0.371 ± 0.012 
vs 0.308 ± 0.019  mol/min; P=0.061; Figure 3.6). On stratifying CAD patients according 
to the presence or absence of T2D, O2
- levels were observed to be elevated in patients with 
T2D on comparison with control subjects  (0.391 ± 0.034 vs 0.308 ± 0.019  mol/min; 
P=0.058; Figure 3.6) and CAD patients without T2D (0.391 ± 0.034 vs 0.360 ± 0.011 
 mol/min; P=0.537; Figure 3.6). However, results did not reach statistical significance. 
 
 
3.3.5 HSVEC Superoxide Dismutase Expression 
 
Given results indicating a trend towards increased O2
- production in HSVECs isolated from 
patients with CAD as compared to control subjects and in those CAD patients with T2D as 
compared to those without, it was of interest to investigate expression of the superoxide 
dismutases, SOD1, SOD2 and SOD3, in cells from all patient groups.  
 
Expression of SOD3 mRNA was undetectable in HSVECs from all patient groups. 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.5  HSVEC  Basal  Superoxide  Production  Measured  by  Lucigenin 
Chemiluminescence. Basal superoxide levels were assessed in HSVECs isolated from controls 
(n=3)  and  patients  with  CAD  (n=3).  Superoxide  production  was  observed  to  be  significantly 
elevated in HSVECs from patients with CAD as compared to controls. *, P < 0.05 
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Figure  3.6.  HSVEC  Basal  Superoxide  Production  Measured  by  Electron  Paramagnetic 
Resonance  Spectroscopy.  Basal  superoxide  levels  were  assessed  in  HSVECs  isolated  from 
controls (n=4) and patients with CAD (n=8). A trend towards elevated superoxide production was 
observed in HSVECs from patients with CAD as compared to controls but results failed to reach 
statistical significance. Within the group of patients with CAD, there was a trend towards increased 
basal superoxide levels in HSVECs from patients with type 2 diabetes (T2D, n=4) as compared to 
those from patients with CAD alone (ND, n=4) and control subjects but again numbers were not 
statistically significantly different. 98 
As shown in Figure 3.7, no significant difference in HSVEC SOD1 mRNA expression was 
observed between patient groups, although a trend towards increased expression in CAD 
patients relative to control subjects ( Ct, -0.818 ± 0.335 vs -0.078 ± 0.313; P=0.250) was 
noted, consistent with elevated O2
- levels in cells from CAD patients. Levels of SOD1 
mRNA appeared slightly lower in HSVECs from CAD patients with T2D than in those 
with CAD alone (-0.669 ± 0.379 vs -0.846 ± 0.395; P=0.853; Figure 3.7) but, as stated, 
results failed to reach statistical significance. 
 
Expression  of  SOD2  mRNA  in  HSVECs  was  found  to  be  increased  by  approximately 
three-fold in cells from CAD patients relative to those from control subjects ( Ct, -5.522 ± 
0.821 vs -3.904 ± 1.224; P=0.34; Figure 3.8A). When stratified according to T2D status, 
there was a greater than two-fold increase in SOD2 expression in cells from CAD patients 
with T2D as compared to those without ( Ct, -6.514 ± 0.815 vs -5.191 ± 1.061; P=0.338;  
Figure 3.8B) but results did not reach statistical significance. No significant increase was 
observed in CAD patients without T2D as compared to controls ( Ct, -5.191 ± 1.061 vs -
3.905 ± 1.203; P=0.501; Figure 3.8A) but there was a significant, almost six-fold increase 
in those CAD patients with T2D ( Ct, -6.514 ± 0.815 vs -3.922 ± 1.225; P=0.044; Figure 
3.8A).  
 
This finding was confirmed at protein level (Figure 3.8B) using mouse anti-SOD2 primary 
antibody  and  rabbit  anti-mouse  IgG-HRP  secondary  antibody.  Densitometry  revealed 
significantly increased SOD2 protein expression in cells from patients with CAD relative 
to controls (7.691 ± 0.353 vs 4.766 ± 0.211 ODU/mm
2; P=0.0001; Figure 3.8C) and in 
both CAD patients with (8.380 ± 0.131 vs 4.766 ± 0.211 ODU/mm
2; P=0.0002; Figure 
3.8C) and without T2D (7.232 ± 0.382 vs 4.766 ± 0.211 ODU/mm
2; P=0.0008; Figure 
3.8C) relative to controls. While expression of SOD2 was observed to be greater in cells 
from CAD patients with T2D as compared to those without (8.380 ± 0.131 vs 7.232 ± 
0.382 ODU/mm
2; P=0.107; Figure 3.8C), results were not statistically significant. 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.7.  HSVEC  SOD1  mRNA  Expression  Relative  to  β-actin  (ACTB)  as  Assessed  by 
TaqMan
® qRT-PCR. Expression of SOD1 was investigated in HSVECs isolated from controls 
(n=6) and patients with CAD (n=23), stratified according to the absence (ND, n=17) or presence 
(T2D, n=6) of type 2 diabetes. A trend towards increased expression was observed in cells from 
CAD  patients  relative  to  those  from  controls  but  results  did  not  reach  statistical  significance. 
Reactions were carried out in singleplex. RQ, relative quantitation. 
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Figure  3.8.  HSVEC  SOD2  mRNA  and  Protein Expression.  (A)  Using  TaqMan
®  qRT-PCR, 
expression of SOD2 relative to β-actin (ACTB) was investigated in HSVECs isolated from controls 
(n=5) and patients with CAD (n=24). Reactions were carried out in singleplex. A trend towards 
increased expression in cells from CAD patients relative to those from controls was observed. 
SOD2 expression was greater in those patients with CAD and type 2 diabetes (T2D, n=6) than in 
those with CAD alone (ND, n=18) and expression was significantly elevated in T2D patients as 
compared to controls. *, P < 0.05 vs controls. (B) SOD2 protein expression in HSVECs isolated 
from  controls  (n=5)  and CAD  patients  (n=5)  with (T2D,  n=2)  and  without (ND,  n=3)  type  2 
diabetes  was  assessed  by  western  blotting.  A  representative  immunoblot  is  shown.  (C) 
Densitometry revealed significantly increased SOD2 expression in cells from  the CAD patient 
population as a whole, CAD patients with ND, and CAD patients with T2D relative to controls 
with the greatest protein expression observed in HSVECs from T2D patients. ‡, †, *, P < 0.001 vs 
control. 
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3.3.6 Relative Quantitation of HSVEC Mitochondria by qRT-PCR 
 
Relative to control subjects, no differences in Ct ratios were observed in the CAD patient 
population  as  a  whole  (1.367  ±  0.062  vs  1.416  ±  0.037;  P=0.500;  Figure  3.9),  CAD 
patients with T2D (1.367 ± 0.062 vs 1.421 ± 0.064; P=0.577; Figure 3.9) and patients with 
CAD alone (1.367 ± 0.062 vs 1.412 ± 0.052; P=0.602; Figure 3.9). In addition, Ct ratios 
were not significantly different between HSVECs from patients with and without T2D 
(1.421 ± 0.064 vs 1.412 ± 0.052; P=0.914; Figure 3.9). 
 
 
3.3.7 Characterisation of Enzymatic Sources of Superoxide Generation 
 
3.3.7.1 Mitochondria 
 
Based on SOD2 expression data (Figure 3.8), it was of interest to investigate mitochondrial 
O2
- production in HSVECs. On pretreating HSVECs with rotenone, the respiratory chain 
inhibitor,  a  trend  towards  a  greater  reduction  in  O2
-  levels  in  patients  with  CAD  as 
compared  to  control  subjects,  as  assessed  by  EPR  spectroscopy,  was  observed  (Figure 
3.10). However, the inhibitor caused no significant reduction in basal O2
- levels in cells 
from either control subjects (0.308 ± 0.019 vs 0.317 ± 0.004 µmol/min; P=0.755; Figure 
3.10) or patients with CAD (0.371 ± 0.012 vs 0.343 ± 0.010 µmol/min; P=0.0.151; Figure 
3.10). On stratifying CAD patients according to T2D status, no significant decreases in 
basal O2
- levels were observed in cells from either patients with CAD and T2D (0.391 ± 
0.034 vs 0.356 ± 0.006 µmol/min; P=0.359; Figure 3.10) or those with CAD alone (0.360 
± 0.011 vs 0.336 ± 0.013 µmol/min; P=0.297; Figure 3.10). 
 
In  the  absence  of  serum,  preincubating  HSVECs  with  the  mitochondria-targeted 
antioxidant, MitoQ10 caused a significant increase, rather than decrease, in basal O2
- levels 
(0.400 ± 0.012 vs 0.519 ± 0.044 µmol/min; P=0.0233; Figure 3.11A), as determined by 
EPR spectroscopy. Pretreatment with decylTPP bromide (DTPP), the non-active control 
for MitoQ10 (324), had no significant effect on HSVEC basal O2
- production (0.400 ± 
0.012 vs 0.442 ± 0.008 µmol/min; P=0.056; Figure 3.11A). In the presence of serum [20%  102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Comparison of HSVEC Mitochondrial Numbers by Polymerase Chain Reaction. 
DNA was extracted from HSVECs isolated from controls (n=3) and patients with CAD (n=7), 
stratified according to the presence (T2D, n=3) or absence (ND, n=4) of type 2 diabetes. Using 
TaqMan
®  probes  for  single  copy  nuclear  β-haemoglobin  (HBB)  and  mitochondrially  encoded 
cytochrome  b  (MT-CYB),  the  abundance  of  mitochondrial  DNA  relative  to  nuclear  DNA  was 
determined by calculating Ct (cycle value threshold value) ratios for each patient. No differences in 
Ct  ratio  were  observed,  suggesting  mitochondrial  numbers  are  similar  between  patients, 
irrespective of disease status. 
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Figure 3.10. Effects of Mitochondrial Respiratory Chain Inhibition on HSVEC Superoxide 
Production as Assessed by Electron Paramagnetic Resonance Spectroscopy. HSVECs isolated 
from controls (n=4) and patients with CAD (n=8) were incubated with (+) and without (-) rotenone, 
an inhibitor of the mitochondrial respiratory chain. CAD patients were stratified according to the 
presence (T2D, n=4) or absence (ND, n=4) of type 2 diabetes. On preincubation with rotenone, a 
greater  decrease  in  O2
-  production  in  cells  from  CAD  patients  as  compared  to  controls  was 
observed, with the slightly larger reduction in CAD patients with T2D. However, results failed to 
reach statistical significance. 
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Figure  3.11.  Effects  of  a  Mitochondria-Targeted  Antioxidant  on  HSVEC  Superoxide 
Production as Assessed by Electron Paramagnetic Resonance Spectroscopy. HSVECs isolated 
from patients with CAD (n=3) were incubated with (+) and without (-) the mitochondria-targeted 
antioxidant, MitoQ10 (MQ10), and the non-active control compound, decylTPP bromide (DTPP). 
(A)  In  the  absence  of  serum,  preincubation  with  MitoQ10  resulted  in  a  significant  increase  in 
cellular O2
- levels, not observed on pretreatment with DTPP. *, P < 0.05. (B) In the presence of 
serum, neither MitoQ10 nor DTPP had a significant effect on HSVEC O2
- levels.  
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(v/v)], preincubation with neither MitoQ10 (0.430 ± 0.023 vs 0.441 ± 0.032 µmol/min; 
P=0.800; Figure 3.11B ) nor DTPP (0.430 ± 0.023 vs 0.468 ± 0.025 µmol/min; P=0.496; 
Figure 3.11B) had a significant effect on cellular O2
- levels. 
 
 
3.3.7.2 Endothelial Nitric Oxide Synthase 
 
With results revealing impaired endothelium-dependent relaxation in vessels from patients 
with CAD (Figure 3.2) and elevated O2
- production in both vessels and HSVECs from 
these  patients  (Figures  3.3,  3.5  and  3.6),  the  contribution  of  uncoupled  eNOS  to  O2
- 
generation in HSVECs from CAD patients was investigated.  
 
Expression studies revealed no difference in NOS3 mRNA levels between patient groups 
(Figure  3.12A),  consistent  with  modulation  of  enzyme  activity  via  post-translational 
phosphorylation. Relative to control subjects, no differences in expression were observed 
in  the  CAD  patient  population  as  a  whole  ( Ct,  -6.090  ±  0.482  vs  -6.211  ±  0.279; 
P=0.841; Figure 3.12A), CAD patients with T2D ( Ct, -6.090 ± 0.482 vs -6.447 ± 0.533; 
P=0.630; Figure 3.12A) and patients with CAD alone ( Ct, -6.090 ± 0.482 vs -6.128 ± 
0.335;  P=0.952;  Figure  3.12A).  In  addition,  NOS3  expression  was  not  significantly 
different between HSVECs from patients with and without T2D ( Ct, -6.447 ± 0.533 vs -
6.128 ± 0.335; P=0.627; Figure 3.12A). As shown in Figure 4.7, no difference in eNOS 
protein  expression  or  eNOS  Ser1177  phosphorylation  was  observed  between  HSVEC 
lysates from patients with CAD and T2D and those with CAD alone. 
 
Preincubating HSVECs with the eNOS inhibitor, L-NAME resulted in a non-significant, 
approximately equal, 20% increase in O2
- production for all patient groups (Figure 3.12B), 
as assessed by EPR spectroscopy.  106 
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Figure 3.12. eNOS mRNA Expression & Contribution to Superoxide Production in HSVECs. 
(A) Using TaqMan
® qRT-PCR, expression of NOS3 relative to β-actin (ACTB) was investigated in 
HSVECs isolated from controls (n=6) and patients with CAD (n=23), stratified according to the 
presence (T2D, n=6) or absence (ND, n=17) of type 2 diabetes. Reactions were carried out in 
multiplex. No difference in expression was observed between patient groups. (B) HSVECs isolated 
from controls (n=4) and patients with CAD (n=8) were incubated with (+) and without (-)  L-
NAME. CAD patients were again stratified according to the presence (T2D, n=4) or absence (ND, 
n=4) of type 2 diabetes. Incubation with L-NAME resulted in a non-significant, approximately 20% 
increase in O2
- for all patient groups, as assessed by EPR. 
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3.3.7.3 NAD(P)H Oxidase 
 
In  order  to  establish  the  contribution  of  NAD(P)H  oxidase  to  O2
-  production  in  the 
endothelium of patients with CAD, mRNA expression of CYBA, encoding the enzyme’s 
p22
phox  subunit,  was  investigated  in  HSVECs.  Results  demonstrated  no  significant 
difference in CYBA mRNA expression between patient groups (Figure 3.13A) although a 
trend  towards  increased  expression  in  CAD  patients  with  T2D  relative  to  both  control 
subjects ( Ct ,4.465 ± 0.384 vs 4.889 ± 0.287; P=0.387; Figure 3.13A) and CAD patients 
without T2D ( Ct ,4.465 ± 0.384 vs 4.791 ± 0.266; P=0.524; Figure 3.13A) was observed.  
 
Attempts to confirm these findings at protein level proved unsuccessful, with failure to 
observe bands of the correct size on photographic film despite the use of 5 different anti-
p22
phox primary antibodies (Table 3.2) and varying incubation and exposure times. 
 
However, on pretreating HSVECs with the NAD(P)H oxidase inhibitor, DPI, a statistically 
significant  reduction  in  basal  O2
-  production,  as  measured  by  EPR  spectroscopy,  was 
observed in cells from CAD patients (0.371 ± 0.012 vs 0.270 ± 0.024 µmol/min; P=0.021; 
Figure 3.13B) but not in those from control subjects (0.308 ± 0.019 vs 0.300 ± 0.020 
µmol/min;  P=0.803;  Figure  3.13B).  Similarly,  incubation  with  apocynin  resulted  in  an 
approximate 12% reduction in basal O2
- levels in HSVECs from patients with CAD (0.371 
± 0.012 vs 0.326 ± 0.032 µmol/min; P=0.263; Figure 3.13B) while only an approximately 
3% reduction was observed in cells from control subjects (0.308 ± 0.019 vs 0.298 ± 0.024 
µmol/min; P=0.774; Figure 3.13B). 
 
On stratifying patients according to the presence of T2D, incubation with DPI caused a 
significant, approximate 32% decrease in basal O2
- production in HSVECs from patients 
with CAD alone (0.360 ± 0.011 vs 0.246 ± 0.035 µmol/min; P=0.010; Figure 3.13B) and 
an approximate 18% decrease in cells from patients with CAD and T2D (0.391 ± 0.034 vs 
0.319 ± 0.034 µmol/min; P=0.113; Figure 3.13B). Pretreatment with apocynin resulted in 
an approximate 16% reduction in basal O2
- levels in CAD patients without T2D (0.360 ± 
0.011 vs 0.302 ± 0.001 µmol/min; P=0.257; Figure 3.13B) but only an approximately 4% 
decrease in those patients with CAD and T2D (0.391 ± 0.034 vs 0.375 ± 0.012 µmol/min; 
P=0.753; Figure 3.13B). 108 
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Figure 3.13. p22
phox mRNA Expression and NAD(P)H Oxidase Contribution to Superoxide 
Production in HSVECs. (A) Using TaqMan
® qRT-PCR, expression of CYBA relative to β-actin 
(ACTB) was investigated in HSVECs isolated from controls (n=7) and patients with CAD (n=23), 
stratified  according  to  the  presence  (T2D,  n=6)  or  absence  (ND,  n=17)  of  type  2  diabetes. 
Reactions were carried out in singleplex. No difference in expression was observed between patient 
groups. (B) HSVECs isolated from controls (n=4) and patients with CAD (n=8) were incubated 
with  (+)  and  without  (-)  diphenylene  iodonium  (DPI)  and  apocynin  (apo)  and  O2
-  production 
investigated using EPR. CAD patients were again stratified according to the presence (T2D, n=4) 
or  absence  (ND,  n=4)  of  type  2  diabetes.  Preincubation  with  both  inhibitors  caused  a  greater 
decrease in O2
- production in cells from CAD patients as compared to controls, with the larger 
reduction in ND patients. Pretreatment with DPI caused a greater reduction in O2
- levels than 
pretreatment with apocynin for all patients groups. †, P < 0.05 vs untreated (-) cells from CAD 
patients. *, P < 0.05 vs untreated (-) cells from ND patients. 
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3.4 Discussion 
 
This  study  involved  comparison  of  endothelial  function  and  O2
-  production  in  human 
saphenous veins. Previous studies have demonstrated human arterial and venous basal O2
- 
generation are closely related (318;334), such that results were not affected by the choice 
of vessel. For practical reasons, molecular studies focused on primary endothelial cells 
isolated from human saphenous veins. However, it is recognised that VSMCs, fibroblasts 
and  other  components  of  the  adventitia  play  important  roles  in  vascular  function  and 
pathogenesis. 
 
As  stated,  endothelial  dysfunction  occurs  in  conjunction  with  CAD  (208).  Previous 
investigations within the group have demonstrated endothelial dysfunction in saphenous 
veins from patients with CAD (159) and results obtained during the course of this project 
have confirmed these findings (Figure 3.2A). Risk factors for CVD are almost universally 
associated with a degree of endothelial dysfunction in humans (87) and indeed, abnormal 
vascular endothelial function is a prominent feature of T2D (100;162). As shown in Figure 
3.2B, a significantly greater depression of relaxation to calcium ionophore was observed in 
saphenous veins from patients with CAD and T2D as compared to those from patients with 
CAD  alone,  confirming  poorer  endothelial  function  in  individuals  with  this  additional 
CVD risk factor. 
 
Increased  vascular  oxidative  stress  has  been  proposed  as  one  potential  mechanism 
underlying  impaired  endothelial  function  in  patients  with  CAD  and  T2D  (179). 
Investigations carried out within this laboratory have revealed endothelial dysfunction in 
saphenous veins from CAD patients to be associated with elevated O2
- levels throughout 
the  vessel  wall  (159),  but  did  not  consider  the  effect  of  T2D  on  this  O2
-  production. 
However, a study by Guzik et al. has previously demonstrated significantly elevated basal 
O2
- release in saphenous veins from patients with CAD and T2D relative to those with 
CAD alone (179). The present study served to confirm that O2
- generation is increased in 
vessels from CAD patients as compared to control subjects (Figure 3.3A). However, on 
comparison  of  O2
-  levels  in  vessels  from  CAD  patients  with  and  without  T2D,  no 
statistically  significant  increase  in  O2
-  production  in  patients  with  T2D  was  observed 
(Figure 3.3B). Conversely, a trend towards reduced vascular O2
- production was evident 
(Figure  3.3B).  This  phenomenon  is  likely  the  result  of  more  aggressive  primary  and 
secondary  prevention  strategies  in  this  vulnerable  group  of  patients  (335).  Indeed,  as 110 
shown in Table 2.1, a higher percentage of study participants with CAD and T2D (78%) 
were found to have been prescribed ACE inhibitors/ARBs than those with CAD alone 
(57%). Furthermore, on comparison with T2D patients recruited by Guzik and colleagues 
(179), participants in the present study were subject to more intensive treatment. 
 
To  investigate  the  molecular  basis  for  the  increased  O2
-  production  and  impaired 
endothelium-dependent  relaxation  in  vessels  from  patients  with  CAD,  endothelial  cells 
were  isolated  from  vascular  tissue  (Figure  3.4A).  As  isolated  cells  were  maintained  in 
culture for several weeks prior to investigation of O2
- production, it seemed likely that the 
effects of pharmacological treatments would be lost, allowing more accurate insight into 
endothelial  O2
-  production,  particularly  in  vessels  from  patients  with  CAD  and  T2D. 
However, an obvious limitation of studying cultured primary endothelial cells is that there 
is currently no clear evidence to suggest these cells, free from physiological stresses, retain 
the in vivo phenotype.  
 
Using  lucigenin  chemiluminescence,  O2
-  levels  were  measured  and  found  to  be 
significantly  elevated  in  HSVECs  from  patients  with  CAD  relative  to  control  subjects 
(Figures  3.5),  appearing  to  support  results  obtained  using  intact  vessel  sections  and 
implicating excess O2
- production in attenuation of endothelium-dependent relaxation in 
CAD  patients.  However,  n  values  were  low  (n=3)  for  these  experiments  and  results 
interpreted with caution.  
 
On increasing patient numbers and assessing O2
- production using EPR spectroscopy, a 
more sensitive technique, a trend towards increased O2
- generation was observed in cells 
isolated  from  patients  with  CAD  (Figure  3.6)  but  numbers  failed  to  reach  statistical 
significance, raising the possibility that in culture the in vivo phenotype of these cells is not 
preserved.  
 
The  cell  permeable  spin  probe,  CMH  (332)  was  used  in  conjunction  with  EPR 
spectroscopy to investigate O2
- production. CMH detects both extra- and intracellular O2
- 
(331;332;336)  but  does  not  directly  react  with  H2O2  (331;337;338).  As  described,  the 
superoxide  dismutases  catalyse  the  conversion  of  O2
-  to  H2O2  and  molecular  oxygen 
(188;233;234)  and  increased  SOD2  mRNA  and  protein  expression  was  observed  in 
HSVECs  from  patients  with  CAD  (Figure  3.8).  These  findings  provide  an  alternative 
explanation for the lack of a significant increase in O2
- generation in cells from patients 111 
with CAD and suggest it may be useful to investigate and compare cellular H2O2 levels in 
the future. 
 
Despite initial findings of EPR spectroscopy, CAD patients were stratified according to 
T2D status and O2
- production again measured using EPR. Here, a trend towards increased 
O2
-  production  in  patients  with  T2D  was  observed  (Figure  3.6),  linking  elevated  O2
- 
production in cells of the endothelium to endothelial dysfunction and indicating reduced 
O2
- levels found in intact vessels could indeed be the result of enhanced pharmacological 
intervention within this patient group. 
 
With results demonstrating a trend towards increased O2
- production in HSVECs isolated 
from patients with CAD as compared to control subjects and in those CAD patients with 
T2D as compared to those without, expression of the superoxide dismutases, SOD1, SOD3 
and, as previously mentioned, SOD2, was investigated in cells from all patient groups.  
 
Expression  of  SOD3  mRNA  was  found  to  be  undetectable  in  cells  from  both  control 
subjects and patients with CAD. This may be due to the fact that unlike SOD1 and SOD2, 
expressed throughout the vessel wall, SOD3 is largely expressed in VSMCs (339). Indeed, 
studies have shown SOD3 expression to be lacking in human cultured endothelial cell lines 
(340;341). 
 
SOD1  is  thought  to  be  the  predominant  SOD  isoform  in  the  endothelium  (167). 
Consequently, given the significantly elevated O2
- levels observed in vessels from CAD 
patients, a significant difference in SOD1 expression may have been expected between 
patient groups. However, while a trend towards increased SOD1 mRNA expression was 
observed  in  cells  from  patients  with  CAD  relative  to  control  subjects  (Figure  3.7), 
consistent  with  an  adaptive  response  to  elevated  O2
-  production,  results  did  not  reach 
statistical significance, nor was there a significant difference in expression between CAD 
patients  with  and  without  T2D  (Figure  3.7).  These  findings  were  not  surprising  given 
results obtained on assessment of cellular O2
- production by EPR spectroscopy (Figure 
3.6). In addition, there is evidence to suggest SOD1 expression is increased in the initial 
stages of atherosclerosis but decreases as the condition progresses (342) and, as outlined, 
HSVECs were isolated from vessels of patients with advanced CAD. Furthermore, SOD1 
expression is known to be upregulated in response to shear stress (343), again raising the 112 
question of whether cultured cells retain the in vivo phenotype and indicating it may be 
prudent to examine SOD1 mRNA expression in vascular tissue homogenates.  
 
Another  possible  explanation  for  cellular  SOD1  expression  data  may  centre  on  the 
increased expression of SOD2 mRNA and protein in HSVECs isolated from vessels of 
patients  with  CAD  (Figure  3.8),  an  increase  clearly  demonstrated  as  not  being  due  to 
differences in number of mitochondria, as determined by abundance of mtDNA (MT-CYB) 
relative  to  nuclear  DNA  (HBB)  (Figure  3.9).  Induction  of  SOD2  mRNA  expression  is 
known to occur in response to oxidative stress (344), suggesting the increase represents an 
adaptive  response  to  elevated  mitochondrial  O2
-  production  in  HSVECs  from  CAD 
patients, in particular those patients with T2D. Mitochondria may therefore be a principal 
source of excess O2
- production in the endothelium of patients with CAD and T2D. 
 
In order to investigate the contribution of mitochondria to endothelial O2
- production in 
patients with CAD, cells were treated with rotenone, the respiratory chain inhibitor. As 
shown  in  Figure  3.10,  a  trend  towards  a  greater  reduction  in  cellular  O2
-  levels  was 
observed in CAD patients relative to control subjects and in patients with CAD and T2D 
relative  to  those  with  CAD  alone.  However,  reductions  in  O2
-  generation  were  not 
significant as may have been expected given SOD2 mRNA and protein expression data 
(Figure  3.8).  Interestingly,  O’Malley  and  colleagues  (325)  demonstrated  rotenone 
markedly  decreased  ROS  production  in  bovine  aortic  endothelial  cell  (BAEC) 
mitochondria as detected by fluorescence but had no effect on O2
- production as assessed 
by  EPR  spectroscopy,  while  Guzik  and  colleagues  (179)  showed  rotenone  had  only  a 
minimal effect on O2
- production in saphenous veins from CAD patients. In addition, as 
previously mentioned, rotenone is not a specific mitochondrial antioxidant (320) and, as 
such, cells were subsequently treated with MitoQ10.  
 
Preincubating cells from CAD patients with MitoQ10 caused a significant increase, rather 
than the anticipitated decrease, in O2
- levels (Figure 3.11A). This increase was not evident 
on preincubation of cells with the non-active control for MitoQ10, DTPP (Figure 3.11A), 
which  comprises  the  lipophilic  TTP  cation  but  lacks  the  ubiquinone  moiety  of  the 
antioxidant  (324).  Despite  suggestion  that  MitoQ10  acts  to  reduce  mtROS  production 
(326;345-347),  like  all  quinones,  it  can  redox  cycle  to  produce  O2
-,  thus  acting  as  a 
prooxidant
  (325;348;349). Indeed, MitoQ10 has been shown to enhance both mitochondrial 
and cellular ROS production in intact endothelial cells (348;350). Serum-free conditions 113 
are  known  to  greatly  exacerbate  MitoQ10  redox  cycling  [(324)  and  personal 
communication with Dr Michael Murphy, MRC Mitochondrial Biology Unit, Cambridge, 
U.K.) and, as shown in Figure 3.11, this was confirmed to be the case in HSVECs isolated 
from patients with CAD.  In the presence of serum, pretreatment with MitoQ10 had no 
significant effect on HSVEC O2
- levels (Figure 3.11B). This result may be explained, at 
least in part, by data indicating MitoQ10 reacts poorly with O2
- per se (351), exerting its 
antioxidant effect by reacting with products of lipid peroxidation (326;351;352). 
 
With experiments involving rotenone and MitoQ10 failing to provide conclusive results, it 
would have been of interest to examine mitochondrial O2
- production further in isolated 
mitochondria by means of EPR spectroscopy (325) or in intact cells using methods such as 
aconitase inactivation (353) and/or oxidation of the mitochondrially targeted hydroethidine 
derivative,  MitoSOX
™  (Invitrogen)  (354;355).  Unfortunately,  limited  vascular  material 
and time constraints meant such investigations were not possible. 
 
As outlined, in addition to mitochondria, uncoupled eNOS is a principal source of O2
- 
production in the endothelium (173). With vessels from CAD patients, particularly those 
with T2D, displaying attenuated endothelium-dependent relaxation, HSVEC eNOS mRNA 
expression, phosphorylation and contribution to elevated O2
- production were investigated 
in CAD patients.  
 
It  has  been  suggested  that  endothelial  dysfunction  could  be  due  to  decreased  eNOS 
expression  (170).  However,  several  studies  have  shown  that  CVD  risk  factors  are 
associated with an increase, rather than a decrease, in eNOS expression (356). Increased 
expression  of  eNOS  in  vascular  tissue  is  thought  to  be  a  consequence  of  an  excess 
production of H2O2 which can increase eNOS mRNA expression through transcriptional 
and  posttranscriptional  mechanisms  (357).  No  significant  difference  in  HSVEC  NOS3 
expression was observed between patient groups (Figure 3.12A), perhaps surprising given 
elevated  levels  of  SOD2  expression  (Figure  3.8),  associated  with  increased  H2O2 
production (358), in cells from CAD patients. A number of drugs with favourable effects 
on CAD phenotype, including ACE inhibitors, ARBs and statins, also upregulate eNOS 
mRNA  expression  (356).  With  a  high  percentage  of  this  study  cohort  prescribed  such 
medications  (Table  2.1),  HSVEC  NOS3  expression  data  may  serve  to  support  the 
hypothesis that effects of pharmacological treatments are not maintained during the cell 
culture process. Additional findings showed eNOS protein expression and levels of eNOS 114 
Ser1177 phosphorylation to be similar in HSVEC lysates from patients with CAD and T2D 
and those with CAD alone (Figure 4.7), suggesting no difference in eNOS activity between 
these patient groups.  
 
Despite the apparent lack of change in HSVEC eNOS expression and activity between 
patient groups, poorer endothelial function in vessels from CAD patients indicates eNOS 
may be uncoupled, producing O2
- rather than NO. Indeed, previous work within our group 
demonstrated significantly reduced O2
- production in saphenous veins of CAD patients on 
pretreatment with the eNOS inhibitor, L-NAME (302). Dysfunctional eNOS has also been 
identified as a source of O2
- production in vessels from patients with CAD and T2D (179). 
However, on preincubating HSVECs with L-NAME, cells from both control subjects and 
CAD  patients  demonstrated  elevated  O2
-  production  (Figure  3.12B).  Numbers  failed  to 
reach statistical significance, making it difficult to draw a  clear conclusion from these 
findings, but it is possible that in cultured HSVECs, eNOS is not a major source of O2
-. 
HSVEC eNOS may instead reduce vascular O2
- release through production of NO, such 
that inhibiting NO production causes an increase in O2
- levels. This has previously been 
shown  to  be  the  case  in  vessels  from  CAD  patients  denuded  of  endothelium  (179). 
Alternatively,  the  possibility  must  be  considered  that  free  from  physiological  stresses, 
cultured  HSVECs  do  not  retain  the  in  vivo  phenotype.  In  the  future,  investigation  of 
cellular NO and ONOO
- production may provide additional insight into HSVEC eNOS 
activity. 
 
NAD(P)H oxidase has  been shown to be a major source of O2
- in intact vessels from 
patients with CAD (208), in particular those CAD patients with T2D (179). The p22
phox 
membrane-bound NAD(P)H oxidase subunit has been identified as crucial for enzymatic 
function (199) and p22
phox expression is significantly increased in coronary arteries from 
patients with CAD relative to those from control subjects (208), and in vessels from CAD 
patients with T2D as compared to those from patients with CAD alone (179). To date, 
similar comparisons have not been carried out in primary human vascular endothelial cells. 
This study found no significant difference in HSVEC p22
phox mRNA expression between 
patient groups (Figure 3.13A), indicating the increased expression previously observed by 
Guzik  and  colleagues  (208)  may  be  specific  to  arteries  or  non-endothelial  cells  of  the 
vasculature.  
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Attempts  to  confirm  p22
phox  expression  data  at  the  protein  level  proved  unsuccessful 
despite using a number of anti-p22
phox primary antibodies under a variety of conditions. As 
described, cellular extracts were used for immunoblotting. Given p22
phox is a membrane-
bound protein, it may have been useful to perform western blotting of cellular membrane 
preparations.  Of  note,  previous  studies  have  successfully  investigated  p22
phox  protein 
expression  in  vascular  homogenates  (179;208)  and  mononuclear  cells  (210).  However, 
such  investigations  have  not  previously  been  performed  in  primary  human  vascular 
endothelial cells. As a result, with no change in p22
phox mRNA expression observed, it was 
necessary to assume a change in protein expression between patient groups would have 
been unlikely.  
 
In  contrast  to  p22
phox  expression  studies,  inhibition  of  endothelial  NAD(P)H  oxidase 
indicated  enzyme  activity  is  altered  in  individuals  with  CAD  (Figure  3.13B).  DPI  and 
apocynin, inhibitors of NAD(P)H oxidase, have been shown to significantly reduce O2
- 
production  in  intact  portions  of  saphenous  veins  from  CAD  patients  (159;302;318). 
Pretreating HSVECs with these inhibitors caused a greater reduction in O2
- production in 
CAD patients than in control subjects (Figure 3.13B). As expected, the greater of these 
reductions was on preincubation with the less specific of the two inhibitors, DPI, which 
caused  a  significant  decrease  in  CAD  patients.  In  addition  to  NAD(P)H  oxidase,  DPI 
inhibits  nitric  oxide  synthases  (359),  xanthine  oxidase  (360),  mitochondrial  complex  I 
(361) and cytochrome P-450 reductase (362). An attempt to address this lack of specificity 
was  made  by  performing  additional  experiments  involving  apocynin  which  blocks 
assembly of the NAD(P)H oxidase complex (159). Although not statistically significant, 
the  differential  reduction  in  O2
-  levels  achieved  by  the  two  inhibitors  implicates  the 
aforementioned flavoproteins in endothelial O2
- generation in CAD. However, it has been 
suggested that apocynin could itself lack selectivity and may require to be metabolised by a 
peroxidase enzyme in order to become active (363).  
 
Interestingly, both DPI and apocynin were observed to cause a greater decrease in cellular 
O2
- production in patients with CAD alone (Figure 3.13B), suggesting NAD(P)H oxidase 
may contribute to O2
- production to a lesser extent in T2D patients. This finding would 
support the earlier hypothesis that mitochondria are a major source of O2
- generation in the 
endothelium of patients with CAD and T2D. 
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While  the  contribution  of  xanthine  oxidase  to  O2
-  generation  in  HSVECs  was  not 
considered during the course of this project, it is recognised that the enzyme has been 
identified as a key source of ROS production in both coronary arteries (208) and saphenous 
veins  (159;302)  from  patients  with  CAD.  In  light  of  these  published  data  and  results 
obtained on treating cells with DPI and apocynin, investigation of xanthine oxidase activity 
and expression may represent a focus of future studies. 
 
In summary, the findings presented in this chapter demonstrate elevated O2
- levels and 
endothelial  dysfunction  in  saphenous  veins  from  patients  with  CAD,  with  poorer 
endothelial  function  in  those  CAD  patients  with  the  additional  CVD  risk  factor,  T2D. 
Results  show  increased  levels  of  SOD2  expression  in  HSVECs  from  CAD  patients, 
suggesting mitochondria may be a principal source of O2
- production in the endothelium of 
these  patients,  in  particular  those  with  T2D.  Findings  also  suggest  that  while  HSVEC 
eNOS is not a major source of O2
- generation in CAD, NAD(P)H oxidase contributes to 
excess O2
- production in the endothelium of patients with this condition. Taken together, 
results support the idea that inhibition of vascular NAD(P)H oxidase represents a means of 
reducing vascular oxidative stress and progression of cardiovascular disease (364;365) and 
suggest that mitochondrially-targeted antioxidants, such as MitoQ10, may have therapeutic 
potential in patients with CAD and T2D. 117 
 
 
 
 
 
4. Endothelial AMP-activated Protein Kinase 
Activity in Coronary Artery Disease 
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4.1 Introduction 
 
Vascular endothelial cells are recognised as being highly glycolytic (228;366). Quintero 
and colleagues confirmed this to be the case in HUVECs, leading them to propose that 
mitochondria  in  these  cells  are  not  preferentially  used  for  bioenergetic  purposes  but 
function primarily in the generation of ROS which act as signalling molecules, facilitating 
activation of enzymes such as AMPK (228). AMPK is now recognised as a potential target 
for  therapeutic  intervention  in  hyperglycaemia-induced  endothelial  dysfunction  (section 
1.5.1).  Following  the  results  outlined  in  Chapter  3,  showing  that  there  is  increased 
expression of SOD2 in HSVECs isolated from patients with CAD and T2D, consistent 
with  increased  mtROS  production,  one  objective  of  this  project  was  to  investigate  the 
activity and activation of AMPK in the endothelium of patients with T2D.   
 
As outlined in section 1.5, AMPK is a widely conserved serine/threonine protein kinase 
involved  in  the  regulation  of  cellular  and  whole  body  energy  status  and  has  a 
heterotrimeric structure, comprising a catalytic α-subunit (α1 or α2) and regulatory β- (β1, 
β2)  and  γ-subunits  (γ1,  γ2,  γ3)  each  of  which  has  two  or  more  isoforms  that  are 
differentially  expressed  in  various  tissues  (248).  Both  α1  and  α2  catalytic  subunits, 
encoded by PRKAA1 and PRKAA2 respectively, are expressed in liver, cardiomyocytes 
and skeletal muscle (367). However, the α1 subunit has been identified as the predominant 
form in endothelial cells (286;297).  
 
Activation  of  AMPK  requires  phosphorylation  at  Thr172  by  an  AMPKK.  Two  major 
AMPKKs have been identified to date, LKB1 and CaMKK (251;253;264). It has been 
proposed that LKB1 activity is constitutive, such that stimuli that increase the AMP/ATP 
ratio,  including  hypoxia,  hypoglycaemia  and  ischemia,  inhibit  dephosphorylation  at 
Thr172 permitting phosphorylation and activation by LKB1 (248). In contrast, activation 
of  AMPK  by  Ca
2+  is  AMP-independent  and  mediated  by  the  α  and/or  β  isoforms  of 
CaMKK (264;265). Very recently, a third upstream kinase, transforming growth factor-1β-
activated kinase, or TAK1, has been identified in yeast (368) and appears to be important 
in cardiac cells (369) but its role in other cell types is still largely undefined. Recent studies 
have  also  revealed  activation  of  AMPK  via  an  AMP-independent,  ROS-mediated 
mechanism with NO (370), H2O2 (296) and ONOO
- (289)  all observed to activate the 
kinase in cultured cells.  
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There are numerous downstream targets of AMPK, including ACC and eNOS. Human 
ACC1 and ACC2 are phosphorylated and inhibited at Ser80 and Ser220 respectively by 
AMPK (287) while the kinase phosphorylates and activates eNOS at Ser1177 as previously 
described (176;282) (section 1.5.2). 
 
 
 
The aims of the experimental work outlined in this chapter were as follows: 
 
(1) to determine whether HSVECs, like HUVECs, favour glycolysis over oxidative 
phosphorylation; 
(2) to compare AMPK activity in HSVECs isolated from patients with CAD alone and 
with CAD and T2D; 
(3) to  investigate  upstream  mediators  of  AMPK  activation  in  HSVECs,  including 
mtROS 
 
 
 
4.2 Materials & Methods  
 
4.2.1 Study Participants 
 
Patients with CAD were as described in section 2.2. 
 
 
4.2.2 Human Vascular Tissue & Primary Cell Culture 
 
Vascular  tissue  was  obtained  and  prepared  as  described  in  section  2.3  and  HSVECs 
isolated, characterised and cultured as outlined in section 2.4. For experimental procedures 
carried  out  in  Professor  Moncada’s  laboratory  (Wolfson  Institute  For  Biomedical 
Research, University College London), HSVECs were cultured in endothelial cell growth 
medium, EGM 2 (PromoCell, Heidelberg, Germany), supplemented with 2% (v/v) FCS. 120 
For all experiments, cells were used between passages 3 and 5 and procedures carried out 
when cells were approximately 80% confluent. 
 
 
4.2.3 Determination of ATP Production in HSVECs 
 
Determination  of  the  contribution  of  oxidative  phosphorylation  and  glycolysis  to  the 
generation of ATP in HSVECs was carried out in Professor Moncada’s laboratory, using 
the method of Quintero and colleagues (228). HSVECs were grown for 24 hours in 96-well 
plates  [PerkinElmer  (Waltham,  MA)  3603  clear  bottom,  black  walls,  seeding  density 
10,000 cells per well] in phenol-red free ECM2 supplemented with 2% (v/v) FCS. On the 
day of the experiment, fresh medium was added and cells pretreated with 20 mM 2-deoxy-
D-glucose  (2DG)  and  0.5   M  rotenone  (both  Sigma-Aldrich  Company  Ltd).  2DG  is  a 
glycolytic pathway inhibitor and rotenone, as stated, is an inhibitor of the mitochondrial 
respiratory chain (228). ATP was measured by the luciferin/luciferase method with the 
PerkinElmer  ATPlite
™  Luminescence  Assay  System,  following  the  manufacturer’s 
protocol. Chemiluminescence was determined in a TopCount (Packard Biosciences) and 
data analysed in Excel (Microsoft).  
 
 
4.2.4 Western Blot Analysis 
 
Cell  lysates  were  prepared  as  outlined  in  section  2.6.3  unless  experiments  involved 
treatment of cells with AICAR, the artificial activator of AMPK. For these experiments, 
serum-free medium was removed following overnight incubation and replaced with 5 ml 
KRH buffer +/- 2 mM AICAR (Sigma). Cells were then incubated for 1 hour at 37ºC in a 
CO2–free  incubator  and  lysates  prepared  as  previously  described.  Total  protein 
concentration of each sample was determined by Pierce BCA Protein Assay according to 
the manufacturer’s protocol and using the Wallac Victor
2 plate reader. Western blots were 
then carried out as outlined in sections 2.8.1 unless otherwise indicated. 
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4.2.4.1 Primary Antibodies 
 
Primary antibodies utilised during this study are listed in Table 4.1.   
 
 
4.2.4.2 Secondary Antibodies 
 
Secondary antibodies utilised during this study are listed in Table 4.2. 
 
 
4.2.4.3 AMPK Thr172 Phosphorylation at Different Oxygen Concentrations 
 
Western blots to assess AMPK Thr172 phosphorylation at different O2 concentrations were 
carried  out  in  Professor  Moncada’s  laboratory,  using  the  method  of  Quintero  and 
colleagues (228). On the day of the experiment, fresh medium was added and hypoxia 
achieved by incubating cells at 37ºC in an O2-controlled hypoxic chamber (Coy Laboratory 
Products, Ann Arbor, MI) for 2 hours. Cells were washed with PBS, scraped off in ice-cold 
PhosphoSafe
™  Extraction  Buffer  (Novagen,  Nottingham,  U.K.)  and  centrifuged  for  10 
minutes  at  13,000  x  g  (4ºC).  From  clear  supernatants,  protein  concentration  was 
determined using the Bio-Rad DC Protein Assay kit (Bio-Rad, Herts, U.K.) using bovine 
serum albumin (BSA) as control. Sample aliquots were boiled for 2 minutes, and 20  g of 
total  protein  with  equal  volumes  of  reducing  loading  dye  electrophoresed  in  precast 
SDS/PAGE  4-15%  gradient  gels  (Bio-Rad).  Full  Range  Rainbow  Molecular  Weight 
Markers were included on blots. Proteins were transferred onto Hybond-P nitrocellulose 
membranes  overnight  at  25  volts  in  transfer  buffer  and  assessed  for  equal  loading  / 
transference  by  Ponceau  S  Solution  (Sigma-Aldrich)  staining.  Membranes  were  then 
blocked (with shaking) in TBS-T + 5% (w/v) fat-free milk powder for approximately 45 
minutes  before  a  five  hour  incubation  at  4ºC  (with  shaking)  in  a  rabbit  anti-phospho-
AMPK-α1-Thr-172 primary antibody solution, followed by a 45 minute incubation with 
HRP-conjugated goat anti-rabbit IgG. ECL (GE Healthcare) was used for detection. Films 
were exposed for between 30 seconds and 5 minutes and developed in a Kodak X-OMAT 
1000. 122 
 
Epitope  Clonality  Host 
Species 
Dilution  Diluent   
(w/v in  
TBS-T) 
Source 
α-ACC1     
N-term  
(cDEP)   
polyclonal  sheep  1:1000  5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie, 
University of 
Dundee, Dundee, 
U.K. 
 
CDEPSPLAKTLEL
NQ (C + residues 2-
15 of rat ACC) 
coupled to KLH 
α-ACC Ser79   polyclonal  rabbit  1:1000  5% BSA  Cell Signalling 
Technology, Beverly, 
MA, U.S.A.     
(#3661) 
α-AMPKα1  polyclonal  sheep  1:1000  5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie 
(371) 
α-AMPKα2  polyclonal  sheep  1:1000  5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie 
(371) 
α-AMPKα1 
Thr172  
polyclonal  rabbit  1:1000  5% BSA  Cell Signalling 
Technology, Beverly, 
MA, U.S.A.     
(#2531) 
α-CaMKKα   monoclonal 
(clone: F-2) 
mouse  1:200  5% fat-free 
milk powder 
Santa Cruz 
Biotechnology, CA, 
U.S.A.                   
(sc-17827) 
α-eNOS  polyclonal 
 
rabbit   1:5000   1% BSA  Sigma-Aldrich, St 
Louis, MO, U.S.A. 
N2643 
α-eNOS 
Ser1177  
 
polyclonal  rabbit  1:1000  5% BSA  Cell Signalling 
Technology, Beverly, 
MA, U.S.A.    
(#9571) 
 
Table 4.1. Primary Antibodies – continued overleaf 123 
α-LKB1  polyclonal  sheep  1:500  5% fat-free 
milk powder 
A generous gift from 
Prof. D.G. Hardie  
LKB1 antibody was 
raised against the 
whole protein in 
sheep and purified 
using protein G. 
 
Table 4.1. Primary Antibodies. BSA, bovine serum albumin; KLH, keyhole limpet haemocyanin 124 
 
Linked 
Molecule 
Epitope  Host 
Species 
Dilution  Diluent       
(w/v in TBST) 
Source 
HRP  α-mouse IgG   sheep  1:1000  5% fat-free 
milk powder or 
BSA 
GE Healthcare 
U.K. Ltd, Bucks, 
U.K.  
(#NA 931) 
 
HRP  α-rabbit IgG   goat  1:5000  5% fat-free 
milk powder 
Vector 
Laboratories Inc., 
Burlingame, CA, 
U.S.A. 
(#PI-1000) 
HRP  α-rabbit IgG   donkey  1:1000  5% fat-free 
milk powder or 
BSA 
GE Healthcare 
U.K. Ltd, Bucks, 
U.K. 
(#NA 934) 
 
HRP  protein 
G−peroxidase 
from 
streptococcus sp.  
n/a  1:1000  5% fat-free 
milk powder or 
BSA 
Sigma-Aldrich, St 
Louis, MO, U.S.A. 
(#P8170) 
 
Table 4.2. Secondary Antibodies. BSA, bovine serum albumin; IgG, immunoglobulin G; n/a, not 
applicable 
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4.2.4.4 Densitometric Quantification of Protein Bands 
 
Densitometric quantification of protein bands, relative to an internal invariant control was 
carried out as outlined in section 2.8.2.  
 
 
4.2.5 PRKAA1 & PRKAA2 mRNA Expression 
 
RNA was extracted from HSVECs as per section 2.5 and PRKAA1 and PRKAA2 mRNA 
expression levels assessed as outlined in section 2.7 using Applied Biosystems Custom 
TaqMan
®  Gene  Expression  Assays  for  PRKAA1  (Hs01562315_m1)  and  PRKAA2 
(Hs00178903_m1)  and  TaqMan
®  Endogenous
  Control,  GAPDH  (4326317E).  Reactions 
were carried out in singleplex. 
 
 
4.2.6 AMPK Activity Assay 
 
AMPK  was  immunoprecipitated  from  lysates  and  assayed  using  the  SAMS  substrate 
peptide (HMRSAMSGLHLVKRR), employing a variation on the method of Davies et al. 
(372)  as  outlined  by  Hardie  and  colleagues  (373).  SAMS  peptide  was  synthesised  by 
Pepceuticals Ltd (Nottingham, U.K.). 
 
 
4.2.6.1 Preparation of HSVEC Lysates 
 
Cell  lysates  were  prepared  as  outlined  in  section  2.6.3  unless  experiments  involved 
treatment of cells with test substances, AICAR (2 mM), MitoQ10 (1  M) and DTPP (1  M). 
Concentrations of test substances were obtained from relevant literature (176;328). Serum-
free medium was removed following overnight incubation and replaced with 5 ml KRH 
buffer +/- test substances as indicated. Cells were then incubated for 1 hour at 37ºC in a 
CO2–free  incubator  and  lysates  prepared  as  previously  described.  Total  protein 126 
concentration of each sample was determined by Pierce BCA Protein Assay kit according 
to the manufacturer’s protocol and using the Wallac Victor
2 plate reader. 
 
 
4.2.6.2 Immunoprecipitation of AMPK 
 
5 µl (packed volume) of Protein G-Sepharose™ 4 Fast Flow beads (GE Healthcare) were 
washed  by  centrifugation  (14,000  x  g,  20  seconds,  4ºC)  with  3  x  1  ml  of 
immunoprecipitate (IP) buffer [50 mM Tris-HCl, pH 7.4 at 4ºC, 150 mM NaCl, 50 mM 
NaF, 5 mM Na4P2O7, 1 mM EDTA, 1mM EGTA: 1 x stock was prepared and before use 
1mM dithiothreitol (DTT), 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/ml soybean trypsin 
inhibitor, 1mM NaVO3, 1% (v/v) glycerol, 1% (v/v) Triton X-100 (final concentrations) 
were added]. Beads were then resuspended in 200 µl IP buffer. 2  g per sample of affinity-
purified  sheep  anti-AMPKα1  and  α2  catalytic  subunit  isoform-specific  antibodies  were 
added to the Protein G-Sepharose™ slurry which was subsequently mixed by rotating for 1 
hour at 4ºC. 
 
The slurry was then centrifuged (14,000 x g, 3 minutes, 4ºC), supernatant removed and the 
remaining pellet washed, as before, with 1 ml ice cold  IP buffer. The final pellet was 
resuspended in a volume of IP buffer sufficient to allow for one 20 µl slurry aliquot per 
sample. To each 20 µl aliquot, 200 µg of cell lysate was added and final volumes made 
approximately equal by adding 200 µl IP buffer per sample. Samples were then mixed by 
rotating for 2.5 hours at 4ºC. 
 
Following mixing, samples were centrifuged (14,000 x g, 3 minutes, 4ºC) and supernatants 
removed before pellets were washed with 2 x 1ml ice-cold IP buffer containing 1 M NaCl 
(to remove non-specifically bound protein), 2 x 1 ml ice-cold IP buffer and, finally, 1 x 1 
ml HEPES-Brij buffer [50 mM HEPES, pH 7.4, 1 mM DTT, 0.02% (v/v) Brij-35 (Sigma)]. 
All washes were by means of centrifugation at 14,000 x g and 4ºC for 20 seconds. After 
the  final  wash,  as  much  supernatant  as  possible  was  removed  and  immunoprecipitates 
frozen at -20 ºC until activity assays were performed. 
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4.2.6.3 Assaying AMPK Activity 
 
Reaction mixtures (20 µl) containing 5 µl HEPES-Brij buffer, 5 µl 1 mM AMP in HEPES-
Brij buffer, 5 µl 1 mM SAMS peptide in HEPES-Brij buffer and 5 µl immunoprecipitate 
resuspended in HEPES-Brij buffer were prepared on ice and the reaction initiated by the 
addition  of  5  µl  [γ-
32P]ATP  (Amersham)  solution  [1  mM  [γ-
32P]ATP  with  a  specific 
activity in the range of 250,000 to 500,000 counts per minute per nmol (cpm nmol
-1), and 
25 mM MgCl2]. For each sample, reactions were carried out in duplicate. Negative control 
reactions were prepared for all samples by substituting SAMS with HEPES-Brij buffer. 
After  incubation  at  30ºC  for  10  minutes,  15  µl  of  reaction  mixture  was  removed  and 
spotted onto 1 cm
2 pieces of P-81 phosphocellulose paper (Whatman plc, Kent, U.K.). 
Paper was then dropped into 1% (v/v) phosphoric acid to stop the reaction. The P-81 paper 
squares  were  washed  in  fresh  phosphoric  acid  3  times  and  then  rinsed  with  water. 
Incorporation  of 
32P  into  the  substrate  peptide  was  determined  by  liquid  scintillation 
counting using a LS 6500 Scintillation Counter [Beckman Coulter (U.K.) Ltd - Biomedical 
Research,  Bucks,  U.K]  after  immersing  filters  in  Ecoscint  scintillation  fluid  [National 
Diagnostics (U.K.) Ltd, Yorkshire, U.K.] 
 
 
4.2.7 Statistical Analysis 
 
Statistical analyses were performed as outlined in section 2.9. 
 
 
 
4.3 Results 
 
4.3.1 HSVEC ATP Production 
 
In HSVECs isolated from 3 patients with CAD, on comparison with untreated cells, there 
was a greater decrease in intracellular ATP generation on pretreatment with 2DG (118.96 ± 
5.26 vs 36.26 ± 2.11  mol/10
6 cells; P<0.0001; Figure 4.1) than on pretreatment with 128 
rotenone (118.96 ± 5.26 vs 100.90 ± 5.26  mol/10
6 cells; P=0.175; Figure 4.1) and an 
additive effect when inhibitors were used in combination (118.96 ± 5.26 vs 7.62 ± 6.85 
 mol/10
6 cells; P<0.0001; Figure 4.1). 
 
 
4.3.2  Effect  of  Oxygen  Concentration  on  HSVEC  AMPK  Thr172 
Phosphorylation 
 
Western blotting to assess AMPK activation in HSVECs isolated from patients with CAD 
revealed marked phosphorylation of the enzyme across a range of oxygen concentrations, 
including 21% O2 or ‘normoxia’ (Figure 4.2).  
 
 
4.3.3 HSVEC AMPK Activity 
 
Based on results shown in Figure 4.2, total AMPK activity was assessed in HSVEC lysates 
from cells cultured at 21% O2 using a synthetic peptide kinase assay. As shown in Figure 
4.3, AMPK activity was increased in cells from patients with CAD as compared to those 
from  control  subjects  (0.045  ±  0.007  vs  0.022  ±  0.006  nmol/min/mg;  P=0.046).  On 
comparison with control subjects, a greater increase in AMPK activity was observed in 
HSVECs from patients with CAD and T2D (0.062 ± 0.011 vs 0.022 ± 0.006 nmol/min/mg; 
P=0.007; Figure 4.3) than in cells from patients with CAD alone (0.031 ± 0.005 vs 0.022 ± 
0.006 nmol/min/mg; P=0.261; Figure 4.3). AMPK activity was also significantly higher in 
HSVECs from patients with CAD and T2D than in those from patients with CAD alone 
(0.062 ± 0.011 vs 0.031 ± 0.005 nmol/min/mg; P=0.014; Figure 4.3). Treating cells with 
AICAR resulted in an equal, approximately two- to three-fold, increase in kinase activity 
for all patient groups (Figure 4.3). 129 
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Figure 4.1. ATP Production in HSVECs. Using the luciferin/luciferase method, ATP production 
was assessed in HSVECs isolated from CAD patients (n=3). HSVECs were pretreated with (+) the 
glycolytic  pathway  inhibitor,  2-deoxy-D-glucose  (2DG),  and  rotenone,  an  inhibitor  of  the 
mitochondrial respiratory chain. *, † P< 0.0001 relative to basal values for untreated cells.  130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.2.  Effect  of  Oxygen  Concentration  on  AMPKα1  Thr172  Phosphorylation  in 
HSVECs from CAD Patients. HSVECs isolated from 3 patients with CAD were incubated for 2 
hours  at  different  oxygen  (O2)  concentrations  (21%,  3%  and  <0.5%)  in  a  controlled  hypoxic 
chamber and AMPK Thr172 phosphorylation assessed by western blotting of cell lysates.  
patient #1  patient #2 patient #3
21  3  0.5 21 3  0.5 21  3  0.5
patient #1  patient #2 patient #3
21  3  0.5 21 3  0.5 21  3  0.5
62 kDa 
% O2 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.3.  Comparison  of  Total  AMPK  Activity  in  Immunoprecipitates  from  HSVEC 
Lysates Cultured at 21% Oxygen. HSVEC lysates were prepared from cells isolated from control 
subjects (n=8) and patients with CAD (n=10). These CAD patients were stratified according to 
absence (ND, n=5) or presence (T2D, n=5) of type 2 diabetes. Cells were incubated with (+) and 
without (-) AICAR. ‡, P < 0.05 and †, P < 0.01 vs control subjects. *, P < 0.05 vs CAD patients 
without  diabetes.  Incubation  with  AICAR  resulted  in  a  non-significant,  approximately  two-  to 
three-fold increase in AMPK activity for all patient groups. 
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AICAR 132 
AMPK activation at 21% O2 was further investigated and compared in HSVECs from CAD 
patients  with  and  without  T2D  by  means  of  western  blot  analysis  using  sheep  anti-
AMPKα1 and rabbit anti-AMPKα1 Thr172 primary antibodies with donkey anti-rabbit IgG 
and protein G-peroxidase secondary antibodies respectively (Figure 4.4A). Patient samples 
were  compared  to  an  internal  invariant  control  sample.  Densitometry  revealed  no 
statistically significant difference in AMPKα1 expression between patient groups (Figure 
4.4B) and showed preincubating cells with AICAR had no effect on protein expression 
(Figure  4.4B).  Densitometrical  analysis  demonstrated  a  trend  towards  higher  levels  of 
phosphorylation of AMPKα1 in cells from CAD patients with T2D but results did not 
reach  statistical  significance  (Figure  4.4C).  Treatment  with  AICAR  caused  an 
approximately equal, three-fold increase in AMPK phosphorylation in HSVECs from both 
patient groups (Figures 4.4A and 4.4C). 
 
 
4.3.4 HSVEC PRKAA1 & PRKAA2 mRNA Expression 
 
Despite  increased  AMPK  activity  in  HSVECs  from  patients  with  CAD,  no  change  in 
mRNA expression of PRKAA1, encoding the AMPKα1 catalytic subunit, was observed 
between patient groups (Figure 4.5), consistent with modulation of AMPK activity via 
post-translational phosphorylation.  
 
Expression of PRKAA2 mRNA, encoding the α2 subunit, was undetectable in HSVECs. 
 
 
4.3.5 HSVEC AMPK Substrate Phosphorylation 
 
Given the increased AMPK activity observed in HSVECs from patients with CAD, it was 
of interest to investigate phosphorylation of AMPK substrates, ACC and eNOS, in cells 
from these patients.  133 
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Figure 4.4 Comparison of AMPKα1 Thr172 Phosphorylation in HSVEC Lysates Cultured at 
21% Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, 
n=5) type 2 diabetes and AMPKα1 Thr172 phosphorylation (pAMPKα1) in the presence (+) and 
absence (-) of AICAR assessed by western blotting of cell lysates. Representative immunoblots are 
shown. (B) Densitometrical analysis demonstrated no significant difference in AMPKα1 expression 
between patient groups. Pretreatment with AICAR (+) had no effect on AMPKα1 expression in 
cells from either group of patients. (C) Densitometry revealed a trend towards increased levels of 
pAMPKα1 in HSVECs from T2D patients in the absence (-) of AICAR. Pretreatment with AICAR 
(+) caused an approximate three-fold increase in AMPK phosphorylation in HSVECs from both 
patient groups. 
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Figure  4.5.  HSVEC  PRKAA1  mRNA  Expression  Relative  to  GAPDH  as  Assessed  by 
TaqMan
® qRT-PCR. Expression of PRKAA1 was investigated in HSVECs isolated from controls 
(n=5) and patients with CAD (n=20), stratified according to the absence (ND, n=15) or presence of 
type 2 diabetes (T2D, n=5). No difference in PRKAA1 expression was observed between patient 
groups. RQ, relative quantitation 135 
Western blotting to assess ACC phosphorylation was carried out using rabbit anti-ACC-
Ser79, an antibody which recognises both phosphorylated ACC species (ACC1 and ACC2) 
(Figure 4.6A). Again, an internal invariant control sample was used as a standard. Treating 
cells with AICAR caused a marked increase in ACC phosphorylation in HSVECs from 
CAD patients both with and without T2D (Figure 4.6A). Due to technical issues, ACC 
phosphorylation  was  determined  relative  to  AMPKα1  (Figure  4.4A).  Densitometrical 
analysis demonstrated a trend towards increased ACC phosphorylation in cells from CAD 
patients with T2D and revealed a significant increase in ACC phosphorylation in HSVECs 
from both patients with CAD alone (0.122 ± 0.085 vs 5.06 ± 0.966; P=0.0009) and patients 
with CAD and T2D (0.441 ± 0.239 vs 3.86 ± 0.579; P=0.0006) on treatment with AICAR 
(Figure 4.6B). 
 
Phosphorylation of eNOS was also assessed by means of western blot using rabbit anti-
eNOS and rabbit anti-eNOS-Ser1177 antibodies using an internal invariant control sample 
as  a  standard  (Figure  4.7A).  Densitometry  revealed  a  trend  towards  increased 
phosphorylation in HSVECs isolated from CAD patients with T2D as compared to those 
without and an increase in eNOS phosphorylation in cells from both patients groups on 
treatment with AICAR (Figure 4.7B). 
 
 
4.3.6 HSVEC AMPK Upstream Kinase Phosphorylation 
 
In order to determine the reason for increased AMPK activity in HSVECs from patients 
with CAD and T2D, protein expression of upstream AMPKKs, LKB1 and CaMKKα was 
investigated and compared in HSVECs from patients with CAD and T2D and CAD alone 
using an internal invariant control sample as a standard. 
 
LKB1 western blotting showed similar band intensities in samples from HSVECs from 
CAD patients with and without T2D (Figure 4.8A) and densitometry revealed equal levels 
of LKB1 expression in cells from both patient groups (Figure 4.8B). Sheep anti-LKB1 
primary  antibody and protein G−peroxidase from streptococcus sp. secondary  antibody 
were used. 136 
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Figure 4.6. Comparison of ACC Ser80 Phosphorylation in HSVEC Lysates Cultured at 21% 
Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, n=5) 
type 2 diabetes and ACC Ser79 phosphorylation in the presence (+) and absence (-) of AICAR 
assessed  by  western  blotting  of  cell  lysates.  A  representative  immunoblot  is  shown.  (B) 
Densitometry  revealed  a  trend  towards  increased  levels  of  ACC  phosphorylation  at  Ser79  in 
HSVECs from T2D patients in the absence (-) of AICAR. Pretreatment with AICAR (+) caused a 
significant  increase  in  ACC  Ser79  phosphorylation  in  HSVECs  from  both  patient  groups.  †, 
P<0.001 vs T2D (- AICAR). *, P<0.001 vs ND (- AICAR). 
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Figure 4.7 Comparison of eNOS Ser1177 Phosphorylation in HSVEC Lysates Cultured at 
21% Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, 
n=5) type 2 diabetes and eNOS Ser1177 phosphorylation in the presence (+) and absence (-) of 
AICAR assessed by western blotting of cell lysates. Bands of the relevant size (140 kDa) were 
observed for the majority of patients but were of varying density. A representative immunoblot is 
shown. (B) Densitometry revealed a trend towards increased levels of eNOS phosphorylation at 
Ser1177  in  HSVECs  from  T2D patients  in the  absence  of  AICAR.  Pretreatment  with  AICAR 
caused no significant increase in eNOS Ser1177 phosphorylation in HSVECs from either patient 
group. 
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Figure 4.8. Comparison of LKB1 Protein Expression in HSVEC Lysates Cultured at 21% 
Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, n=5) 
type  2  diabetes  and  LKB1  protein  expression  in  the  presence  (+)  and  absence  (-)  of  AICAR 
assessed by western blotting of cell lysates. Bands of the relevant size (50 kDa) were observed for 
all patients and appeared of approximately equal density. A representative immunoblot is shown. 
(B)  Densitometrical  analysis  revealed  approximately  equal  levels  of  LKB1  expression  across 
patient and treatment groups. 
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Western  blotting  to  assess  CaMKKα  expression  was  carried  out  using  mouse  anti-
CaMKKα primary antibody and sheep anti-mouse IgG secondary antibody (Figure 4.9A). 
Densitometrical analysis demonstrated no significant difference in CaMKKα expression in 
cells from either group on pretreatment with AICAR or between patient groups in the 
absence of AICAR (Figure 4.9B). However, on pretreatment with AICAR, expression was 
observed to be significantly different between patient groups (T2D vs ND; 1.184 ± 0.262 
vs 4.363 ± 1.258; P=0.04) (Figure 4.9B). 
 
 
4.3.7 Mitochondrial ROS-Mediated AMPK Activation in HSVECs 
 
The contribution of mtROS to AMPK activation was investigated by treating HSVECs 
from CAD patients with the mitochondria-targeted antioxidant, MitoQ10, in the presence 
and absence of AICAR. To control for non-specific effects of MitoQ10, cells were treated 
with the non-active control compound, DTPP which, as previously stated, comprises the 
lipophilic  TTP  cation  but  lacks  the  ubiquinone  moiety  of    MitoQ10  (324).  Exposing 
HSVECs to MitoQ10 resulted in a reduction in AMPK activity which was attenuated on 
addition of AICAR (Figure 4.10). The MitoQ10-mediated decrease in AMPK activity was 
greater  in  HSVECs  from  CAD  patients  with  T2D  (0.056  ±  0.004  vs  0.009  ±  0.01 
nmol/min/mg; P=0.016) than in those from patients with CAD alone (0.035 ± 0.005 vs 
0.014  ±  0.0002  nmol/min/mg;  P=0.052)  for  whom  the  effects  of  MitoQ10,  in  both  the 
presence and absence of AICAR, were non-significant (Figure 4.10). 140 
A 
 
 
 
 
 
B 
*
0
1
2
3
4
5
6
C
a
M
K
K
α
(
O
D
U
/
m
m
2
)
- + - +
T2D T2D ND ND
AICAR
*
0
1
2
3
4
5
6
C
a
M
K
K
α
(
O
D
U
/
m
m
2
)
- + - +
T2D T2D ND ND
AICAR
 
 
Figure 4.9. Comparison of CaMKKα Protein Expression in HSVEC Lysates Cultured at 21% 
Oxygen. (A) HSVECs were isolated from CAD patients with (T2D, n=5) and without (ND, n=5) 
type 2 diabetes and CaMKKα protein expression in the presence (+) and absence (-) of AICAR 
assessed by western blotting of cell lysates. Bands of the relevant size (63 kDa) were observed for 
all patients but were of varying density. (B) Densitometry revealed no significant difference in 
CaMKKα expression in cells from either group on pretreatment with AICAR or between patient 
groups in the absence of AICAR. CaMKKα expression was observed to be significantly different 
between patient groups on pretreatment with AICAR. *, P < 0.05 vs ND (+ AICAR). 
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Figure 4.10. Effect of Mitochondrial-ROS on AMPK Activation in HSVEC Lysates Cultured 
at 21% Oxygen. Cells from CAD patients without type 2 diabetes (ND, n=5) and with type 2 
diabetes (T2D, n=5) were incubated in the presence (+) and absence of AICAR, MitoQ10 and 
decylTPP bromide (DTPP). Total AMPK was immunoprecipitated from lysates which were then 
assayed for AMPK activity. *, P < 0.05 vs basal value for cells from ND patients, †, P < 0.05 vs 
basal value for T2D patients, ‡ P < 0.01 vs value in presence of DTPP for T2D patients. 
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4.4 Discussion 
 
Vascular endothelial cells are highly glycolytic (228;366) and this has been confirmed as 
being  the  case  for  HSVECs  with  results  suggesting  that  in  terms  of  ATP  production, 
HSVECs can compensate more effectively when the electron transport chain is blocked 
than  when  glycolysis  is  blocked  (Figure  4.1).  A  potential  reason  for  the  favouring  of 
glycolysis by endothelial cells has been proposed by Quintero and colleagues, whereby 
mitochondria are not preferentially used bioenergetically in HUVECs, allowing them to 
function primarily in the generation of ROS for signalling purposes (228).  
 
It  is  well  documented  that  AMPK  is  activated  in  response  to  hypoxic  stress  with 
phosphorylation  of  the  enzyme  observed  at  low  O2  concentrations  in  HUVECs  but 
undetectable at 21% O2 or ‘normoxia’ (228). However, as shown in Figure 4.2, constitutive 
AMPK  phosphorylation  was  observed  in  HSVECs  isolated  from  patients  with  CAD, 
indicating cardiovascular disease phenotype is linked to enzyme activation. Indeed, at 21% 
O2,  HSVEC  AMPK  activity was  significantly  greater  in  cells  from  patients  with  CAD 
relative to control subjects (Figure 4.3). Furthermore, on stratifying patients according to 
the presence of T2D, AMPK activity was significantly increased in cells from patients with 
CAD and T2D as compared to both control subjects and patients with CAD alone (Figure 
4.3). As previously outlined, the anti-diabetic drug, metformin exerts a portion of its effect 
through AMPK and approximately 43% of T2D patients studied were being treated with 
the drug. However, for the purpose of this study, the effect of metformin treatment on 
AMPK activation was not considered relevant as cells were cultured for several weeks 
prior to preparation of lysates such that effects of pharmacological treatments were likely 
to have been lost. Observed differences were consequently considered to be the result of 
differences in the genetic backgrounds of patients.  
 
Incubating  HSVECs  with  AICAR  resulted  in  a  non-significant,  approximately  equal 
increase in AMPK activity for all patient groups, suggesting disease status does not affect 
sensitivity of cells to this artificial activator of AMPK.  
 
On comparison of AMPKα1 Thr172 phosphorylation in HSVEC lysates cultured at 21% 
oxygen, AICAR again caused an approximately equal increase in phosphorylation in cells 
from  patients  with  and  without  T2D  (Figure  4.4).  A  trend  towards  higher  levels  of 
phosphorylation in HSVECs from patients with CAD and T2D was observed but, unlike 143 
for the activity assay, results failed to reach significance. This can perhaps be explained by 
the  fact  that  results  obtained  via  western  blotting  are  far  less  quantifiable  than  those 
obtained by means of the more sensitive kinase assay. 
 
Despite the increase in AMPK activity in patients with CAD relative to controls and in 
those CAD patients with T2D relative to both those without T2D and control subjects, no 
difference in AMPKα1 mRNA (Figure 4.5) or protein (Figures 4.4A and 4.4B) expression 
was observed between patient groups, confirming modulation of AMPK activity via post-
translational phosphorylation. In addition, PRKAA2 mRNA expression was undetectable in 
HSVECs isolated from patients from each group, corroborating findings that the α1 subunit 
is the predominant form in endothelial cells. 
 
Increased AMPK activity in HSVECs from patients with CAD and T2D relative to those 
with  CAD  alone  was  not  mirrored  by  any  significant  increase  in  phosphorylation  of 
downstream targets, ACC and eNOS, at Ser80 and Ser1177 respectively (Figures 4.6 and 
4.7). However, a trend towards increased phosphorylation of both substrates in cells from 
T2D patients was observed (Figures 4.6 and 4.7). Again, this may be due to the fact that 
analysis of western blots is less quantitative than the kinase assays carried out to determine 
AMPK activity. Also, while there was a narrow range of expression of AMPK, there was 
substantial variation in expression of eNOS particularly. Furthermore, it should be noted 
that AMPK assays are performed in saturating AMP, and therefore reflect the increase in 
activity of the kinase due to phosphorylation at Thr172. However, the ACC and eNOS 
phosphorylation  observed  reflect  AMPK  activation  that  is  a  combination  of  increased 
phosphorylation and increased allosteric activation by AMP. As such, it is perhaps not 
surprising that increased AMPK activity in HSVECs from patients with CAD and T2D did 
not translate to a significant increase in phosphorylation of substrates. 
 
Expression of upstream AMPKKs, LKB1 and CaMKKα, was investigated in an attempt to 
determine the mechanisms underlying the observed increase in AMPK activity in HSVECs 
from patients with CAD and T2D. While AICAR has no effect on expression of these 
kinases, lysates from HSVECs pretreated with AICAR were used in an attempt to keep 
samples consistent throughout experimental procedures. 
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As shown in Figure 4.8, LKB1 expression remained constant irrespective of patient disease 
status and, as expected, preincubation of cells with AICAR. Therefore, increased HSVEC 
AMPK activity in T2D patients does not occur as a result of elevated LKB1 expression.  
 
For CaMKKα, immunoblots indicated substantial variation in protein expression between 
individual patient samples (Figure 4.9A). However, in lysates from cells not subject to 
preincubation  with  AICAR,  CaMKKα  expression  was  not  found  to  be  statistically 
significantly different in CAD patients with T2D as compared to those with CAD alone 
(Figure 4.9B), suggesting observed differences may simply represent natural variation in 
the  human  population.  Interestingly,  pretreatment  with  AICAR  had  no  statistically 
significant effect on CaMKKα expression within patient groups but caused a significant 
difference in expression between groups (Figure 4.9B). As stated, AICAR does not directly 
affect expression of CaMKK. Consequently, the changes upon AMPK stimulation may 
reflect changes in subcellular localisation of CaMKKα such that there are apparent changes 
in expression within the lysates examined.  
 
Limited  cellular  material  meant  expression  of  CaMKKβ  was  not  investigated.  The  β 
isoform  is  thought  to  predominate  in  terms  of  AMPK  activation  (264;265)  and  so 
additional studies focusing on expression of this isoform are crucial in order to obtain 
accurate and comprehensive insight into CaMKK expression in HSVECs. Furthermore, 
with immunoblotting for CAMKKα yielding variable results, for future studies it may be 
useful  to  employ  an  alternative  method  for  investigation  of  CaMKK-mediated  AMPK 
activation,  such  as  assaying  AMPK  activity  after  treatment  of  cells  with  the  CaMKK 
inhibitor, STO-609 (287). 
 
Given the apparent lack of change in activity of upstream AMPK kinases, the glycolytic 
nature of these cells and the increased expression of SOD2 (Figure 3.8), it seems likely that 
endothelial  AMPK  activation  in  CAD  patients  occurs,  at  least  in  part,  in  an  mtROS-
mediated manner and that this activation is enhanced in those CAD patients with T2D who 
display  severe  endothelial  dysfunction  (Figure  3.2B)  and  increased  SOD2  expression 
(Figure 3.8), consistent with increased mtROS production. As previously described, within 
the mitochondrial matrix, SOD2 catalyses the conversion of O2
- to H2O2 and molecular 
oxygen  (234).  Interestingly,  H2O2  has  been  shown  to  activate  AMPK  under  hypoxic 
conditions in cultured cells (295;296).  
 145 
In  order  to  test  this  hypothesis  concerning  the  mtROS-mediated  activation  of  AMPK, 
HSVECs  isolated  from  vessels  of  CAD  patients  were  treated  with  the  mitochondria-
targeted antioxidant, MitoQ10. As outlined in Chapter 3, MitoQ10 has been shown to react 
poorly with O2
- (351) but is reported to scavenge oxidants, including H2O2, ONOO
- and 
their  derivatives,  under  hyperglycaemic  conditions  in  cultured  endothelial  cells  (374). 
Treatment with MitoQ10 caused a significant decrease in AMPK activation in cells from 
CAD patients with type 2 diabetes which was attenuated on addition of AICAR, known to 
stimulate  kinase  activity  in  cultured  endothelial  cells  (262;297;375)  (Figure  4.10).  The 
non-active  control  for  MitoQ10,  DTPP,  had  no  effect  on  AMPK  activity  in  a  parallel 
experiment (Figure 4.10), indicating results can be attributed to the antioxidant action of 
MitoQ10 specifically. The same effect was not seen in cells from CAD patients without 
T2D (Figure 4.10). 
 
Taken together, these findings indicate a novel, mtROS-mediated activation of AMPK in 
the endothelium of patients with CAD and T2D and suggest a role for AMPK in defence 
against oxidative stress and endothelial dysfunction. Indeed, as described, activated AMPK 
phosphorylates  eNOS  at  Ser1177  in  cultured  endothelial  cells  (176;282)  and  has  been 
shown  to  increase  endothelium-dependent  vasodilation  in  an  animal  model  (252). 
Furthermore, the anti-diabetic drug, metformin which exerts a portion of its effect through 
AMPK,  has  been  reported  to  decrease  intracellular  production  of  mtROS  in  aortic 
endothelial  cells  (376),  while  activation  of  AMPK  has  been  shown  to  reduce 
hyperglycaemia-induced mtROS production by induction of SOD2 in HUVECs (377). In 
addition,  Colombo  and  Moncada  have  recently  shown  that  in  HUVECs,  AMPKα1  is 
responsible  for  the  expression  of  a  number  of  genes  involved  in  antioxidant  defence, 
including SOD2 (378). Thus, AMPK activation would appear to have a beneficial effect on 
endothelial function by suppressing oxidative stress and increasing NO bioavailability in 
endothelial cells.  
 
In summary, these findings suggest AMPK is part of a feedback or adaptive mechanism in 
the endothelium of patients with CAD and T2D, with a role in defence against oxidative 
stress. It seems likely that the elevated mtROS production of T2D results in activation of 
AMPK which, in turn, activates eNOS, thus increasing NO bioavailability and attenuating 
endothelial dysfunction. Under conditions of oxidative stress, NO may react with O2
- to 
form ONOO
- which has been shown to activate AMPK in the  endothelium (297;379). 146 
Endothelial AMPK may also induce SOD2 activity, resulting in production of H2O2 which 
may itself activate AMPK (295;296) (Figure 4.11). 
 
Results  support  a  novel,  mtROS-mediated  mechanism  for  AMPK  activation  in  the 
endothelium  and  suggest  mitochondria  contribute  to  increased  O2
-  production  and 
endothelial  dysfunction  in  patients  with  coronary  artery  disease  and  type  2  diabetes. 
Mitochondria-targeted antioxidants, used in combination with pharmacological activators 
of AMPK, may therefore have potential as an early intervention strategy in the treatment of 
endothelial dysfunction in these patients. 147 
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Figure  4.11.  Proposed  Mechanism  of  Mitochondrial  Reactive  Oxygen  Species-Mediated 
AMPK  Activation  in  Endothelial  Cells.  Results  suggest  a  potentially  mitochondrial  reactive 
oxygen species (mtROS)-mediated increase in AMPK activity in patients with coronary artery 
disease and type 2 diabetes. AMPK may therefore be part of a feedback or adaptive mechanism 
with  a  role  in  defence  against  oxidative  stress  in  the  endothelium,  regulating  expression  of 
antioxidant genes, including SOD2, and contributing to the control of vascular tone, via activation 
of endothelial nitric oxide synthase (eNOS).  148 
 
 
 
 
 
5. Gene Expression Profiling of Endothelial Cells in 
Coronary Artery Disease 
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5.1 Introduction 
 
 
Microarray technology is a powerful tool, allowing exploration of genome complexity at a 
fundamental  level  (380).  Transcriptional  profiling  using  high-density  microarrays  has 
provided unique insight into disease mechanisms, drug responses, regulatory pathways and 
gene function, through comparison of mRNA transcript levels in cells / tisues in a given 
pathological state with an appropriate control (381).  
 
One such pathological state is CAD, where the application of microarray technology has 
resulted  in  identification  of  unique  subsets  of  genes  associated  with  specific  disease 
processes (382). Indeed, transcript profiling has revealed associations of interesting genes, 
such as ICAM-2, with CAD (383) and identified a loss of coronary artery differentiated 
smooth  muscle  cell  gene  expression  as  a  primary  signature  of  disease  progression  in 
atherosclerosis (384).  
 
To date, few published studies have compared gene expression profiles of CAD patients 
with  and  without  T2D  (381;384;385).  A  study  by  Voisine  and  colleagues  identified 
quantitative and qualitative differences in gene expression profile in atrial myocardium 
samples  from  patients  with  T2D  undergoing  cardiopulmonary  bypass  and  cardioplegic 
arrest, with the majority of differentially expressed genes encoding transcription activators 
and mediators of the inflammatory response (381). Similarly, King et al. (384) assessed 
gene expression profiles of coronary artery segments and observed differential expression 
of  a  number  of  genes  involved  in  insulin  signalling  in  vessels  from  diabetic  patients. 
However,  it  seems  likely  that  many  of  the  chronic  endothelial  effects  of  T2D  will  be 
reflected  in  transcriptional  regulation  at  cellular  level,  either  as  a  direct  response  to 
hyperglycaemia and abnormalities of insulin signalling, or as a secondary response to the 
effects of these stresses. This intimates the need to examine transcript profiles of isolated 
endothelial cells in order to identify pathways and candidate genes that may contribute to 
the more severe endothelial dysfunction observed in vessels from CAD patients with T2D 
(Figure  3.2B).  As  such,  this  study  involved  comparison  of  gene  expression  profiles  in 
primary HSVECs isolated from CAD patients with and without T2D. 
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The aims of the experimental work outlined in this chapter were as follows: 
 
1)  to identify differentially expressed genes in primary HSVECs isolated from CAD 
patients with and without T2D; 
2)  to analyse microarray data using Ingenuity Pathway Analysis software in order to 
identify canonical metabolic pathways affected by differentially expressed genes; 
3)  to confirm differential expression of selected genes using qRT PCR 
 
 
 
5.2 Materials & Methods 
 
5.2.1 Study Participants 
 
CAD patients with and without T2D were as described in section 2.2. Twelve patients with 
CAD alone and six patients with CAD and T2D were selected for the study. Selected 
patients were age, sex and smoking status matched. All patients were male, aged between 
60 and 72 years of age and non-smokers. 
 
 
5.2.2 Human Vascular Tissue & Primary Cell Culture 
 
Vascular  tissue  was  obtained  and  prepared  as  described  in  section  2.3  and  HSVECs 
isolated, characterised and cultured as outlined in section 2.4.  
 
 
5.2.3 RNA Extraction, Quantification & Validation 
 
Total  RNA  was  extracted  from  HSVECs,  DNase  treated  and  quantified  using  the 
NanoDrop
® ND-100 Spectrophotometer as per section 2.5. Total RNA sample integrity 
was then verified by electrophoresis of 500 ng on an Agilent Bioanalyzer 2100.  151 
5.2.4 Biotinylated cRNA Synthesis 
 
The  Illumina
®  TotalPrep  RNA  Amplification  Kit  was  used  to  generate  biotinylated, 
amplified  cRNA  for  hybridisation  with  Illumina  Sentrix
®  arrays,  according  to  the 
manufacturer’s protocol. 
 
 
5.2.4.1 First & Second Strand cDNA Synthesis 
 
Reverse transcription to synthesise first strand cDNA was carried out by bringing 500 ng 
of total RNA to a volume of 11 µl with nuclease-free H2O before adding 9 µl Reverse 
Transcription Master Mix (prepared at room temperature and containing 1 µl T7 Oligo(dT) 
Primer, 2 µl 10 X First Strand Buffer, 4 µl dNTP Mix, 1 µl RNase Inhibitor and 1 µl 
ArrayScript for a single 20 µl reaction), mixing thoroughly by pipetting and incubating 
samples at 42ºC for 2 hours.  
 
Second strand cDNA was then synthesised immediately by adding 80 µl Second Strand 
Master Mix (prepared on ice and containing 63 µl nuclease-free H2O, 10 µl 10 X Second 
Strand Buffer, 4 µl dNTP Mix, 2 µl DNA Polymerase and 1 µl RNase H for a single 100 µl 
reaction) to each sample, mixing thoroughly by pipetting and flicking the tube 3-4 times 
before centrifuging briefly to collect the reaction in the bottom of the tube. Samples were 
then incubated for 2 hours at 16ºC in a thermal cycler. Following the 2 hour incubation, 
cDNA purification was carried out straight away. 
 
 
5.2.4.2 Double Stranded cDNA Purification 
 
cDNA was purified to remove RNA, primers, enzymes and salts that would inhibit in vitro 
transcription. 250 µl cDNA Binding Buffer was added to each sample and the mixture 
mixed thoroughly by pipetting and flicking the tube before being applied to the centre of a 
cDNA Filter Cartridge seated in a wash tube. Cartridges were centrifuged for a minute at 
10,000 x g, flow-through discarded and cartridges replaced in wash tubes. 500 µl Wash 
Buffer was the applied to each cDNA Filter Cartridge and cartridges centrifuged at 10,000 152 
x g for a minute. Flow-through was discarded and cartridges centrifuged for an additional 
minute to remove traces of Wash Buffer. Next, cDNA Filter Cartridges were transferred to 
cDNA Elution Tubes, 10 µl nuclease-free H2O (preheated to 50-55ºC) applied to the centre 
of filters and samples incubated at room temperature for 2 minutes before centrifugation 
for 1.5 minutes at 10,000 x g. A further 9 µl preheated nuclease-free H2O was then applied 
to filters and samples centrifuged for 2 minutes at 10,000 x g to elute the double-stranded 
cDNA in an approximate volume of 17.5 µl. In vitro transcription (IVT) to synthesise 
complementary RNA (cRNA) was then carried out immediately. 
 
 
5.2.4.3 In Vitro Transcription to Synthesise cRNA 
 
Multiple copies of biotinylated  cRNA were  generated  from the double-stranded cDNA 
template by adding 7.5 µl IVT Master Mix (prepared at room temperature and containing 
2.5 µl T7 10 X Reaction Buffer, 2.5 µl T7 Enzyme Mix and 2.5 µl Biotin-NTP Mix for a 
single 25 µl reaction) to each sample, mixing thoroughly by pipetting and flicking the tube 
and subsequently centrifuging briefly to collect the reaction mixture at the bottom of the 
tube.  Samples  were  then  incubated  at  37ºC  for  between  4  and  14  hours  before  75  µl 
nuclease-free  H2O  was  added  to  each  sample  to  stop  the  reaction  and  bring  the  final 
volume to 100 µl. Purification of cRNA was then performed immediately. 
 
 
5.2.4.4 cRNA Purification & Validation 
 
cRNA  purification  to  remove  unincorporated  NTPs,  salts,  enzymes  and  inorganic 
phosphate involved adding 350 µl cRNA Binding Buffer followed immediately by 250 µl 
100% ethanol to each sample. Samples were then mixed by pipetting before being applied 
to the centre of a cRNA Filter Cartridge placed in a cRNA Collection Tube. Samples were 
subsequently centrifuged for 1 minute at 10,000 x g, flow-through discarded and cartridges 
replaced in collection tubes. Next, 650 µl Wash Buffer was applied to each cartridge which 
was then centrifuged for 1 minute at 10,000 x g. Flow-through was again discarded and 
cartridges centrifuged for an additional minute to remove trace amounts of Wash Buffer. 
Cartridges were then transferred to fresh cRNA Collection Tubes and 100 µl nuclease-free 153 
H2O (preheated to 50-60ºC) added to the centre of the filter. Samples were left at room 
temperature for 2 minutes before being centrifuged for 1.5 minutes at 10,000 x g to elute 
purified cRNA. 
 
Purified  cRNA  was  quantified  using  the  NanoDrop
®  ND-100  Spectrophotometer  and 
quality assessed via electrophoresis of 500 ng on an Agilent Bioanalyzer 2100.  
 
 
5.2.5 Microarray Hybridisation & Data Collection 
 
cRNA  was  prepared  for  hybridisation  with  Illumina
®  HumanWG-6  v3.0  Expression 
Beadchips, using the Illumina
® Whole-Genome Expression Direct Hybridization Assay. 
Illumina
® HumanWG-6 v3.0 Expression Beadchips contain 48,804 probes, targeting a total 
of 25,440 annotated genes. 1.5 µg of cRNA was brought to a total volume of 10 µl with 
RNase-free  water  and  mixed  before  incubation  at  room  temperature  for  10  minutes  to 
resuspend cRNA. Hybridisation reagents (GEX-HYB and GEX-HCB) were incubated at 
58ºC for 10 minutes to dissolve any salts that may have precipitated in storage. 20 µl GEX-
HYB was subsequently added to each cRNA sample. 200 µl GEX-HCB was then applied 
to  each  hybridisation  chamber  (Hyb  Chamber)  and  BeadChips  inserted  into  chambers. 
cRNA samples were preheated at 65ºC for 5 minutes then briefly vortexed and centrifuged 
to collect liquid. Samples were allowed to cool to room temperature before 30 µl was 
applied to each array. Samples were randomised on chips and technical duplicates of all 
T2D samples included. Hyb Chambers were incubated for 16-20 hours (overnight) in a 
58ºC oven rotating at 60 rpm. 
 
Beadchips  were  washed  and  stained  following  standard  protocols.  Following  overnight 
incubation, BeadChips were removed from Hyb Chambers and submerged in 250 ml Wash 
E1BC solution (prepared by adding 3 ml E1BC buffer to 1 L RNase-free H2O) before 
being incubated for 10 minutes in 1 X High-Temp Wash Buffer (prepared by adding 50 ml 
10 X stock to 450 ml RNase-free H2O) preheated to 55ºC. After 10 minutes, BeadChips 
were transferred to a fresh 250 ml Wash E1BC solution at room temperature and placed on 
an orbital shaker at maximum speed for 5 minutes. Chips were then transferred to a 250 ml 
100% ethanol solution and placed on the orbital shaker (maximum speed) for 10 minutes. 
A 2 minute wash in a fresh Wash E1BC solution was performed before each chip was 154 
blocked  in  4  ml  Block  E1  buffer  for  10  minutes  at  medium  rocking  speed  and  room 
temperature.  Detection  was  performed  by  placing  chips  in  2  ml  Block  E1  buffer  with 
streptavidin-Cy3 (2 µl 1 mg/ml stock per chip), covering to protect from light and rocking 
at medium speed for 10 minutes. A third room temperature wash in 250 ml Wash E1BC 
was  then  carried  out  with  shaking  for  5  minutes.  Finally,  to  dry  chips,  they  were 
centrifuged for 4 minutes at 275 rcf and room temperature.  
 
Following completion of the hybridisation procedure, BeadChips were scanned and images 
extracted using specific protocols on an Illumina
® BeadArray Reader. 
 
 
5.2.6 Microarray Data Analysis  
 
5.2.6.1 Quality Control 
 
Illumina
®  Gene  Expression  Beadchips  have  internal  control  features  to  monitor  both 
sample-independent  and  sample-dependent  data  quality.  Control  data  results  were 
visualised with BeadStudio software. 
 
 
5.2.6.2 Gene Expression Data Analysis 
 
5.2.6.2.1 Illumina
® BeadStudio Analysis 
 
Initial analysis of microarray data was performed using Illumina
® BeadStudio software. 
Quantile normalisation of the data was carried out without background subtraction. Each 
probe is represented by multiple beads (30 on average) on an Illumina
® Gene Expression 
Beadchip. Normalised values for each bead representing a given probe were averaged to 
obtain  the  estimate  of  expression  for  that  probe.  Unpaired  2  sample  t-tests  were  then 
conducted  on  these  averaged  values  using  the  Illumina
®  custom  error  model  (386). 
Differentially expressed probes were identified using a difference (diff) score cut-off of +/- 
13.0103, equating to a P value ≤ 0.05. Differentially expressed probes were then uploaded 155 
to Ingenuity Pathway Analysis (IPA) software (387) and analysed to identify canonical 
metabolic pathways of interest containing most significantly differentially expressed genes. 
 
 
5.2.6.2.2 Ingenuity Pathway Analysis 
 
Canonical pathways analysis identified the pathways from the IPA library of canonical 
pathways that were most significantly associated with the data set. Genes from the data set 
that met the P value cut-off of 5% and were associated with a canonical pathway in the 
Ingenuity  Pathways  Knowledge  Base  (IPKB)  were  considered  for  the  analysis.  The 
significance  of  the  association  between  the  data  set  and  the  canonical  pathway  was 
measured in two ways. Firstly, a ratio of the number of genes with differentially expressed 
probes from the data set that mapped to the canonical pathway divided by the total number 
of genes with probes in the data set that mapped to the pathway was displayed. Secondly, 
in addition to this ratio, Fisher’s exact test was used to calculate a P value determining the 
probability  that  the  association  between  the  significant  genes  in  the  data  set  and  the 
canonical pathway could be explained by chance alone. 
 
 
5.2.6.2.3 Rosetta Resolver
® Analysis 
 
Additional  analysis  of  microarray  data  was  carried  out  by  uploading  raw  data  from 
BeadStudio software to the Rosetta Resolver
® Gene Expression Data Management and 
Analysis  System.  Data  were  normalised  using  Rosetta  error  models  (388)  to  give  one 
averaged, normalised value for each probe before principal component analysis (PCA) was 
performed. PCA is a data reduction method which identifies linear combinations of probes 
that explain the most variability in the data and can be used to visualise data for quality 
assessment purposes (389). The PCA revealed an outlier in one sample from the T2D 
group of patients and, after further investigation, this outlier was removed from subsequent 
analysis. Following PCA, an error weighted analysis of variance (ANOVA) with a false 
discovery rate (FDR) (390) threshold of 0.05 was used on the remaining data to identify 
differentially expressed probes. Again, differentially expressed probes were uploaded to 
IPA  and  analysed  to  identify  the  canonical  metabolic  pathways  most  associated  with 
significantly differentially expressed genes.  156 
5.2.6.2.4 Integration of Analyses Results 
 
The  number  of  differentially  expressed  genes  common  to  BeadStudio  and  Rosetta 
Resolver
® analyses was identified using a Venn diagram.  
 
 
5.2.7 TaqMan
® Real-Time RT-PCR 
 
TaqMan
® qRT-PCR was utilised to confirm differential expression observed in microarray 
experiments.  The  same  total  RNAs  isolated  for  microarray  experiments  were  used  as 
templates for the synthesis of cDNA as per section 2.7.1 and mRNA expression levels 
assessed  as  outlined  in  section  2.7.2.  Applied  Biosystems  Custom  TaqMan
®  Gene 
Expression Assays for ACAD11 (Hs00259854_m1), AGTR2 (Hs00169126_m1), ATP5G3 
(Hs00266085_m1),  IDH3G  (Hs00188065_m1),  PIK3R2  (Hs00178181_m1),  PRKAG1 
(Hs00176952_m1) and SDHC (Hs00818427_m1) were used with TaqMan
® Endogenous 
Control, β-actin (ACTB, 4326315E). Reactions were carried out in singleplex or multiplex 
as indicated. 
 
 
 
5.3 Results 
 
5.3.1 Total RNA & cRNA Validation 
 
Electrophoresis of HSVEC total RNA samples on the Agilent Bioanalyzer 2100 confirmed 
RNA quality prior to cDNA synthesis, as indicated by defined bands for 28S and 18S 
ribosomal RNA (rRNA) species and little evidence of small RNA species below the 18S 
band (Figure 5.1). RNA Integrity Numbers (RINs) were consistently above 9.0.  
 
Following in vitro transcription to synthesise biotinylated cRNA, cRNA quality was also 
assessed by electrophoresis on the Agilent Bioanalyzer 2100. Results demonstrated 157 
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Figure 5.1. Agilent Bioanalyzer 2100 Assessment of Total RNA Quality. (A) Electrophoresis of 
representative total RNA samples revealed bands for 28S and 18S ribosomal RNA (rRNA). Green 
bands represent a 200 base pair size marker used to align samples and controls. kb, kilobases (B) A 
representative individual electropherogram showing sharp peaks for 28S and 18S rRNA. No RNA 
species smaller than 18S rRNA were observed, indicative of intact RNA. 
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approximately  normal  distribution  of  cRNA  species  for  all  samples  and  approximately 
equal concentrations (Figure 5.2). 
 
 
5.3.2 Microarray HSVEC mRNA Expression Profiling 
 
5.3.2.1 Microarray Data Quality Control 
 
Direct Hyb Control Plots obtained for samples were consistent with BeadStudio example 
control plots, verifying the validity of microarray gene expression data (Figure 5.3). 
 
 
5.3.2.2 Beadstudio Analysis 
 
Using Illumina
® BeadStudio software, a total of 727 probes were found to be differentially 
expressed between HSVECs from patients with CAD and T2D and patients with CAD 
alone. Expression of 293 probes was upregulated in cells from patients with T2D while 
434  probes  were  downregulated  in  cells  from  these  patients.  A  complete  list  of 
differentially expressed probes is included as Table A1 in the Appendix. 
 
 
5.3.2.2.1 Ingenuity Pathway Analysis 
 
Analysis of BeadStudio microarray data using IPA software identified the citrate cycle as a 
canonical metabolic pathway significantly affected by the presence of T2D (Figure 5.4), 
with  significance  based  on  the  number  of  genes  with  differentially  expressed  probes 
mapping to the pathway (Table 5.1 and Figure 5.5). Given the role of mitochondria in T2D 
pathogenesis (section 1.3.4.3.1), ATP5G3, IDH3G and SDHC were selected as candidate 
genes  for  further  study.  However,  SDHAL1  was  identified  as  a  pseudogene  and 
consequently no attempt was made to confirm its differential expression. 
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Figure  5.2.  Agilent  Bioanalyzer  2100  Assessment  of  cRNA  Quality.  (A)  Electrophoresis  of 
representative  samples  showing  the  distribution  of  complementary  RNA  (cRNA)  species  on 
separation according to size. Green bands represent a 200 base pair (bp) size marker used to align 
samples and controls. kb, kilobases (B) Representative electropherogram showing approximately 
normal distribution of cRNAs. The sharp peak at the extreme left of the trace corresponds to the 
200 bp size marker. 
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Figure 5.3. Microarray Data Quality Control. Quality control results for microarray data were 
visualised using BeadStudio software. Direct Hyb Control Plots generated for samples (bottom 
panel) were consistent with Beadstudio Direct Hyb Control Plot examples (top panel), verifying the 
validity of gene expression microarray data. Details of BeadStudio control plots are provided in the 
table (right hand panel). *, sample-independent control metrics 
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ratio of the number of differentially expressed genes from the data set mapping to the canonical pathway divided by the total number of genes mapping to 
the pathway  
 
Figure 5.4. IPA Canonical Pathway Analysis of BeadStudio Microarray Data. Canonical metabolic pathways significantly affected by the presence of type 2 
diabetes were observed to cross the threshold value (P≤0.05). Significance is based on the number of differentially expressed genes in the pathway. Differentially 
expressed genes involved in the citrate cycle and retinoic acid receptor (RAR) activation were identified as candidate genes for further investigation.  162 
 
Gene Symbol  Gene Name  Diff Score  Fold Change 
ATP5G3  ATP synthase, H
+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9)  -18.009  -1.397 
IDH3G  isocitrate dehydrogenase 3 (NAD
+) gamma  13.807  1.306 
SDHAL1  succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1  -15.807  -1.393 
SDHC  succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa  -26.557  -1.346 
 
 
Table 5.1. Differentially Expressed Citrate Cycle Genes. IPA canonical pathway analysis of BeadStudio microarray data identified 4 genes within the citrate cycle 
pathway  as  being  differentially  expressed  in  cells  from  patients  with  CAD  and  type  2  diabetes  (T2D).  ATP5G3,  SDHAL1  and  SDHC  were  observed  to  be 
downregulated in cells from patients with T2D, while IDH3G was upregulated in these patients. 163 
 
 
Figure 5.5. Citrate Cycle Canonical Pathway. The citrate cycle metabolic pathway showing candidate genes differentially expressed in HSVECs from patients 
with type 2 diabetes (Ingenuity Pathway Analysis).  164 
Expression of PRKAG1, encoding the regulatory γ1-subunit of AMPK, was observed to be 
significantly  downregulated  in  CAD  patients  with  T2D  (Table  A1)  and  involved  in  a 
number  of  significantly  affected  metabolic  pathways,  including  retinoic  acid  receptor 
(RAR) activation, the most significantly affected canonical pathway (Table 5.2 and Figure 
5.6). With AMPK implicated in T2D (section 1.5.1 and Chapter 4), PRKAG1 was also 
selected as a candidate gene and its expression further investigated. 
 
 
5.3.2.2.2  Confirmation  of  Differential  Expression  of  Candidate  Genes  by 
TaqMan
® Real-Time RT-PCR 
 
On  attempting  to  confirm  differential  expression  of  microarray  candidate  genes  by 
TaqMan
® qRT-PCR, no statistically significant difference in HSVEC ATP5G3 ( Ct, 5.706 
± 0.412 vs 5.477 ± 0.680; P=0.763; Figure 5.7A) and IDH3G ( Ct, 3.429 ± 0.168 vs 3.659 
± 0.223; P=0.418; Figure 5.7B) mRNA expression was found in cells isolated from CAD 
patients  with  and  without  T2D.  Similarly,  no  significant  difference  in  HSVEC  SDHC 
mRNA expression was observed between patients with CAD and T2D and patients with 
CAD alone ( Ct, 3.556 ± 0.176 vs 3.708 ± 0.392; P=0.692; Figure 5.7C). However, the 
direction of change in SDHC expression reflected that observed on analysis of microarray 
data with a trend towards decreased expression in patients with CAD and T2D (Figure 
5.7C).  
 
As shown in Figure 5.7D, no significant difference in HSVEC PRKAG1 mRNA expression 
was observed between patients with CAD and T2D and patients with CAD alone ( Ct, 
1.315 ± 0.317 vs 1.487 ± 0.417; P=0.746) but, a trend towards decreased expression in 
CAD patients with T2D was noted, reflecting the direction of change observed on analysis 
of microarray data (Figure 5.7D). 
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Gene Symbol  Gene Name  Diff Score  Fold Change 
CCNH  cyclin H  -20.875  -1.289 
GTF2H1  general transcription factor IIH, polypeptide 1, 62kDa  13.661  1.223 
IL3RA  interleukin 3 receptor, alpha (low affinity)  -14.374  -1.263 
MAP2K4  mitogen-activated protein kinase kinase 4  -15.044  -1.228 
MAP3K1  mitogen-activated protein kinase kinase kinase 1  15.91  1.259 
PIK3CA  phosphoinositide-3-kinase, catalytic, alpha polypeptide  14.406  1.223 
PRKAG1  protein kinase, AMP-activated, gamma 1 non-catalytic subunit  -14.846  -1.255 
PRKCI  protein kinase C, iota  14.289  1.222 
RDH5  retinol dehydrogenase 5 (11-cis/9-cis)  15.75  1.249 
RDH11  retinol dehydrogenase 11 (all-trans/9-cis/11-cis)  16.835  1.253 
 
 
Table 5.2. Differentially Expressed Genes Involved in Retinoic Acid Receptor (RAR) Activation. IPA canonical pathway analysis of BeadStudio microarray 
data identified 10 genes involved in the RAR activation metabolic pathway, including PRKAG1, as being differentially expressed in cells from patients with CAD 
and type 2 diabetes. 
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Figure  5.6.  Retinoic  Acid  Receptor  (RAR)  Activation  Canonical Pathway.  RAR  metabolic 
pathway  showing  candidate  gene  PRKAG1  as  being  differentially  expressed  in  HSVECs  from 
patients with type 2 diabetes (Ingenuity Pathway Analysis). 167 
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Figure 5.7. BeadStudio Candidate Gene mRNA Expression Relative to β-actin (ACTB) as 
Assessed by TaqMan
® qRT-PCR. (A) ATP5G3,(B) IDH3G, (C) SDHC and (D) PRKAG1 mRNA 
expression was investigated and compared in HSVECs isolated from CAD patients with (T2D, 
n=5) and without (ND, n=10) type 2 diabetes. No statistically significant differences in mRNA 
expression  were  observed.  For  ATP5G3,  IDH3G  and  PRKAG1,  reactions  were  carried  out  in 
singleplex. For SDHC, reactions were carried out in multiplex. RQ, relative quantitation 168 
5.3.2.3 Rosetta Resolver
® Analysis 
 
Using Rosetta Resolver
® software, a total of 92 probes were found to be differentially 
expressed  in  HSVECs  from  patients  with  CAD  and  T2D  as  compared  to  those  from 
patients with CAD alone (Figure 5.8). In certain cases, more than one probe corresponded 
to  a  particular  gene.  This,  coupled  with  the  fact  that  IPA  does  not  yet  recognise  all 
Illumina
® probes, meant data generated from IPA revealed 77 genes to be differentially 
expressed in cells from patients with T2D. Of these 77 genes, expression of 15 genes was 
upregulated and expression of the remaining 62, downregulated. A complete list of these 
differentially expressed genes is included as Table A2 in the Appendix.  
 
Expression of ACAD11, encoding acyl-Coenzyme A dehydrogenase family, member 11, 
was observed to be significantly downregulated in CAD patients with T2D (Table A2). 
Given  the  role  of  acyl-Coenzyme  dehydrogenases  in  β-oxidation  of  fatty  acids  in  the 
mitochondria and the fact that mitochondria and AMPK have been implicated in T2D, 
ACAD11 was selected as a candidate gene for further investigation. 
 
 
5.3.2.3.1 Ingenuity Pathway Analysis 
 
Analysis of Rosetta Resolver
® microarray data using IPA software identified G-protein 
coupled receptor signalling as the canonical metabolic pathway most significantly affected 
by  the  presence  of  T2D  in  patients  with  CAD  (Figure  5.9).  As  previously  described, 
significance  was  based  on  the  number  of  genes  with  differentially  expressed  probes 
mapping to the pathway (Table 5.3 and Figure 5.10). AGTR2, and PI3KR2 were selected as 
candidate genes for further study.  
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Figure 5.8. Differentially Expressed Probes Identified by Rosetta Resolver
® Analysis. (A) The 
Illumina
® probes’ false discovery rates (FDRs) ordered on a log10 scale. The 92 in blue are below 
the  5%  FDR  cut-off,  indicated  by  the  red  dashed  line.  Remaining  probes  (‘Unchanged’  and 
‘Invariant’) are non-significantly differentially expressed. (B) Data displayed as log-ratios on the y-
axis against mean intensity ratios on the x-axis. The 92 significantly differentially expressed probes 
are shown in blue, whilst remaining probes are in grey. 
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ratio of the number of differentially expressed genes from the data set mapping to the canonical pathway divided by the total number of genes mapping to 
the pathway  
  
 
Figure 5.9. IPA Canonical Pathway Analysis of Rosetta
® Resolver Microarray Data. Canonical metabolic pathways significantly affected by the presence of 
type 2 diabetes were observed to cross the threshold value (P≤0.05). Significance is based on the number of differentially expressed genes in the pathway. 
Differentially expressed genes involved in G-protein coupled receptor signalling were identified as candidate genes for further investigation. 171 
Gene Symbol  Gene Name  Fold Change  P-value 
AGTR2  angiotensin II receptor, type 2  1.453  0.0239 
PDE8A  phosphodiesterase 8A  -1.263  0.0319 
PIK3R2  phosphoinositide-3-kinase, regulatory subunit 2 (beta)  -1.221  0.0358 
 
 
Table 5.3. Differentially Expressed G-protein Coupled Receptor Signalling Genes. IPA canonical pathway analysis of BeadStudio microarray data identified 3 
genes within the G-protein coupled receptor signalling pathway as being differentially expressed in cells from patients with CAD and type 2 diabetes (T2D). AGTR2 
was observed to be upregulated in cells from patients with T2D, while PDE8A and PIK3R2 were downregulated in these patients. 
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Figure 5.10. G-protein Coupled Receptor Signalling Canonical Pathway. G-protein coupled 
receptor  signalling  metabolic  pathway  showing  candidate  genes  differentially  expressed  in 
HSVECs from patients with type 2 diabetes (Ingenuity Pathway Analysis).  
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5.3.2.3.2  Confirmation  of  Differential  Expression  of  Candidate  Genes  by 
TaqMan
® Real-Time RT-PCR 
 
As  shown  in  Figure  5.11A,  no  significant  difference  in  HSVEC  ACAD11  mRNA 
expression was observed between patients with CAD and T2D and patients with CAD 
alone ( Ct, 7.815 ± 0.236 vs 7.185 ± 0.301; P=0.205) as assessed by TaqMan
® qRT-PCR. 
Similarly, HSVEC PI3KR2 mRNA expression was found not be statistically significantly 
different in HSVECs isolated from CAD patients with and without T2D ( Ct, 6.161 ± 
0.186  vs  5.527  ±  0.151;  P=0.067;  Figure  5.11B).  Expression  of  AGTR2  mRNA  was 
undetectable in HSVECs from either patient group. 
 
 
5.3.2.4  Identification  of  Differentially  Expressed  Genes  Common  to 
BeadStudio & Rosetta Resolver
® Microarray Data 
 
A total of 45 differentially expressed genes were found to be common to both BeadStudio 
and Rosetta Resolver
® data sets as represented in a Venn diagram (Figure 5.12) and listed 
in Table 5.4. Commonly differentially expressed genes included candidate genes, ACAD11 
and AGTR2. Other candidate genes were not found to be differentially expressed in both 
data sets. 
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Figure  5.11.  Rosetta  Resolver
®  Candidate  Gene  mRNA  Expression  Relative  to  β-actin 
(ACTB)  as  Assessed  by  TaqMan
®  qRT-PCR.  Expression  of  (A)  ACAD11  and  (B)  PIK3R2 
mRNA expression was investigated in HSVECs isolated from CAD patients with (T2D, n=5) and 
without (ND, n=10) type 2 diabetes. No statistically significant differences in mRNA expression 
were observed. Reactions were carried out in singleplex. RQ, relative quantitation 
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Figure 5.12. Differentially Expressed Genes Common to BeadStudio & Rosetta Resolver
® 
Analyses of Microarray Data. Venn diagram illustrating that 45 differentially expressed genes 
were found to be common to both BeadStudio and Rosetta Resolver
® data sets. For both analyses, 
numbers indicate differentially expressed genes rather than probes. 
 
 
45  32  576 
Rosetta Resolver
® 
(77) 
BeadStudio 
(621) 176 
Gene Symbol  Gene Name 
ABCC5  ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
ACAD11  acyl-Coenzyme A dehydrogenase family, member 11 
AFG3L1  AFG3 ATPase family gene 3-like 1 (S. cerevisiae) 
AGTR2  angiotensin II receptor, type 2 
AMT  aminomethyltransferase 
AMY2A  amylase, alpha 2A (pancreatic) 
CCDC113  coiled-coil domain containing 113 
CFDP1  craniofacial development protein 1 
CROP  cisplatin resistance-associated overexpressed protein 
DGKQ  diacylglycerol kinase, theta 110kDa 
E4F1  E4F transcription factor 1 
EFHD1  EF-hand domain family, member D1 
ERGIC2  ERGIC and golgi 2 
FAP  fibroblast activation protein, alpha 
GNRH1  gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) 
HIP1R  huntingtin interacting protein 1 related 
KIAA1328  KIAA1328 
LOC283932  hypothetical LOC283932 
LOC727762  similar to NADH:ubiquinone oxidoreductase B15 subunit 
LOC729137  hypothetical protein LOC441528 
LRCH4 
leucine-rich repeats and calponin homology (CH) domain 
containing 4 
LZTFL1  leucine zipper transcription factor-like 1 
MFSD1  major facilitator superfamily domain containing 1 
MGC42630  family with sequence similarity 27, member E3 
NSUN5B  NOL1/NOP2/Sun domain family, member 5B 
NUTF2  nuclear transport factor 2 
PDE8A  phosphodiesterase 8A 
RAB22A  RAB22A, member RAS oncogene family 
RALBP1  ralA binding protein 1 
RDH5  retinol dehydrogenase 5 (11-cis/9-cis) 
RIC8B  resistance to inhibitors of cholinesterase 8 homolog B (C. elegans) 
SAA4  serum amyloid A4, constitutive 
SETD6  SET domain containing 6 
SLC23A3  solute carrier family 23 (nucleobase transporters), member 3 
SLC38A6  solute carrier family 38, member 6 
STK36  serine/threonine kinase 36, fused homolog (Drosophila) 
TDRD9  tudor domain containing 9 
TM9SF3  transmembrane 9 superfamily member 3 
USHBP1  Usher syndrome 1C binding protein 1 
WDR60  WD repeat domain 60 
ZBTB12  zinc finger and BTB domain containing 12 
ZNF266  zinc finger protein 266 
ZNF439  zinc finger protein 439 
ZNF569  zinc finger protein 569 
ZNF83  zinc finger protein 83 
 
Table  5.4.  Differentially  Expressed  Genes  Common  to  BeadStudio  &  Rosetta  Resolver
® 
Analyses of Microarray Data. A total of 45 differentially expressed genes were found to be 
common to both BeadStudio and Rosetta Resolver
® data sets 177 
5.4 Discussion 
 
Experimental  work  described  in  this  chapter  explored  differential  gene  expression  in 
primary HSVECs isolated from CAD patients with and without the additional CVD risk 
factor, T2D. These studies were performed in an attempt to identify candidate genes and 
pathways contributing to the more severe endothelial dysfunction observed in vessels from 
patients with CAD and T2D (Figure 3.2B). This work represents a novel investigation as 
previous attempts to identify differences in gene expression profiles between CAD patients 
with and without T2D have focused on intact cardiac tissue (381;384). 
 
Expression  profiles  of  over  25,000  annotated  genes  were  assessed  using  Illumina
® 
HumanWG-6 v3.0 Expression BeadChips. Primary analysis of microarray data was carried 
out  using  BeadStudio  software  which  generated  a  list  of  727  differentially  expressed 
probes (Table A1).  
 
On  uploading  BeadStudio  data  to  IPA,  the  citrate  cycle  was  identified  as  a  canonical 
metabolic  pathway  significantly  affected  by  T2D  (Figure  5.4).  As  outlined  in  section 
1.3.4.3.1,  electron  donor  overproduction  by  the  citrate  cycle  is  known  to  contribute  to 
increased  mtROS  production  in  T2D,  thus  facilitating  progression  of  endothelial 
dysfunction (230). Furthermore, reduced glucose oxidation and storage in T2D have been 
observed to occur in parallel with reduced activity of the citrate cycle (391) and microarray 
analysis has revealed expression of a number of citrate cycle genes to be reduced in muscle 
biopsies from patients with T2D, including ATP5G3 and SDHC (392), genes observed to 
be  downregulated  here  (Table  5.1).  Consequently,  ATP5G3,  SDHC  and  a  third 
differentially expressed gene affecting the citrate cycle metabolic pathway, IDH3G (Table 
5.1), were selected as candidate genes for further study. As shown in Table 5.1, SDHAL1 
was  also  recognised  as  a  differentially  expressed  gene  involved  in  the  citrate  cycle. 
However, it was identified as a pseudogene and thus no attempt was made to confirm its 
differential expression. 
 
Fold  changes  in  citrate  cycle  gene  expression  were  relatively  modest  (Table  5.1)  and 
therefore it is perhaps not surprising that differential expression of ATP5G3, IDH3G and 
SDHC was not confirmed using TaqMan
® qRT-PCR and the 2
-  Ct comparative method, a 
method  limited  in  its  ability  to  accurately  detect  less  than  a  two-fold  change  in  gene 
expression (301). Given the complex nature of T2D, it seems likely that modest changes in 178 
expression of several genes in a given pathway will be important and, as stated, previous 
studies  have  suggested  that  coordinated  reduction  in  expression  of  genes  of  oxidative 
metabolism are implicated in T2D (392). Of note, analysis of microarray data revealed 
downregulation  of  ATP5G3  expression  and  upregulation  of  IDH3G  expression  in  cells 
from CAD patients with T2D (Table 5.1). The fact that TaqMan
® qRT-PCR demonstrated 
a trend towards a change in expression in the opposite direction for both genes (Figure 
5.7A and B), may be explained by the fact that due to limited human cellular material, 
qRT-PCR experiments did not incorporate the entire microarray patient group.  
 
Interestingly, although not confirmed by qRT-PCR, downregulation of ATPG3 and SDHC 
in HSVECs from patients with T2D could lead to reduced flux through the citrate cycle 
and  a  decrease  in  ATP  synthesis  which,  in  turn,  would  lead  to  an  increase  in  AMPK 
activity  (248).  Reduced  expression  of  citrate  cycle  genes  in  the  endothelium  of  CAD 
patients with T2D may therefore contribute to the increased AMPK activity observed in 
HSVECs isolated from these patients (Figure 4.3). 
 
PRKAG1 encodes the regulatory γ1-subunit of AMPK and was observed to be involved in 
a number of metabolic pathways significantly affected by T2D, including IGF-1 signalling 
(Figure  5.4)  and  the  most  significantly  affected  pathway,  RAR  activation  (Figure  5.4, 
Table 5.2 and Figure 5.6). As outlined, AMPK is recognised as a therapeutic target in T2D 
(137;143) and with results suggesting AMPK activity is increased in HSVECs isolated 
from patients with both CAD and T2D (Figure 4.3), PRKAG1 was selected as a fourth 
candidate gene from BeadStudio microarray data. Again, BeadStudio analysis revealed a 
modest reduction in PRKAG1 expression which was not confirmed by  TaqMan
® qRT-
PCR. This finding was perhaps to be expected as AMPK subunits do not exist as single 
entities, found only within heterotrimers of α-, β- and γ-subunits (248) and expression of 
all  three  should  therefore  remain  the  same.  No  difference  in  expression  of  PRKAA1, 
encoding the α1-catalytic subunit, was observed in HSVECs from CAD patients with T2D 
(Figure 4.5). Therefore, if PRKAG1 expression was indeed downregulated in cells from 
these patients, it would follow that expression of PRKAG2 and/or PRKAG3, encoding the 
γ2- and γ3-subunits respectively, would be upregulated. However, neither PRKAG2 nor 
PRKAG3 were identified as being differentially expressed on analysis of microarray data 
and, as such, downregulation of PRKAG1 appears to be a spurious finding, potentially 
representing a false positive outcome. 
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NRF2-mediated  oxidative  stress  response  and  IGF-1  signalling,  canonical  metabolic 
pathways significantly affected by the presence of T2D (Figure 5.4), were of potential 
interest  in  terms  of  T2D  pathogenesis.  However,  it  should  be  noted  that  BeadStudio 
analysis  had  limited  statistical  merit  as  no  FDR  cut-off  was  applied  or  background 
subtraction of data performed. This may explain why differential expression of candidate 
genes was not confirmed by qRT-PCR and is why, with human cellular material limited, 
differentially  expressed  genes  involved  in  additional  canonical  pathways  were  not 
investigated further. Instead, a more statistically robust analysis of microarray data using 
Rosetta Resolver
® software was performed. 
 
Uploading microarray data to the Rosetta Resolver
® Gene Expression Data Management 
and Analysis System permitted identification of an outlier using PCA. This outlier, a T2D 
patient,  was  subsequently  excluded  from  further  analysis.  Rosetta  Resolver
®  analysis, 
incorporating  more  stringent  statistical  limits,  generated  a  list  of  fewer  significantly 
differentially  expressed  genes  (Table  A2)  than  BeadStudio  analysis.  In  addition,  IPA 
revealed a decrease in the number of canonical metabolic pathways significantly affected 
(Figure 5.9). G-protein coupled receptor signalling was observed to be the pathway most 
significantly  affected  by  the  presence  of  T2D  (Figure  5.9)  with  AGTR2  and  PIK3R2 
identified as differentially expressed genes involved in this metabolic process (Table 5.3).  
 
Expression of AGTR2, encoding the Ang II type 2 receptor, was found to be modestly 
upregulated in HSVECs from patients with T2D (Table 5.3). Ang II is one of the main 
effector  molecules  of  the  RAS,  known  to  play  a  deleterious  role  in  the  initiation  and 
progression of atherosclerosis (393). Ang II mediates its physiological effects by binding 
Ang II type 1 (AT1) and type 2 (AT2) receptors on the cell membrane (394;395) (Figure 
5.13). AT1 receptor binding has been shown to mediate vasoconstrictor responses and cell 
growth and proliferation of VSMCs, cardiomyocytes and coronary endothelial cells. As 
such,  the  AT1  receptor  has  been  implicated  in  various  cardiovascular  pathologies, 
including atherosclerosis and stroke (393;395) and ARBs act to block the adverse effects 
of  Ang  II  through  direct  interaction  with  this  receptor  (393;396).  Conversely,  the  AT2 
receptor  mediates  vasodilatory  responses  and  biological  processes  that  counteract  the 
trophic responses mediated through AT1 receptor (395;397).  
 
Previously described findings of this study suggest CAD patients with T2D have poorer 
endothelial function (Figure 3.2) and are subject to increased oxidative stress in the  180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. Renin-Angiotensin System Enzymatic Cascades. The main effector molecule of the 
renin-angiotensin  system  (RAS),  angiotensin  II  (Ang  II),  can  be  generated  in  an  angiotensin 
converting enzyme (ACE)-dependent or independent manner. ACE-dependent Ang II formation 
occurs via a two step reaction: renin catalyses the conversion of angiotensinogen to angiotensin I 
(Ang  I)  which  is  subsequently  hydrolysed  by  ACE  to  form  Ang  II.  Alternatively,  the  direct 
conversion of angiotensinogen to Ang I can occur independently of ACE via enzymes such as 
tissue plasminogen activator (tPA), cathepsin G and tonin. In addition, chymase and cathepsin G 
are  able to catalyse  the  ACE-independent  hydrolysis  of  Ang  I  to  Ang  II.  Ang  II  mediates  its 
physiological  effects  by  binding  angiotensin  II  type  I  (AT1)  and  angiotensin  II  type  2  (AT2) 
receptors on the cell membrane. The receptors display a heterogenous tissue distribution with the 
AT1 receptor present in adult cardiovascular tissues and the AT2 receptor observed to be highly 
expressed  during  foetal  development.  AT1  receptor  binding  has  been  shown  to  mediate 
vasoconstrictor  responses.  Conversely,  the  AT2  receptor  mediates  vasodilatory  responses.  A 
recently  discovered  ACE-related  carboxypeptidase  (ACE2)  catalyses  the  cleavage  of  Ang  I  to 
angiotensin 1-9 (Ang 1-9) and mediates the transformation of Ang II into angiotensin 1-7 (Ang 1-
7), a known vasodilator (398;399). Ang 1-9 may also be directly converted to Ang 1-7 by ACE. 
Adapted from (395;396). 
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endothelium (Figure 3.8) as compared to patients with CAD alone. As such, it seemed 
possible that upregulation of AGTR2 expression in cells from T2D patients represented an 
adaptive  response  to  adverse  effects  of  the  AT1  receptor.  However,  while  analysis  of 
microarray  data  revealed  differential  expression  of  AGTR2,  expression  levels  detected 
were very low. Consequently, on attempting to confirm differential expression of the gene 
using  TaqMan
®  qRT-PCR,  AGTR2  mRNA  levels  were  undetectable.  This  finding  is 
concordant  with  previous  studies  which  have  found  that  the  AT2  receptor  is  highly 
expressed  during  foetal  development,  with  mRNA  levels  less  abundant  in  adult 
cardiovascular tissue (394;395). 
 
Identified as a second candidate gene from the Rosetta Resolver
® data set (Table 5.3 and 
Figure 5.10), PIK3R2 encodes the regulatory (IRS-binding) subunit of PI3K, p85β (400). 
As outlined in section 1.1, PI3K plays a pivotal role in insulin signalling and development 
of T2D and the p85β subunit has been shown to be involved in insulin sensitivity in mice 
(401). Differential expression of PIK3R2 in the endothelium of patients with T2D could 
therefore contribute to reduced sensitivity to insulin, leading to a decrease in NO synthesis 
and  the  attenuated  endothelial  function  observed  in  these  patients  (Figure  3.2).  In  this 
instance, microarray data analysis again revealed a modest fold change in gene expression 
which was not confirmed by TaqMan
® qRT-PCR (Figure 5.11B). Indeed, once more qRT-
PCR demonstrated a trend towards a change in expression in the direction opposite to that 
observed on analysis of microarray data (Table 5.3 and Figure 5.11B), possibly the result 
of PCR experiments involving only a subset of microarray patients. Given the potential 
significance of differential PIK3R2 expression in the endothelium of patients with T2D, 
this kinase may merit further investigation in the future. 
 
Although  not  observed  to  be  involved  in  metabolic  pathways  significantly  affected  by 
T2D, ACAD11 was found to be differentially expressed on Rosetta Resolver
® analysis of 
microrray data (Table A2). The gene encodes one of the most recently identified subtypes 
of  the  acyl-Coenzyme  A  dehydrogenase  (ACAD)  family  and  is,  as  yet,  of  unknown 
function (402). However, with a number of ACAD subtypes involved in mitochondrial β-
oxidation of fatty acids (402;403), a process implicated in development of T2D and insulin 
resistance (230), ACAD11 was selected for further investigation. 
 
ACAD11 expression was observed to be downregulated in cells from patients with T2D on 
Rosetta  Resolver
®  analysis  of  microarray  data  (Table  A2).  Although  presently 182 
uncharacterised, if ACAD11 represents an ACAD family member required for β-oxidation 
of fatty acids, downregulation of its expression may imply impaired β-oxidation and thus 
reliance on glucose oxidation in the endothelium of patients with T2D. This situation could 
potentially be associated with the increased AMPK activity observed in HSVECs isolated 
from patients with CAD and T2D (Figure 4.3), as increasing activity of the kinase, with a 
view to stimulating fatty acid oxidation, could be an attempt to overcome the problem of 
increased glucose oxidation. However, TaqMan
® qRT-PCR failed to confirm differential 
expression of ACAD11, instead revealing a trend towards increased expression in CAD 
patients with T2D (Figure 5.11A).  
 
On examination of both microarray data sets, a total of 45 differentially expressed genes 
were  identified  as  being  common  to  both  BeadStudio  and  Rosetta  Resolver
®  analyses 
(Table 5.4 and Figure 5.12). Perhaps unsurprisingly, given the limited statistical merit of 
the analysis, none of the candidate genes identified from the BeadStudio data set were 
included in the list of common genes, supporting the notion that this analysis may have 
given rise to a number of false positives. AGTR2 and ACAD11, candidate genes selected 
from Rosetta Resolver
® analysis, were found to be common to both lists of differentially 
expressed genes. However, PIK3R2 was not identified as a common gene. This gene was 
selected from the more statistically robust Rosetta Resolver
® data set and so despite its 
absence from the BeadStudio list, it is still an interesting candidate. PDE8A, encoding 
phosphodiesterase 8A, was another gene identified as common to both data sets. Rosetta 
Resolver
® analysis revealed PDE8A to be modestly downregulated in patients with T2D 
and involved in G-protein coupled receptor signalling (Figure 5.9 and Table 5.3). Further 
investigation  of  PDE8A  expression  was  not  carried  out  due  to  limited  human  cellular 
material and time constraints but, with the isoenzyme, PDE8B suggested to have a role in 
insulin response to glucose in rat pancreatic β-cells (404), PDE8A may represent a focus of 
future studies.  
 
The transcriptional profiling described in this chapter represents the first human microarray 
study  to  be  carried  out  within  this  laboratory  and  was  not  without  limitations  and 
difficulties. The application of stringent statistical limits resulted in relatively few genes 
being identified as differentially expressed between patient groups. There may be a number 
of  potential  explanations  for  this,  including,  as  previously  suggested,  that  human 
endothelial cells fail to retain the in vivo phenotype in culture. One possible strategy to 
overcome this issue could involve microarray analysis of pooled RNAs from passage 0 183 
cells.  Furthermore,  complex  diseases,  such  as  T2D,  are  likely  to  be  the  result  of  low-
magnitude  alterations  in  expression  of  multiple  genes  and  therefore  the  small  subject 
numbers in this study limits the power to detect differences between groups. In addition, as 
previously  discussed,  using  TaqMan
®  qRT-PCR  and  the  2
-  Ct  method  to  validate 
differential expression means anything less than a two-fold change in gene expression is 
considered  insignificant  (301).  Given  these  limitations,  complementary  methodologies, 
including proteomics and microRNA (miRNA) profiling, may aid in the elucidation of 
molecular mechanisms adversely affected in the endothelium of patients with CAD and 
T2D.  With  increasing  evidence  to  implicate  endothelial  dysfunction  in  T2D  disease 
progression  (162),  integration  of  these  technologies,  allowing  examination  of  gene 
transcription and translation in the endothelium of CAD patients with T2D, seems key to 
understanding diabetic vascular complications. 184 
 
 
 
 
 
6. General Discussion 
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Endothelial  dysfunction  occurs  in  conjunction  with  CAD  and  is  observed  in  both  the 
coronary and peripheral vasculature (405). Accumulating evidence suggests a causative 
role for vascular oxidative stress in endothelial dysfunction and the pathogenesis of CAD 
(159). The prevalence of CAD in patients with T2D is more than ten times greater than in 
the general population and poorer clinical outcomes are observed in CAD patients with 
T2D than in those without (335;406;407). Previous investigations carried out within this 
laboratory  have  demonstrated  endothelial  dysfunction  and  elevated  O2
-  production  in 
saphenous veins from patients with advanced CAD (159). In addition to confirming these 
findings, this study has considered the effects of T2D on endothelial function and vascular 
O2
- production, revealing more severe endothelial dysfunction in vessels from those CAD 
patients with T2D. Through application of a wide range of molecular techniques, cellular 
mechanisms  underlying  this  oxidative  stress  and  endothelial  dysfunction  have  been 
investigated in primary endothelial cells isolated from CAD patients.  
 
Having confirmed elevated O2
- production in vessels from patients with CAD and with Al 
Benna  et  al.  reporting  that  this  increase  occurs  throughout  the  vessel  wall  (159), 
preliminary  cellular  work  involved  investigation  of  HSVEC  O2
-  production.  EPR 
spectroscopy  failed  to  confirm  significantly  increased  O2
-  release  in  cells  from  CAD 
patients relative to those from controls, raising the possibility that cultured primary cells, 
free  from  physiological  stresses,  do  not  retain  the  in  vivo  phenotype.  While  it  is 
acknowledged that this may represent a potential limitation of the study, in focusing on 
cultured primary endothelial cells, a pragmatic approach to the exploration of endothelium-
specific mechanisms of oxidative stress has been adopted.  
 
Subsequent  investigations  revealed  increased  HSVEC  SOD2  protein  and  mRNA 
expression  in  CAD  patients,  in  particular  those  with  T2D.  This  increase  in  SOD2 
expression  is  likely  to  represent  an  adaptive  response  to  elevated  mitochondrial  O2
- 
production as accumulating evidence suggests mitochondrially-derived ROS contribute to 
oxidative  stress  and  endothelial  dysfunction  in  a  range  of  cardiovascular  pathologies, 
including  CAD  and  T2D  (222;224;225).  Attempts  to  establish  the  contribution  of 
mitochondria to cellular O2
- production involved treatment of HSVECs with rotenone and 
MitoQ10. The results of these studies were inconclusive but the role of mitochondria in 
HSVEC O2
- generation clearly merits further investigation. As such, alternative methods, 
including MitoSOX
™ (Invitrogen) staining, will be employed to this end in the future. 
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With HSVECs isolated from CAD patients failing to retain the significantly elevated O2
- 
phenotype but displaying increased SOD2 expression, H2O2 may represent a more useful 
marker  of  oxidative  stress  in  the  endothelium  of  these  patients.  Known  to  induce 
endothelial dysfunction (408), H2O2 is a more stable molecule than O2
- which may render 
its detection in HSVECs less challenging. Thus, in addition to assessment of mitochondrial 
O2
- production, future studies are likely to involve comparisons of cellular H2O2, using 
Amplex
®  Red  (Invitrogen)  technology  or  EPR  spectroscopy,  employing  the  method 
recently described by Dikalov and colleagues (409). 
 
Expression of SOD2 mRNA was significantly increased in HSVECs from CAD patients 
with T2D relative to those from patients with CAD alone, as assessed by TaqMan
® qRT-
PCR. However, this differential expression was not confirmed on comparison of global 
gene  expression  profiles  in  cells  from  these  patients.  This  was  perhaps  not  surprising, 
given  qRT-PCR  and  microarray  experiments  did  not  involve  investigation  of  gene 
expression  in  cells  isolated  from  the  same  clinical  subjects,  a  consequence  of  limited 
vascular material. This finding therefore serves to highlight the difficulty of studying gene 
expression in outbred human populations.  
 
Despite  obvious  limitations  of  the  microarray  experiment  described  in  Chapter  5,  it 
remains the first study of its kind to examine global gene expression in primary endothelial 
cells  from  CAD  patients  with  and  without  T2D.  Furthermore,  in  revealing  differential 
expression of a number of genes potentially linked to mitochondrial function, the study 
serves to support a key role for mitochondrial dysfunction in the pathogenesis of CAD and 
T2D. However, the difficulties associated with small subject numbers and confirmation of 
differential expression of candidate genes, in addition to the possibility that cultured cells 
do not retain the in vivo phenotype, indicates alternative or complementary technologies 
may  prove  more  successful  in  elucidating  molecular  mechanisms  adversely  affected  in 
patients with CAD and T2D. Proteomics, which involves the identification of polymorphic 
protein expression and isoforms between samples, is increasingly being applied in complex 
disease research and has been utilised within this laboratory in the context of CAD; urinary 
protein biomarkers were assayed in control subjects and patients with CAD and a signature 
polypeptide pattern specific to CAD patients distinguished (410).  
 
In addition to proteomics, miRNA technology has attracted considerable research interest 
in  recent  years.  MicroRNAs  are  non-coding  RNA  molecules  involved  in  post-187 
transcriptional  control  of  gene  expression  (411).  The  ability  of  miRNAs  to  affect 
expression of complex diseases such as CAD and T2D is considered likely since they are 
known  to  target  multiple  mRNAs  (412).  Indeed,  genome-wide  expression  profiling  of 
miRNAs  in  patients  with  heart  disease  (ischaemic  cardiomyopathy,  dilated 
cardiomyopathy and aortic stenosis) revealed disease-specific miRNA expression patterns 
particular to each condition on comparison with healthy control subjects (413). In terms of 
diabetes, specific miRNAs involved in insulin production, secretion and action have been 
identified in recent years (414;415). In particular, studies involving murine models have 
reported miR-9 and miR-375 to be involved in regulation of insulin secretion (416;417), 
while  miR-124a2  has  recently  been  implicated  in  pancreatic  β-cell  development  and 
function (418). However, despite growing evidence that miRNAs are important in T2D, 
few  studies  of  global  miRNA  expression  in  human  insulin  target  tissues  have  been 
published to date. The present study was limited due to the majority of samples being 
collected  before  well  established  techniques  to  capture  miRNAs  became  available  but 
future studies may focus on these small RNA components. 
 
While the microarray experiment of Chapter 5 represents a novel piece of work, the key 
findings of this project centre around AMPK. Recently identified as a potential therapeutic 
target in vascular disease (419), AMPK is currently the subject of extensive research. A 
paper  from  Professor  Salvador  Moncada’s  group,  published  in  2006,  revealed  that  the 
kinase is activated in a mtROS-mediated manner in endothelial cells (228). Consequently, 
the finding that SOD2 expression is significantly increased in HSVECs from patients with 
CAD, consistent with increased mtROS production, led to investigation of AMPK activity 
in these cells. Activity  of the kinase was observed to be significantly increased in the 
endothelium of CAD patients with T2D despite no change in activity of upstream kinases, 
LKB1  and  CaMKK,  suggesting  an  alternative,  potentially  mtROS-mediated  method  of 
activation in these individuals. Indeed, it seemed likely that these patients, with an extra 
risk factor for CVD, poorer endothelial function and significantly increased endothelial 
SOD2 expression, would be subject to increased mitochondrially-produced ROS in the 
endothelium, resulting in the increased AMPK activity observed. As described in Chapter 
4, treatment of cells with the mitochondria-targeted antioxidant, MitoQ10 revealed AMPK 
is indeed activated in a mtROS-mediated manner in the endothelium of patients with CAD 
and T2D, representing the major, novel finding of this project.  
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In terms of what mtROS-mediated activation of AMPK means in relation to enzymatic 
function, it appears AMPK is part of a feedback or adaptive mechanism with a role in 
defence against oxidative stress in the endothelium of patients with CAD and T2D. The 
kinase may contribute to control of vascular tone through phosphorylation of eNOS and 
stimulation of NO production (176;282), or by inducing expression of genes involved in 
antioxidant  defence,  including  SOD2  itself  (377;378).  As  such,  assessment  of  HSVEC 
SOD2 expression following treatment of cells with AICAR and MitoQ10 will be carried out 
in the near future.  
 
In  addition  to  inducing  expression  of  SOD2,  there  is  now  evidence  to  suggest  AMPK 
inhibits production of O2
- by NAD(P)H oxidase. A recent study by Alba and colleagues 
demonstrated  that  AMPK  inhibits  activation  of  NAD(P)H  oxidase  in  neutrophils  by 
phosphorylating  the  p47
phox  subunit,  thus  preventing  its  translocation  to  the  plasma 
membrane  (420).  The  findings  described  in  Chapter  3  of  this  thesis  indicate  a  lesser 
contribution of vascular NAD(P)H oxidase to O2
- production in endothelial cells of patients 
with CAD and T2D than in cells from patients with CAD alone. This result may therefore 
be explained by the fact that increased endothelial AMPK activity in CAD patients with 
T2D results in suppression of NAD(P)H oxidase activation in the endothelium of these 
patients. 
 
With vascular complications the leading cause of death in patients with CAD and T2D 
(8;30), the body of work presented here further supports the idea that a well tolerated 
therapeutic  activator  of  AMPK  should  successfully  improve  glycaemic  control  while 
maintaining or restoring endothelial function. Agents presently known to activate AMPK, 
such as metformin, appear to act indirectly and exhibit a number of unpleasant side effects 
(419).  Attempts  have  been  made  to  generate  alternative  AMPK-activating  agents, 
including the thienopyridone A769662, which induces AMPK activity via a mechanism 
involving  the  β-  and  γ-subunits  (421).  However,  this  compound  may  have  potentially 
limiting side effects and is reported to inhibit the function of the 26S proteasome by an 
AMPK-independent  mechanism,  leading  to  cell  cycle  arrest  in  mouse  embryonic 
fibroblasts in vitro (422). Despite this observation, treatment of ob/ob mice with A769662 
lowered  plasma  glucose,  reduced  body  weight  gain,  and  significantly  decreased  both 
plasma  and  liver  triglyceride  levels  (423).  It  remains  to  be  determined  whether  the 
compound can improve vascular function.  
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Results  presented  here  suggest  activators  of  AMPK  will  prove  most  useful  when 
administered in conjunction with mitochondria-targeted antioxidants, such as MitoQ10. The 
ubiquinone has recently been shown to improve endothelial function and attenuate cardiac 
hypertrophy in a rodent model of CVD, the SHRSP (424). In addition, it has reached two 
human phase 2 clinical trials and is reported to be protective against liver damage in a 
small study of patients with chronic hepatitis C (425) and well tolerated when taken over 
the period of a year by patients with Parkinson’s disease (426). At the time of writing, an 
application  has  been  made  by  this  group  to  the  Medicines  and  Healthcare  products 
Regulatory  Agency  (MHRA)  for  a  clinical  trial  of  MitoQ10  in  patients  with  CAD 
undergoing CABG surgery. Should this application prove successful, the contribution of 
mitochondrially-derived  ROS  to  oxidative  stress  and  endothelial  dysfunction,  and  the 
translational relevance of modulation of AMPK activity by mtROS could be determined 
through  examination  of  vessels  and  cells  isolated  from  trial  participants.  Alternatively, 
future in vivo studies may utilise the SHRSP, with investigations of mtROS production and 
kinase activity following oral administration of MitoQ10. 
 
In  conclusion,  the  findings  presented  in  this  thesis  confirm  CAD  is  associated  with 
endothelial dysfunction and elevated vascular O2
- production and provide insight into the 
cellular  mechanisms  underlying  these  processes  in  the  endothelium.  This  study 
demonstrates  a  novel,  mtROS-mediated  mechanism  for  AMPK  activation  in  the 
endothelium  of  patients  with  coronary  artery  disease  and  type  2  diabetes  and  suggests 
mitochondria contribute to increased O2
- production and endothelial dysfunction in these 
patients.  In  terms  of  clinical  perspective,  results  indicate  that  mitochondria-targeted 
antioxidants, used in combination with pharmacological activators of AMPK, may have 
therapeutic  potential  as  an  early  intervention  strategy  in  the  treatment  of  endothelial 
dysfunction in these patients. 190 
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Illumina® 
Probe ID 
Gene 
Symbol 
T2D Diff 
Score 
Illumina® 
Probe ID  Gene Symbol 
T2D Diff 
Score 
ILMN_1862910    -51.512  ILMN_1776428  STK17A  -20.689 
ILMN_1722397  LOC729137  -41.691  ILMN_1813769  ARRDC3  -20.636 
ILMN_1788955  PDLIM1  -40.376  ILMN_1750722  RPS7  -20.494 
ILMN_1752269  ACSS1  -33.752  ILMN_1694075  GADD45A  -20.261 
ILMN_1719949  LOC644019  -31.901  ILMN_1699022  ENDOD1  -20.221 
ILMN_1740466  FAM46A  -28.802  ILMN_1777849  IL7R  -20.189 
ILMN_1663765  LOC647346  -28.787  ILMN_1696810  ADMR  -20.078 
ILMN_1669404  KISS1  -28.355  ILMN_1765633  FAM10A7  -20.03 
ILMN_1732575  SEC14L1  -27.921  ILMN_1675684  APOBEC3C  -19.899 
ILMN_1730201  DTNA  -27.194  ILMN_1874778  LOC729310  -19.813 
ILMN_1703140  NEDD4  -27.098  ILMN_1705364  BAT3  -19.752 
ILMN_1696537  DDIT4L  -26.676  ILMN_1731639  CASP3  -19.464 
ILMN_1746241  SDHC  -26.557  ILMN_1675797  EPDR1  -19.464 
ILMN_1652763  LOC389203  -26.039  ILMN_1656327  GLT1D1  -19.396 
ILMN_1659365  LOC653071  -25.739  ILMN_1803375  ODZ1  -19.368 
ILMN_1794505  SHFM1  -24.905  ILMN_1794038  FAM49A  -19.24 
ILMN_1759344  LOC652226  -24.892  ILMN_1662097  SLC25A43  -19.035 
ILMN_1720430  C20orf149  -24.198  ILMN_1683494  TMEM154  -18.807 
ILMN_1806266  RAP1GDS1  -23.93  ILMN_1694100  PRIM2  -18.801 
ILMN_1665865  IGFBP4  -23.751  ILMN_1821335    -18.582 
ILMN_1652638  LRRC58  -23.634  ILMN_1655222  LOC389833  -18.483 
ILMN_1749078  TIMP2  -23.12  ILMN_1725705  CLPP  -18.439 
ILMN_1745578  ETS2  -22.945  ILMN_1705630  LOC641700  -18.309 
ILMN_1745593  STMN1  -22.764  ILMN_1707356  CFL2  -18.264 
ILMN_1880421    -22.471  ILMN_1830906    -18.235 
ILMN_1757387  UCHL1  -22.451  ILMN_1836185    -18.189 
ILMN_1666022 
TNFRSF10
D  -22.167  ILMN_1675312  LOC389833  -18.144 
ILMN_1716407  SORBS2  -22.01  ILMN_1770466  ATP5G3  -18.009 
ILMN_1655236  GFPT2  -21.798  ILMN_1695872  LOC641992  -17.995 
ILMN_1673676  SNX5  -21.759  ILMN_1654563  EFNB1  -17.95 
ILMN_1687538  ETS1  -21.695  ILMN_1742065  GCNT4  -17.95 
ILMN_1667970  LOC728825  -21.661  ILMN_1717855  PFDN1  -17.881 
ILMN_1751851  CECR1  -21.569  ILMN_1767556  C10orf10  -17.85 
ILMN_1702168  HSD17B12  -21.535  ILMN_1665736  LOC648024  -17.809 
ILMN_1655046  NUTF2  -21.535  ILMN_1764261  TMEM128  -17.782 
ILMN_1675156  CDC42  -21.522  ILMN_1665682  IL15RA  -17.762 
ILMN_1701613  RARRES3  -21.431  ILMN_1736356  STK32B  -17.664 
ILMN_1698478  SNAPC2  -21.333  ILMN_1764225  GAGE6  -17.569 
ILMN_1800837  CFDP1  -21.281  ILMN_1780060  FCN3  -17.45 
ILMN_1718182  THRA  -21.167  ILMN_1674620  SGCE  -17.404 
ILMN_1716518  NACA  -21.145  ILMN_1662016  SCRN2  -17.269 
ILMN_1694569  LOC650224  -20.899  ILMN_1800131  LOC652826  -17.267 
ILMN_1721535  COG5  -20.883  ILMN_1726415  CCNA1  -17.258 
ILMN_1742250  CCNH  -20.875  ILMN_1693108  RUVBL1  -17.253 
ILMN_1808041  RPL10A  -20.855  ILMN_1774545  LOC339240  -17.21 
ILMN_1656651  MR1  -20.853  ILMN_1756862  APOL3  -17.115 
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ILMN_1792814  FLJ43870  -17.075  ILMN_1683375  MCL1  -15.397 
ILMN_1726523  OR10G3  -17.072  ILMN_1841025    -15.39 
ILMN_1660248  WTAP  -17.061  ILMN_1779213  TFG  -15.371 
ILMN_1911874    -17.033  ILMN_1836965    -15.352 
ILMN_1801661  KRT7  -16.965  ILMN_1772743  PIGK  -15.351 
ILMN_1810941  COMT  -16.964  ILMN_1677483  EXOSC1  -15.309 
ILMN_1750225  MYCT1  -16.914  ILMN_1815032  SOX7  -15.298 
ILMN_1765701  LOC399942  -16.887  ILMN_1788283  COTL1  -15.296 
ILMN_1677610  OVCA2  -16.768  ILMN_1676289  NCAM1  -15.273 
ILMN_1869431    -16.701  ILMN_1831325    -15.236 
ILMN_1676173  PARVB  -16.676  ILMN_1783681  MRPL34  -15.235 
ILMN_1711899  ANXA2  -16.659  ILMN_1671267  NF2  -15.219 
ILMN_1908488    -16.655  ILMN_1774086  CBX3  -15.209 
ILMN_1690063  LOC651143  -16.52  ILMN_1827211    -15.168 
ILMN_1729142  PRR6  -16.439  ILMN_1912500    -15.145 
ILMN_1713574  LOC643493  -16.369  ILMN_1669376  DRAM  -15.13 
ILMN_1705982  LOC645284  -16.347  ILMN_1748591  ODC1  -15.11 
ILMN_1889126    -16.313  ILMN_1754249  LOC442535  -15.106 
ILMN_1726354  EXOSC7  -16.276  ILMN_1673363  CD97  -15.088 
ILMN_1658639  SLC46A3  -16.275  ILMN_1690125  PDLIM7  -15.067 
ILMN_1781270  LOC646071  -16.236  ILMN_1739534  MAP2K4  -15.044 
ILMN_1737163  SH3BGRL3  -16.163  ILMN_1763989  SEC63  -15.036 
ILMN_1697665  LOC653972  -16.162  ILMN_1877681    -15.035 
ILMN_1762071  C17orf80  -16.112  ILMN_1661825  TNFRSF6B  -15.027 
ILMN_1727402  HCLS1  -16.11  ILMN_1687887  PSMC4  -15.018 
ILMN_1801020  ADK  -16.064  ILMN_1815656  SERINC3  -15.012 
ILMN_1682935  LYPLAL1  -15.954  ILMN_1853049    -14.97 
ILMN_1680579  ATP2B4  -15.918  ILMN_1882522    -14.941 
ILMN_1757347  C22orf9  -15.897  ILMN_1667597  LOC644865  -14.935 
ILMN_1906438    -15.836  ILMN_1763688  C17orf49  -14.877 
ILMN_1707815  SDHALP1  -15.807  ILMN_1758939  RIPK2  -14.855 
ILMN_1740591  LOC649292  -15.771  ILMN_1774687  PRKAG1  -14.846 
ILMN_1846641    -15.752  ILMN_1854518    -14.841 
ILMN_1794875  MAG1  -15.672  ILMN_1801043  GSN  -14.836 
ILMN_1711928  FLJ20920  -15.665  ILMN_1775634  AGTR2  -14.792 
ILMN_1691048 
SLC22A18
AS  -15.663  ILMN_1785284  ALDH6A1  -14.756 
ILMN_1661417  MAGED2  -15.652  ILMN_1716859  TDO2  -14.737 
ILMN_1690566  RASSF4  -15.652  ILMN_1732916  CCDC17  -14.723 
ILMN_1672922  CYTL1  -15.634  ILMN_1827239    -14.715 
ILMN_1654322  ATP1B3  -15.567  ILMN_1697945  FRMD4B  -14.703 
ILMN_1787750  CD200  -15.555  ILMN_1800487  CDC26  -14.693 
ILMN_1685240  PTRH1  -15.513  ILMN_1660718  GABBR2  -14.691 
ILMN_1652549  DTNA  -15.496  ILMN_1808713  HSD17B2  -14.68 
ILMN_1790249  F8A1  -15.423  ILMN_1658053  DYNLRB1  -14.668 
ILMN_1739103  MPZL1  -15.404  ILMN_1790271  EEF1B2  -14.658 
ILMN_1705116  C6orf85  -15.403  ILMN_1678312  LOC388397  -14.656 
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ILMN_1817598    -14.654  ILMN_1740777  ZBTB12  -13.921 
ILMN_1820226    -14.647  ILMN_1708605  LOC652481  -13.884 
ILMN_1682112  PCDHA10  -14.627  ILMN_1829475    -13.88 
ILMN_1669923  SSR2  -14.591  ILMN_1886034    -13.878 
ILMN_1870248    -14.501  ILMN_1879243    -13.871 
ILMN_1689467  CCDC86  -14.497  ILMN_1894376    -13.828 
ILMN_1912718    -14.49  ILMN_1774949  PIGP  -13.82 
ILMN_1688178  CGI-96  -14.448  ILMN_1795944  PRR13  -13.818 
ILMN_1785692  LOC728098  -14.445  ILMN_1651329  LOC651538  -13.797 
ILMN_1851746    -14.428  ILMN_1862963    -13.796 
ILMN_1767006  PSMB8  -14.425  ILMN_1856010    -13.745 
ILMN_1676333  LOC645465  -14.388  ILMN_1807492  LOC643668  -13.736 
ILMN_1747344  IL3RA  -14.374  ILMN_1728914  PRUNE  -13.732 
ILMN_1714752  ZNF658  -14.366  ILMN_1730553  DDR2  -13.73 
ILMN_1679949  SLC25A23  -14.352  ILMN_1852928    -13.701 
ILMN_1741259  LOC649209  -14.32  ILMN_1686610  APBA3  -13.675 
ILMN_1652205  LOC645785  -14.309  ILMN_1916026    -13.643 
ILMN_1743432  DGUOK  -14.3  ILMN_1839168    -13.628 
ILMN_1884228    -14.27  ILMN_1886655    -13.603 
ILMN_1764573  XIST  -14.267  ILMN_1917294    -13.585 
ILMN_1766643  HOP  -14.255  ILMN_1794046  MTX2  -13.568 
ILMN_1710482  APLP2  -14.251  ILMN_1749907  LOC441241  -13.539 
ILMN_1679133  SERPINB1  -14.249  ILMN_1674315  POLA  -13.522 
ILMN_1692077  MXRA7  -14.223  ILMN_1666174  CECR1  -13.512 
ILMN_1665040  RBMS3  -14.189  ILMN_1780988  LOC401720  -13.504 
ILMN_1915629    -14.177  ILMN_1751124  RGMB  -13.504 
ILMN_1680280  LOC644923  -14.175  ILMN_1728071  KRAS  -13.484 
ILMN_1870679    -14.167  ILMN_1807981  SIGIRR  -13.482 
ILMN_1769027  CDC42SE1  -14.164  ILMN_1880671    -13.467 
ILMN_1879882    -14.155  ILMN_1657348  LOC650909  -13.436 
ILMN_1822952    -14.146  ILMN_1732750  CHCHD8  -13.43 
ILMN_1800000  FAM131B  -14.14  ILMN_1888844    -13.424 
ILMN_1752562  CXCL5  -14.087  ILMN_1663754  ZNF442  -13.42 
ILMN_1899777    -14.086  ILMN_1656621  CHMP2A  -13.418 
ILMN_1706571  SLC35D2  -14.079  ILMN_1679700  LOC389672  -13.404 
ILMN_1815081  AQP1  -14.075  ILMN_1712347  LOC644422  -13.404 
ILMN_1689669  MDK  -14.074  ILMN_1914595    -13.396 
ILMN_1740487  CMTM7  -14.062  ILMN_1811303  NR5A2  -13.363 
ILMN_1800224  NOLC1  -14.044  ILMN_1814998  FKSG30  -13.323 
ILMN_1661351  C17orf81  -14.038  ILMN_1912586    -13.298 
ILMN_1692733  NRARP  -14.026  ILMN_1694140  AFAP1L1  -13.29 
ILMN_1658743  CCNDBP1  -14.004  ILMN_1803277  MVP  -13.29 
ILMN_1692916  LOC646135  -13.969  ILMN_1693233  KIAA0513  -13.227 
ILMN_1654462  LOC440084  -13.966  ILMN_1709440  CPM  -13.207 
ILMN_1884842    -13.962  ILMN_1817948    -13.193 
ILMN_1753924  KRT19  -13.956  ILMN_1888230    -13.191 
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ILMN_1704471  NR1D2  -13.188  ILMN_1802096  ABTB1  13.398 
ILMN_1850685    -13.161  ILMN_1694399  ICA1  13.429 
ILMN_1770071  IFITM4P  -13.157  ILMN_1811535  JUB  13.451 
ILMN_1905101    -13.143  ILMN_1720431  ZNF420  13.457 
ILMN_1851207    -13.139  ILMN_1789074  HSPA1A  13.46 
ILMN_1718852  PLCL1  -13.113  ILMN_1688479  LRRC42  13.468 
ILMN_1733841  TCF7L1  -13.112  ILMN_1735765  RAB14  13.481 
ILMN_1709643  TMEM69  -13.11  ILMN_1699206  KIAA1727  13.488 
ILMN_1714144  GPR108  -13.101  ILMN_1673817  REP15  13.489 
ILMN_1786331  TRIM16  -13.076  ILMN_1719149  LOC653663  13.494 
ILMN_1712525  UBE2E3  -13.049  ILMN_1859908    13.497 
ILMN_1915123    -13.04  ILMN_1782247  GCN5L2  13.5 
ILMN_1797666  SLC27A6  -13.039  ILMN_1752510  FAM13A1  13.504 
ILMN_1903877    -13.032  ILMN_1655702  ABHD5  13.526 
ILMN_1680341  PPIE  -13.027  ILMN_1809139  AHCTF1  13.535 
ILMN_1768867  AP3B1  -13.021  ILMN_1722423  SHPRH  13.539 
ILMN_1811222  LOC643213  -13  ILMN_1881865    13.542 
ILMN_1839051    13.005  ILMN_1707464  MST1  13.589 
ILMN_1736901  ZDHHC23  13.017  ILMN_1709227  CCDC84  13.617 
ILMN_1728180  CROP  13.028  ILMN_1664139  FAM29A  13.624 
ILMN_1708485  BIN3  13.033  ILMN_1743402  SIX4  13.643 
ILMN_1655167  ZNF502  13.043  ILMN_1799381  SNORD14A  13.643 
ILMN_1687303  ACAD10  13.046  ILMN_1707481  BTBD15  13.654 
ILMN_1806809  ZNF189  13.057  ILMN_1726693  GTF2H1  13.661 
ILMN_1696806  CTNND1  13.06  ILMN_1810385  ATR  13.667 
ILMN_1786024  POLR3H  13.07  ILMN_1832120    13.685 
ILMN_1717112  LOC642787  13.083  ILMN_1701991  SYNJ1  13.692 
ILMN_1804111  CETN3  13.089  ILMN_1793290  WDR60  13.703 
ILMN_1699767  PDE8A  13.099  ILMN_1776094  PPCS  13.725 
ILMN_1799688  CDC23  13.118  ILMN_1725644  UBE2D2  13.731 
ILMN_1662130  LOC730316  13.12  ILMN_1915783    13.735 
ILMN_1737878  FLJ34047  13.164  ILMN_1708110  TMEM144  13.738 
ILMN_1730118  ZNF644  13.204  ILMN_1753393  OSGEP  13.752 
ILMN_1720844  SSX2IP  13.232  ILMN_1716733  MYOM2  13.755 
ILMN_1743288  LOC652570  13.236  ILMN_1737635  RAD1  13.771 
ILMN_1696757  TTC14  13.244  ILMN_1685820  RAB40B  13.772 
ILMN_1884750    13.258  ILMN_1863592    13.777 
ILMN_1743078  LOC643031  13.3  ILMN_1655922  SAPS2  13.779 
ILMN_1724017  LOC732450  13.307  ILMN_1713752  SERINC3  13.781 
ILMN_1813603  SF3B1  13.307  ILMN_1703891  TBC1D9  13.801 
ILMN_1736077  LIAS  13.314  ILMN_1682762  IDH3G  13.807 
ILMN_1870668    13.327  ILMN_1659082  ZCRB1  13.807 
ILMN_1708064  MAP4  13.36  ILMN_1767665  LOC493869  13.812 
ILMN_1749081  AUTS2  13.361  ILMN_1767642  C11orf46  13.816 
ILMN_1666082  HEATR3  13.373  ILMN_1812208  SUV420H2  13.822 
ILMN_1669982  CCDC85A  13.397  ILMN_1698365  LOC387921  13.824 
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ILMN_1785661  FAM108B1  13.828  ILMN_1759074  DUSP19  14.451 
ILMN_1717263  PRELID2  13.849  ILMN_1761833  SLC40A1  14.458 
ILMN_1798448  IDS  13.869  ILMN_1749838  MZF1  14.497 
ILMN_1700896  SAP30  13.872  ILMN_1656132  PNLDC1  14.5 
ILMN_1821052    13.889  ILMN_1701434  RAP1B  14.529 
ILMN_1672302  STK32C  13.891  ILMN_1806601  GRSF1  14.598 
ILMN_1692429  PQBP1  13.911  ILMN_1701247  LOC132241  14.616 
ILMN_1684183  RAD9A  13.916  ILMN_1707240  PTBP2  14.621 
ILMN_1671992  LOC650128  13.917  ILMN_1807704  LOC338799  14.632 
ILMN_1856932    13.931  ILMN_1736042  ME1  14.657 
ILMN_1711828  ANKRD10  13.94  ILMN_1914800    14.669 
ILMN_1895385    13.942  ILMN_1794522  EIF5A  14.683 
ILMN_1690783  TREML1  13.954  ILMN_1840934    14.685 
ILMN_1704431  LOC554203  13.981  ILMN_1717834  MGC11102  14.695 
ILMN_1800164  PPFIA1  14.02  ILMN_1692041  POT1  14.715 
ILMN_1751474  ARHGAP29  14.046  ILMN_1765310  TCEAL2  14.72 
ILMN_1704398  FZD9  14.061  ILMN_1765019  SACM1L  14.728 
ILMN_1772658  KIAA0947  14.063  ILMN_1707434  LOC653778  14.735 
ILMN_1688464  MAP6D1  14.083  ILMN_1757052  SLC16A1  14.738 
ILMN_1786976  RAB22A  14.086  ILMN_1667510  C12orf65  14.742 
ILMN_1688056  UGP2  14.104  ILMN_1853116    14.771 
ILMN_1775328  MTG1  14.141  ILMN_1683533  CCDC66  14.773 
ILMN_1671839  TAF1C  14.16  ILMN_1784436  KIAA1688  14.79 
ILMN_1733084  LOC147645  14.172  ILMN_1770818  LOC642342  14.792 
ILMN_1668027  LOC727762  14.175  ILMN_1728517  FNTB  14.806 
ILMN_1784037  ZBTB40  14.179  ILMN_1683129  CCNL1  14.813 
ILMN_1697024  LOC730432  14.198  ILMN_1664833  MRPL50  14.815 
ILMN_1800676  TMEM49  14.208  ILMN_1812559  SLC7A6  14.815 
ILMN_1691290  CELSR3  14.211  ILMN_1758679  TMEM168  14.816 
ILMN_1727738  RAB33B  14.223  ILMN_1866464    14.822 
ILMN_1810514  SLC25A44  14.254  ILMN_1795407  CRYZL1  14.85 
ILMN_1698007  LOC651872  14.27  ILMN_1712027  RSBN1L  14.862 
ILMN_1787826  SLC36A1  14.272  ILMN_1666178  TP53I13  14.863 
ILMN_1725188  PRKCI  14.289  ILMN_1913678    14.865 
ILMN_1684278  SNORD38A  14.315  ILMN_1752798  LOC642780  14.886 
ILMN_1747442  P4HA1  14.316  ILMN_1753413  TRIOBP  14.908 
ILMN_1716658  ZNF543  14.37  ILMN_1758941  REEP5  14.938 
ILMN_1757660  CAPS  14.391  ILMN_1661107  SNORD34  14.973 
ILMN_1677165  SF3B1  14.405  ILMN_1835722    14.978 
ILMN_1705468  PIK3CA  14.406  ILMN_1775423  C10orf88  14.986 
ILMN_1671221  GAPVD1  14.429  ILMN_1685703  ACOX2  14.99 
ILMN_1656656  COX19  14.43  ILMN_1665290  LOC643995  15.024 
ILMN_1789095  BMPR2  14.435  ILMN_1703985  C19orf25  15.055 
ILMN_1899404    14.436  ILMN_1830984    15.063 
ILMN_1761058  ACAD11  14.437  ILMN_1774945  NRG3  15.1 
ILMN_1904135    14.442  ILMN_1750256  ALS2  15.122 
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ILMN_1807031  C14orf28  15.165  ILMN_1788237  LOC652755  16.216 
ILMN_1767601  C21orf94  15.215  ILMN_1813240  EIF1AX  16.225 
ILMN_1706608  LOC338799  15.232  ILMN_1815035  DENND2C  16.254 
ILMN_1811117  LOC400986  15.256  ILMN_1803018  KIFC2  16.27 
ILMN_1696935  RBM39  15.318  ILMN_1723418  CEL  16.306 
ILMN_1753607  PNO1  15.319  ILMN_1785933  C19orf18  16.323 
ILMN_1664449  ALG5  15.364  ILMN_1652736  RPS6KA3  16.385 
ILMN_1703273  UACA  15.374  ILMN_1683112  FANCC  16.437 
ILMN_1672947  CAST  15.391  ILMN_1786789  FAM102B  16.445 
ILMN_1829768    15.446  ILMN_1682757  PFKFB2  16.447 
ILMN_1743933  TSHZ3  15.456  ILMN_1816925  LOC730459  16.487 
ILMN_1693538  STK36  15.466  ILMN_1675541  EEF1B2  16.554 
ILMN_1766195  ZNF558  15.476  ILMN_1689086  CTSC  16.634 
ILMN_1660125  SFMBT2  15.51  ILMN_1678904  ENO3  16.67 
ILMN_1694367  SNORD35B  15.534  ILMN_1768754  PILRB  16.694 
ILMN_1711208  CELSR2  15.542  ILMN_1715351  SCYE1  16.729 
ILMN_1707337  MSTO1  15.553  ILMN_1768004  PDCD4  16.745 
ILMN_1736623  NCKIPSD  15.568  ILMN_1736184  GSTM3  16.75 
ILMN_1770152  ADAMTS18  15.591  ILMN_1773992  CCRL1  16.772 
ILMN_1715096  C6orf168  15.64  ILMN_1736017  LOC643834  16.802 
ILMN_1706825  PKN2  15.654  ILMN_1768719  RDH11  16.835 
ILMN_1657619  DNAJB14  15.667  ILMN_1688455  KIAA0564  16.842 
ILMN_1762262  PKIA  15.698  ILMN_1766950  PCDHB13  16.863 
ILMN_1787813  SLC5A3  15.698  ILMN_1654518  LRCH4  16.866 
ILMN_1788778  Sep-11  15.701  ILMN_1664802  WSB1  16.941 
ILMN_1770892  YY1  15.707  ILMN_1715526  ZDHHC21  16.979 
ILMN_1773395  RDH5  15.75  ILMN_1656378  NMT2  17.001 
ILMN_1677963  TMCC1  15.757  ILMN_1852793    17.015 
ILMN_1785266  OFD1  15.796  ILMN_1782487  LOC400759  17.018 
ILMN_1786168  LOC400464  15.807  ILMN_1791840  RALBP1  17.036 
ILMN_1677484  SNAPC4  15.818  ILMN_1800401  ZNF69  17.061 
ILMN_1741506  LOC149134  15.843  ILMN_1745389  KIAA1328  17.096 
ILMN_1698521  SH2B1  15.86  ILMN_1683487  ZNF154  17.243 
ILMN_1723020  MAP3K1  15.91  ILMN_1665331  AMT  17.329 
ILMN_1734011 
RP13-
15M17.2  15.912  ILMN_1658809  SEZ6  17.35 
ILMN_1801869  WDR75  15.963  ILMN_1682038  SNORA25  17.392 
ILMN_1696043  FLVCR2  16.013  ILMN_1666690  ACRC  17.4 
ILMN_1683023  PDGFC  16.013  ILMN_1718932  MTRR  17.415 
ILMN_1862001    16.079  ILMN_1788931  DOCK8  17.518 
ILMN_1714283  TLE2  16.081  ILMN_1664096  ZNF491  17.548 
ILMN_1746208  CCAR1  16.086  ILMN_1813344  C20orf7  17.573 
ILMN_1774265  UNQ830  16.096  ILMN_1736237  DLAT  17.621 
ILMN_1774589  IQCC  16.102  ILMN_1741468  FAP  17.634 
ILMN_1739587  UTY  16.155  ILMN_1737561  LOC88523  17.697 
ILMN_1776347  TCP1  16.158  ILMN_1663532  RIC8B  17.699 
ILMN_1695079  ZNF101  16.204  ILMN_1748374  LOC400304  17.703 
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ILMN_1657701  TMEM137  17.711  ILMN_1666615  PREPL  19.068 
ILMN_1676946  AP3M2  17.723  ILMN_1721657  RSU1  19.093 
ILMN_1755222  C9orf82  17.747  ILMN_1743280  LRRC37B  19.162 
ILMN_1739583  ROCK1  17.761  ILMN_1695606  EFNB3  19.177 
ILMN_1712719  MAP7  17.79  ILMN_1698261  PDE6B  19.198 
ILMN_1664177  ATXN7L2  17.791  ILMN_1752117  TMEM55A  19.289 
ILMN_1729515  PIN4  17.856  ILMN_1813179  LOC401074  19.316 
ILMN_1685052  DNAH1  17.936  ILMN_1709747  ENDOGL1  19.475 
ILMN_1767279  LOC648245  18.061  ILMN_1724789  CD59  19.54 
ILMN_1741219  RRAGB  18.061  ILMN_1866216    19.562 
ILMN_1784706  GABRE  18.096  ILMN_1670752  KIAA0907  19.614 
ILMN_1890175    18.108  ILMN_1815705  LZTFL1  19.626 
ILMN_1660864  RHBDL1  18.139  ILMN_1767558  LRP5  19.668 
ILMN_1748427  ZNF239  18.146  ILMN_1892638    19.688 
ILMN_1764764  MUM1  18.163  ILMN_1908989    19.748 
ILMN_1682589  M6PR  18.173  ILMN_1801045  SPIN3  19.778 
ILMN_1860821    18.272  ILMN_1749253  TUBD1  19.817 
ILMN_1653794  C6orf160  18.306  ILMN_1723124  GALK2  19.907 
ILMN_1678998  LRRC14  18.328  ILMN_1784783  NME5  19.924 
ILMN_1760281  PRPF4B  18.391  ILMN_1677532  TARDBP  20.007 
ILMN_1795835  LOC338758  18.397  ILMN_1726989  C1orf86  20.083 
ILMN_1757910  HIP1R  18.404  ILMN_1810533  SLC6A15  20.147 
ILMN_1747650  BMP6  18.429  ILMN_1749915  C1orf63  20.209 
ILMN_1891455    18.465  ILMN_1727553  LOC63920  20.236 
ILMN_1738749  MAST3  18.483  ILMN_1706506  ZNF454  20.439 
ILMN_1720916  SETD7  18.49  ILMN_1868805    20.491 
ILMN_1681367  ZNF642  18.529  ILMN_1759084  INTS8  20.527 
ILMN_1768117  RBM25  18.55  ILMN_1778464  TMEM1  20.75 
ILMN_1691395  ZBTB11  18.565  ILMN_1722450  NSUN5B  20.769 
ILMN_1813430  TRIM69  18.584  ILMN_1672565  RG9MTD1  20.778 
ILMN_1679558  LOC283874  18.622  ILMN_1782222  KIAA1033  20.793 
ILMN_1707051  NFATC1  18.63  ILMN_1721034  ZNF227  20.839 
ILMN_1898124    18.764  ILMN_1798826  MRPS25  20.848 
ILMN_1674297  HCFC2  18.77  ILMN_1726368  ZNF135  20.957 
ILMN_1712798  ZNF608  18.778  ILMN_1759407  USHBP1  20.984 
ILMN_1669931  TM9SF3  18.79  ILMN_1796119  C6orf113  21.051 
ILMN_1721741  ATPBD1B  18.8  ILMN_1672122  PH-4  21.137 
ILMN_1757408  ZNF256  18.816  ILMN_1696469  LOC648509  21.184 
ILMN_1843756    18.865  ILMN_1734867  NR2C1  21.285 
ILMN_1893633  LOC439949  18.897  ILMN_1758105  ZNF791  21.299 
ILMN_1788118  SLC23A3  18.943  ILMN_1743427  SCYL3  21.302 
ILMN_1801762  PFDN4  18.952  ILMN_1716921  ZNF83  21.387 
ILMN_1790103  ZNF569  18.96  ILMN_1673478  C5orf5  21.414 
ILMN_1713744  C14orf132  18.977  ILMN_1746782  LRRC16  21.506 
ILMN_1792109  AFG3L1  19.025  ILMN_1779448  EFHD1  21.634 
ILMN_1670322  FCHO2  19.052  ILMN_1789364  ZNF789  21.681 
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ILMN_1657011  LOC286208  21.689  ILMN_1781361  LOC400986  24.518 
ILMN_1681760  LOC728518  21.713  ILMN_1910120  LOC730092  24.876 
ILMN_1703555  SNORD31  21.737  ILMN_1751362  FASTKD1  24.938 
ILMN_1756992  MUC1  21.765  ILMN_1898691    25.009 
ILMN_1668055  SAA4  21.911  ILMN_1652147  MRPL43  25.102 
ILMN_1798085  EID2B  21.916  ILMN_1809894  TMEM117  25.126 
ILMN_1714848  ZNF354A  21.965  ILMN_1747824  ZNF85  25.136 
ILMN_1665810  CCDC113  22.105  ILMN_1663646  DMXL1  25.519 
ILMN_1827736    22.113  ILMN_1735275  WDSUB1  25.636 
ILMN_1754757  SCNN1D  22.21  ILMN_1727466  KCNMB4  25.708 
ILMN_1730888  ZNF680  22.392  ILMN_1710954  LOC283932  25.954 
ILMN_1690839  PPAPDC3  22.455  ILMN_1759062  NIPBL  26.188 
ILMN_1788689  PHIP  22.456  ILMN_1782098  SMO  26.524 
ILMN_1720287  E4F1  22.493  ILMN_1753823  IL17D  26.709 
ILMN_1793578  ZFP37  22.555  ILMN_1745501  DNALI1  27.223 
ILMN_1791006  AHI1  22.619  ILMN_1712766  ERGIC2  27.338 
ILMN_1761044  GNB1L  22.632  ILMN_1849693    27.408 
ILMN_1670379  ANTXR1  22.692  ILMN_1802519  VPS36  27.821 
ILMN_1745790  MRPL42P5  22.696  ILMN_1807136  LOC729559  27.938 
ILMN_1814221  NPTX1  22.721  ILMN_1867188    28.015 
ILMN_1745991  GNRH1  22.742  ILMN_1676302  FAM113A  28.406 
ILMN_1684726  C2orf27  22.773  ILMN_1802053  ZNF91  28.983 
ILMN_1811050  CCDC88A  22.996  ILMN_1811029  TLK1  29.073 
ILMN_1719064  KCTD10  23.165  ILMN_1727923  ZNF140  29.289 
ILMN_1746924  ZNF610  23.185  ILMN_1716264  ANKRD1  29.505 
ILMN_1696004  LRRK1  23.209  ILMN_1651964  ABCC5  29.711 
ILMN_1892548    23.238  ILMN_1789751  MFSD1  29.818 
ILMN_1651364  PCBD2  23.25  ILMN_1737818  C12orf43  29.866 
ILMN_1719290  CRYZL1  23.268  ILMN_1913641    30.162 
ILMN_1665135  RBBP6  23.445  ILMN_1893511    31.152 
ILMN_1812666  DNAJC15  23.698  ILMN_1662147  MANEAL  32.856 
ILMN_1745852  WDR33  23.704  ILMN_1724009  SETD6  34.229 
ILMN_1691772  ZSCAN29  23.731  ILMN_1662038  LARGE  34.239 
ILMN_1753782  ZNF266  24.006  ILMN_1811110  TDRD9  35.458 
ILMN_1873278  LOC731895  24.021  ILMN_1698185  WDR90  36.252 
ILMN_1793017  DGKQ  24.026  ILMN_1806473 
NGFRAP1L
1  36.806 
ILMN_1801303  AMY2A  24.081  ILMN_1818617    37.692 
ILMN_1738124  ZNF772  24.146  ILMN_1716555  MGC42630  40.455 
ILMN_1751393  ZNF684  24.302  ILMN_1696622  SLC38A6  44.889 
ILMN_1811301  INPP5E  24.314  ILMN_1792972  ZNF439  47.176 
ILMN_1849186    24.316  ILMN_1725314  GBP3  49.23 
ILMN_1911717    24.513       
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ABCC5  ATP-binding cassette, sub-family C (CFTR/MRP), member 5  NM_005688.2  0.00958  -1.25529 
ACAD11  acyl-Coenzyme A dehydrogenase family, member 11  NM_032169.4  0.00412  -1.44834 
AFG3L1  AFG3 ATPase family gene 3-like 1 (S. cerevisiae)  NR_003226.1 
3.00E-
05  -1.64806 
AGTR2  angiotensin II receptor, type 2  NM_000686.4  0.0239  1.45261 
AMT (includes EG:275)  aminomethyltransferase  NM_000481.2  0.03663  -2.06699 
AMY2A  amylase, alpha 2A (pancreatic)  NM_000699.2  0.04685  -1.52472 
BLZF1  basic leucine zipper nuclear factor 1 (JEM-1)  NM_003666.2  0.01698  -1.23465 
C10ORF120  chromosome 10 open reading frame 120  NM_001010912.1  0.01645  1.23922 
C10ORF97  chromosome 10 open reading frame 97  NM_024948.2  0.02841  -1.17917 
C14ORF39  chromosome 14 open reading frame 39  NM_174978.1  0.03079  1.51268 
C17ORF54  chromosome 17 open reading frame 54  NM_182564.1  0.00842  1.5758 
C19ORF18  chromosome 19 open reading frame 18  NM_152474.3  0.03607  -1.54723 
C1ORF63  chromosome 1 open reading frame 63  NM_020317.3  0.00588  -1.88027 
C6ORF123  chromosome 6 open reading frame 123  NM_014356.2  0.02219  1.71414 
CCDC113  coiled-coil domain containing 113  NM_014157.2  0.00116  -1.45675 
CFDP1  craniofacial development protein 1  NM_006324.2  0.03607  1.37673 
CFL1  cofilin 1 (non-muscle)  NM_005507.2  0.01086  1.17496 
CROP  cisplatin resistance-associated overexpressed protein  NM_006107.2  0.01538  -2.04803 
DGKQ  diacylglycerol kinase, theta 110kDa  NM_001347.2  0.03809  -1.33223 
E4F1  E4F transcription factor 1  NM_004424.3  0.01635  -1.33492 
EFHD1  EF-hand domain family, member D1  NM_025202.2  0.01086  -4.45841 
ERGIC2  ERGIC and golgi 2  NM_016570.2  0.03412  -1.28905 
FAP  fibroblast activation protein, alpha  NM_004460.2  0.01538  -2.34487 
FLJ21062  hypothetical protein FLJ21062  NM_001039706.1  0.03663  -1.30533 
GDF2  growth differentiation factor 2  NM_016204.1  0.01726  1.2736 
GNL2  guanine nucleotide binding protein-like 2 (nucleolar)  NM_013285.1  0.026  -1.1826 
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GNRH1  gonadotropin-releasing hormone 1 (luteinizing-releasing hormone)  NM_000825.3  0.0198  -1.58069 
HIP1R  huntingtin interacting protein 1 related  XM_001132864.1  0.03809  -1.52871 
KIAA0556  KIAA0556  NM_015202.1  0.04851  -1.23184 
KIAA0574  KIAA0574 protein  XM_001127362.1  0.96044  1.07003 
KIAA1328  KIAA1328  NM_020776.1  0.03557  -1.40981 
KIAA2013  KIAA2013  NM_138346.1  0.02921  1.21295 
KLK4  kallikrein-related peptidase 4  NM_004917.3  0.02841  2.15663 
LOC283932  hypothetical LOC283932  NM_175901.3  0.03079  -1.42516 
LOC440748  hypothetical gene supported by AK124556  XM_498841.3  0.04054  1.39778 
LOC727762  similar to NADH:ubiquinone oxidoreductase B15 subunit  XM_001125898.1  0.0238  -1.7181 
LOC729137  hypothetical protein LOC441528  XM_001129423.1 
1.10E-
04  2.9142 
LRCH4 
leucine-rich repeats and calponin homology (CH) domain 
containing 4  NM_002319.2  0.0238  -1.60402 
LSM14A  LSM14A, SCD6 homolog A (S. cerevisiae)  NM_015578.1  0.04685  -1.14405 
LZTFL1  leucine zipper transcription factor-like 1  NM_020347.2  0.01963  -1.30391 
MFSD1  major facilitator superfamily domain containing 1  NM_022736.1 
6.99E-
06  -1.39625 
MGC12760  ciliary rootlet coiled-coil, rootletin-like 1  XM_001130627.1  0.01784  -1.72953 
MGC42630  family with sequence similarity 27, member E3  NM_175923.3  0.01634  -1.51369 
NSUN5B  NOL1/NOP2/Sun domain family, member 5B  NM_001039575.1  0.01086  -1.57828 
NUTF2  nuclear transport factor 2  NM_005796.1  0.01086  1.41546 
PDE8A  phosphodiesterase 8A  NM_173457.1  0.03186  -1.2629 
PIK3R2  phosphoinositide-3-kinase, regulatory subunit 2 (beta)  NM_005027.2  0.03585  -1.22074 
RAB22A  RAB22A, member RAS oncogene family  NM_020673.2  0.01199  -1.28058 
RALBP1  ralA binding protein 1  NM_006788.3  0.03117  -1.23267 
RDH5  retinol dehydrogenase 5 (11-cis/9-cis)  NM_002905.2  0.03117  -1.43216 
RIC8B  resistance to inhibitors of cholinesterase 8 homolog B (C. elegans)  NM_018157.2  0.00412  -1.31425 
SAA4  serum amyloid A4, constitutive  NM_006512.1  0.03762  -1.96613 
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Gene Symbol  Gene Name  GenBank Accession Number  P value  Fold Change 
SETD6  SET domain containing 6  NM_024860.1  7.70E-04  -1.5567 
SGSM2  small G protein signaling modulator 2  NM_014853.2  0.03186  -1.21567 
SLC23A3  solute carrier family 23 (nucleobase transporters), member 3  NM_144712.2  0.03607  -2.3497 
SLC25A28  solute carrier family 25, member 28  NM_031212.3  0.0238  -1.23134 
SLC38A6  solute carrier family 38, member 6  NM_153811.1  0.0092  -1.5712 
SRMS 
src-related kinase lacking C-terminal regulatory tyrosine and N-
terminal myristylation sites  NM_080823.2  0.02963  -1.86829 
STK35  serine/threonine kinase 35  NM_080836.2  0.03186  -1.15512 
STK36  serine/threonine kinase 36, fused homolog (Drosophila)  NM_015690.2  0.04624  -1.33175 
TCFL5  transcription factor-like 5 (basic helix-loop-helix)  NM_006602.2  0.04014  -1.26548 
TDRD9  tudor domain containing 9  NM_153046.1  7.70E-04  -2.18596 
TM9SF3  transmembrane 9 superfamily member 3  NM_020123.2  0.01199  -1.2211 
TSPAN6  tetraspanin 6  NM_003270.2  0.02841  -1.18427 
ULK1  unc-51-like kinase 1 (C. elegans)  XM_001133335.1  0.0092  -1.24957 
USHBP1  Usher syndrome 1C binding protein 1  NM_031941.3  0.01538  -2.16837 
WDR60  WD repeat domain 60  NM_018051.3  0.01226  -1.33403 
ZBTB12  zinc finger and BTB domain containing 12  NM_181842.1  0.01784  1.57687 
ZDHHC8  zinc finger, DHHC-type containing 8  NM_013373.2  0.01086  -1.266 
ZMYM2  zinc finger, MYM-type 2  NM_197968.1  0.00311  -1.26863 
ZNF212  zinc finger protein 212  NM_012256.2  0.01645  -1.20548 
ZNF266  zinc finger protein 266  NM_006631.2  4.00E-05  -1.33324 
ZNF439  zinc finger protein 439  NM_152262.2  0.01925  -1.68406 
ZNF486  zinc finger protein 486  XM_371152.3  0.0471  -1.24292 
ZNF569  zinc finger protein 569  NM_152484.2  0.01086  -1.29198 
ZNF83  zinc finger protein 83  NM_018300.2  0.02596  -1.47467 
ZUFSP  zinc finger with UFM1-specific peptidase domain  NM_145062.1  0.01949  -1.34485 
 
Table A2. Differentially Expressed Genes Identified From Ingenuity Pathway Analysis (IPA) of Rosetta Resolver
® Microarray Data. IPA identified 77 
differentially expressed genes (P≤0.005) within the Rosetta Resolver
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